Δημοσιεύσεις

Δημοσιεύσεις 1996

CISPLATIN AND CONTINUOUS INFUSION OF FLUOROURACIL FOLLOWED BY RADIATION OF WEEKLY CARBOPLATIN IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER

G. Fountzilas, P. Kosmidis, K.S. Shridhar, A. Kalogera-Fountzila, K. Banis, A. Dimitriadis, V. Avramidis, A. Nikolaou, T. Zaramboukas, D. Skarlos, A. Vritsios, I. Daniilidis

Cancer Invest 1996;14(3):189-96


 A PHASE II STUDY OF PACLITAXEL IN ADVANCED BREAST CANCER RESISTANT TO ANTHRACYCLINES

G. Fountzilas, A. Athanassiadis, T. Giannakakis, D. Bafaloukos, K. Karakousis, N. Dombros, P. Kosmidis, D. Skarlos

Eur J Cancer 1996 Jan;32A(1):47-51


 PROGNOSTIC VARIABLES IN PATIENTS WITH ADVANCED COLORECTAL CANCER TREATED WITH FLUOROURACIL AND LEUCOVORIN-BASED CHEMOTHERAPY

G. Fountzilas, K. Gossios, A. Zisiadis, E. Svarna, D. Skarlos, N. Pavlidis

Med Pediatr Oncol 1996 May;26(5):305-17


 CARBOPLATIN ALONE COMPARED WITH ITS COMBINATION WITH EPIRUBICIN AND CYCLOPHOSPHAMIDE IN UNTREATED ADVANCED EPITHELIAL OVARIAN CANCER: HECOG

D.V.Skarlos, G. Aravantinos, P. Kosmidis, N. Pavlidis, K. Gennatas, M. Beer, N. Mylonakis, P. Makrantonakis, G. Klouvas, S. Karpathios, H. Linardou, C. Konstantaras, G. Fountzilas

Eur J Cancer 1996 Mar;32A(3):421-8


 RECOMBINANT INTERFERON ALFA-2A IN COMBINATION WITH CARBOPLATIN, VINBLASTINE AND BLEOMYCIN IN THE TREATMENT OF ADVANCED MALIGNANT MELANOMA

D. Bafaloukos, N. Pavlidis, G. Fountzilas, D. Skarlos, G. Klouvas, P. Makrantonakis, T. Giannakakis, N. Tsavaris, P. Kosmidis

Am J Clin Oncol 1996 Jun;19(3):296-300


 PACLITAXEL AND CARBOPLATIN IN NON-OPERABLE NON-SMALL CELL LUNG CANCER

P. Kosmidis, N. Mylonakis, G. Fountzilas, E. Samantas, A. Athanasiadis, D. Skarlos

Semin Oncol 1996 Dec;23(6 Suppl 16):68-70


 A PROSPECTIVE RANDOMIZED PHASE III STUDY IN NON-SMALL-CELL LUNG CANCER COMPARING CISPLATIN, IFOSFAMIDE, VINBLASTINE (VIP) VERSUS CISPLATIN, IFOSFAMIDE AND ETOPOSIDE (VIP – 16)

P. Kosmidis, N. Mylonakis, G. Fountzilas, N. Pavlidis, E. Samantas, A. Karabelis, K. Kattis, D. Skarlos

Ann Oncol 1996 Jul;7(5):517-20


 CLINICAL VALUE OF CA 15-3, MUCIN-LIKE CARCINOMA-ASSOCIATE ANTIGEN, TUMOR POLYPEPTIDE ANTIGEN, AND CARCINOEMBRYONIC ANTIGEN IN MONITORING EARLY BREAST CANCER PATIENTS

D. Pectasides, N. Pavlidis, L. Gogou, F. Antoniou, C. Nicolaides, D. Tsikalakis, G. Fountzilas

Am J Clin Oncol 1996 Oct;19(5):459-64


 CYCLOPHOSPHAMIDE, MITOXANTRONE, FLUOROURACIL VERSUS CONVENTIONAL CMF AS ADJUVANT TREATMENT IN NODE-POSITIVE BREAST CANCER PATIENTS

G. Fountzilas, A. Polichronis, K. Katsohis, K. Gennatas, D. Toussis, D. Skarlos, P. Kosmidis, S. Vassilaros, C. Semoglou, T. Giannakakis, E. Fahantidis, G. Klouvas, N. Tsavaris, C. Konstantaras, P. Makrantonakis, C. Kolotas, N. Zamboglou, S. Tsiliakos, D. Hainoglou, N. Mylonakis, N. Pavlidis

Oncology 1996 Mar-Apr;53(2):137-46


 PHASE II STUDY OF 5-FLUOROURACIL AND INTERFERON-GAMMA IN PATIENTS WITH METASTATIC COLORECTAL CANCER

N. Pavlidis, C. Nicolaides, A. Athanassiades, K. Beriatou, D. Skarlos, Th. Giannakakis, P. Kosmidis, N. Karvounis, G. Fountzilas

Oncology 1996 Mar-Apr;53(2):159-62


 SOLUBLE INTERLEUKIN-2 RECEPTORS IN PATIENTS WITH ADVANCED COLORECTAL CARCINOMA

N. Pavlidis, C. Nikolaides, E. Bairaktari, J. Kalef-Ezra, A. Athanassiadis, C. Seferiadis, G. Fountzilas

Int J Biol Markers 1996 Jan-Mar;11(1):6-1


 WIDESPREAD CASTLEMAN DISEASE: CT FINDINGS

K. Gossios, C. Nicolaides, M. Bai, G. Fountzilas

Eur Radiol 1996;6(1):95-8


 FLUORURACIL AND LEUCOVORIN WITH OR WITHOUT INTERFERON ALFA-2b IN ADVANCED COLORECTAL CANCER: ANALYSIS OF A PROSPECTIVE RANDOMIZED PHASE II TRIAL

P.A. Kosmidis, N. Tsavaris, D. Skarlos, D. Theocharis, E. Samantas, N. Pavlidis, E. Briassoulis, G. Fountzilas

J Clinl Oncol 1996 Oct;14(10):2682-7


 THE BENEFICIAL EFFECT OF TAMOXIFEN ON SERUM LIPOPROTEIN-A LEVELS: AN ADDITIONAL ANTI-ATHEROGENIC PROPERTY

M. Elisaf, E. Bairaktari, C. Nicolaides, G. Fountzilas, C. Tzallas, K. Siamopoulos, O. Tsolas, N. Pavlidis

Anticancer Res 1996 Sep-Oct;16(5A):2725-8


 OVARIAN ABLATION IN EARLY BREAST CANCER: OVERVIEW OF THE RANDOMISED TRIALS. EARLY BREAST CANCER TRIALISTS’ COLLABORATIVE GROUP

Lancet 1996 Nov 2;348(9036):1189-96

Δημοσιεύσεις 1997

CHEMOTHEPARY WITH METHOTREXATE, VINBLASTINE, EPIRUBICIN AND CARBOPLATIN (CARBO-MVE) IN TRANSITIONAL CELL UROTHELIAL CANCER. A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

D.V.Skarlos, G. Aravantinos, E. Linardou, C. A. Kostakopoulos, I. Kastriotis, C. Christodoulou, D. Picramenos, Th. Giannakakis, K. Dimopoulos, G. Fountzilas

Eur Urol 1997; 31:420-427


PACLITAXEL AND CARBOPLATIN IN INOPERABLE NON- SMALL CELL LUNG CANCER: A PHASE II STUDY

P.A. Kosmidis, N.Mylonakis, G. Fountzilas, E. Samantas, A. Athanasiadis, E. Andreopoulou, N. Pavlidis, D. Skarlos

Annals of Oncology 1997 Jul;8(7):697-9


5-FLUOROURACIL, INTERFERON – ALPHA – 2b AND CISPLATIN (FAP) FOR ADVANCED UROTHELIAL CANCER. A PHASE II STUDY

P. Kosmidis, C.Bacoyiannis, G. Fountzilas, G. Aravantinos, N. Tsavaris, C. Milathianakis, D. Skarlos

Annals of Oncology 1997 Apr;8(4):373-8


 A PHASE II STUDY OF PACLITAXEL IN PLATINUM PRETREATED OVARIAN CANCER. A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

G. Aravantinos, D.V.Skarlos, P. Kosmidis, A. Athanassiades, D. Bafaloukos, T. Giannakakis, S. Karpathios, G. Fountzilas

European Journal of Cancer 1997 Jan;33(1):160-3


 PACLITAXEL (175 mg/m2) PLUS CARBOPLATIN VERSUS PACLITAXEL (225 mg/m2 ) PLUS CARBOPLATIN IN NON–SMALL CELL LUNG CANCER

P. Kosmidis, N. Mylonakis, G. Fountzilas, E. Samantas, A. Athanassiades, N. Pavlidis, D. Skarlos

Seminars in Oncology 1997 Aug;24(4 Suppl 12):S12-30-S12-33


 PACLITAXEL AND CARBOPLATIN IN RECURRENT OR METASTATIC HEAD AND NECK CANCER: A PHASE II STUDY

G. Fountzilas, A. Athanassiadis, E. Samantas, D. Skarlos, A. Kalogera-Fountzila, A. Nikolaou, H. Bacoyiannis, G. Stathopoulos, P. Kosmidis, J. Daniilidis

Seminars in Oncology 1997 Feb;24(1 Suppl 2):S2-65-S2-67


 PACLITAXEL WITH CARBOPLATIN VR PACLITAXEL WITH CARBOPLATIN ALTERNATING WITH CISPLATIN AS FIRST LINE CHEMOTHERAPY IN ADVANCED EPITHELIAL OVARIAN CANCER: PRELIMINARY RESULTS OF A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

D.V.Skarlos, G. Aravantinos, P. Kosmidis, A. Athanassiadis, G.P. Stathopoulos, N. Pavlidis, D. Bafaloukos, S. Karpathios, P. Papakostas, C. Bamia, G. Fountzilas

Seminars in Oncology 1997 Oct;24(5 Suppl 15):S15-57-S15-61


 A RANDOMIZED STUDY OF EPIRUBICIN MONOTHERAPY EVERY FOUR OR EVERY TWO WEEKS IN ADVANCED BREAST CANCER. A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

G. Fountzilas, A. Athanassiades, T. Giannakakis, E. Briasoulis, D. Bafaloukos, A. Kalogera-Fountzila, A. Onienaoum, H. Kalofonos, D. Pectasides, E. Andreopoulou, C. Bamia, P. Kosmidis, N. Pavlidis, D. Skarlos

Annals of Oncology 1997 Dec;8(12):1213-20


 PACLITAXEL BY 3-H INFUSION AND CARBOPLATIN IN ANTHRACYCLINE-RESISTANT ADVANCED BREAST CANCER. A PHASE II STUDY CONDUCTED BE THE HELLENIC COOPERATIVE ONCOLOGY GROUP

G. Fountzilas, A. Athanassiadis, A. Kalogera-Fountzila, G. Aravantinos, D. Bafaloukos, E. Briasoulis, N. Dombros, I. Ioannidis, N. Pavlidis, P. Kosmidis, D. Skarlos

European Journal of Cancer 1997 Oct;33(11):1893-5


 PROGNOSTIC VARIABLES IN GREEK PATIENTS WITH STAGE II BREAST CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

G. Fountzilas, S. Vasilaros, D. Koukouras, N. Malamos, D. Pectasides, A. Adamou, E. Nenopoulou, K. Kiriakou, I. Zouvani, K. Katsohis, A. Kappas, C. Skopa, C. Semoglou, E. Fahantidis, C. Konstantaras, E. Vasilaki, T. Economopoulos, H. Bacoyiannis, D. Bafaloukos, E. Razi, A. Polichronis, G. Androulakis, T. Papaioannou, N. Pavlidis, D. Skarlos, D. Skarlos, P. Kosmidis

Anticancer research 1997 Nov-Dec;17(6D):4681-9


 ACCELERATED BIFRACTIONATED RADIATION WITH CONCURRENT CISPLATIN ADMINISTRATION IN LOCALLY ADVANCED HEAD AND NECK CANCER: A FEASIBILITY STUDY

G. Fountzilas, A. Athanassiadis, A. Nikolaou, A. Kalogera-Fountzila, J. Tzitzikas, E. Samantas, D. Skarlos, N. Zamboglou, J. Daniilidis

Tumori 1997 Jul-Aug;83(4):735-9


 LONG-TERM SURVIVAL DATA AND PROGNOSTIC FACTORS OF A COMPLETE RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH HEAD AND NECK CANCER TREATED WITH PLATINUM-BASED INDUCTION CHEMOTHERPAY: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

G. Fountzilas, P. Kosmidis, V. Avramidis, A. Nikolaou, A. Kalogera-Fountzila, P. Makrantonakis, C. Bacoyiannis, E. Samantas, D. Skarlos, J. Daniilidis

Medical and Pediatric Oncology 1997 Jun;28(6):401-10


 PACLITAXEL BY THREE-HOUR INFUSION AND CARBOPLATIN IN ADVANCED CARCINOMA OF NASOPHARYNX AND OTHER SITES OF THE HEAD AND NECK

G. Fountzilas, D. Skarlos, A. Athanassiades, A. Kalogera-Fountzila, E. Samantas, C. Bacoyiannis, N. Nicolaou, N. Dombros, E. Briasoulis, M. Dinopoulou, G. Stathopoulos, N. Pavlidis, P. Kosmidis, J. Daniilidis

Annals of Oncology 1997 May;8(5):451-5


 INTENSIFIED CARBOPLATIN REGIMEN WITH GM-CSF SUPPORT IN NON-SMALL CELL LUNG CANCER (NSCLC). A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY (HECOG)

C. Nicolaides, G. Klouvas, G. Fountzilas, A. Athanassiadis, D. Skarlos, E. Samantas, P. Kosmidis, N. Mylonakis, N. Pavlidis

Journal of Experimental & Clinical Cancer Research 1997 Mar;16(1):91-4


 EFFECTIVENESS OF PACLITAXEL AND CARBOPLATIN COMBINATION IN HEAVILY PRETREATED PATIENTS WITH HEAD AND NECK CANCERS

G. P. Stathopoulos, S. Rigatos, P. Papakostas, G. Fountzilas

European Journal of Cancer 1997 Oct;33(11):1780-3


 HAPLOTYPES OF HUMAN LEUKOCYTE ANTIGENS AMONG PATIENTS WITH NASOPHARYNGEAL CANCER IN GREECE

M. Daniilidis, G. Fountzilas, A. Fleva, J. Daniilidis, A. Tourkantonis

Oncology 1997 May-Jun;54(3):185-92


 CONCURRENT RADIATION AND INTRACAROTID CISPLATIN INFUSION IN MALIGNANT GLIOMAS: A FEASIBILITY STUDY

G. Fountzilas, A. Karavelis, P. Makrantonakis, P. Selviaridis, J. Tzitzikas, A. Kalogera-Fountzila, A. Hatzibaloglou, G. Karkavelas, G. Foroglou, A. Tourkantonis

American Journal ofClinical Oncology 1997 Apr;20(2):138-42

Δημοσιεύσεις 1998

CONCURRENT PACLITAXEL AND RADIOTHERAPY. TREATMENT FEASIBILITY STUDIES

H.G. Vogt, T. Martin, A. Capizzello, C. Kolotas, S. Hey, L. Schneider, W. Dornoff, G. Fountzilas, T. Templin, H. Kettner, N. Zamboglou

Strahlentherapie und Onkologie. 1998;174:1: 24-8


TAMOXIFEN FOR EARLY BREAST CANCER: AN OVERVIEW OF THE RANDOMISED TRIALS

Early Breast Cancer Trialists’ Collaborative Group


POLYCHEMOTHERAPY FOR EARLY BREAST CANCER: AN OVERVIEW OF THE RANDOMISED TRIALS

Early Breast Cancer Trialists’ Collaborative Group


DO LH-RH ANALOGUES INDUCE EFFECTS SIMILAR TO TAMOXIFEN ON SERUM LIPID PARAMETERS IN PREMENOPAUSAL WOMEN WITH BREAST CANCER? A PROSPECTIVE STUDY

M. Elisaf, E. Bairaktari, C. Nicolaides, G. Fountzilas, C. Tzallas, O. Tsolas, K. Siamopoulos, N. Pavlidis

Nutr Metab Cardiovasc Dis 1998 ; 8 : 101-105


FIRST-LINE CHEMOTHERAPY WITH PACLITAXEL BY THREE-HOUR INFUSION AND CARBOPLATIN IN ADVANCED BREAST CANCER (FINAL REPORT): A PHASE II STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP

G. Fountzilas, A.M. Dimopoulos, C. Papadimitriou, A. Kalogera-Fountzila, G. Aravantinos, D. Bafaloukos, A. Athanassiades, C. Nicolaides, A. Keramopoulos, N. Pavlidis, P. Kosmidis, D. Skarlos

Ann. Oncol. 1998 Sep;9(9):1031-4


PACLITAXEL AND CARBOPLATIN AS FIRST-LINE CHEMOTHERAPY FOR ADVANCED BREAST CANCER
G. Fountzilas, A. Athanassiades, V. Papadimitriou, M.A Dimopoulos, D. Bafaloukos, G. Aravantinos, C. Nicolaides, H. Kalofonos, P. Papakostas, N. Xiros, E. Razi

Oncology. 1998 Jan;12(1 Suppl 1):45-8


NEO-ANGIOGENESIS IN LOCALLY ADVANCED SQUAMOUS CELL HEAD AND NECK CANCER CORRELATES WITH THYMIDINE PHOSPHORYLASE EXPRESSION AND p53 NUCLEAR ONCOPROTEIN ACCUMULATION

Al. Giatromanolaki, G. Fountzilas, M.I. Koukourakis, P. Arapantoni, V. Theologi, S. Kakolyris, V. Georgoulias, A.L. Harris, K.C. Gatter.

Clin Exp Metastasis. 1998 Oct;16(7):665-72


TROPISETRON IN THE PREVENTION OF ACUTE NAUSEA AND VOMITING IN PATIENTS TREATED WITH HIGH DOSE EPIRUBICIN
C. Nicolaides, T. Giannakakis, D. Skarlos, A. Athanassiadis, G. Fountzilas, D. Damigos, N. Pavlidis

J Exp Clin Cancer Res. 1998 Mar;17(1):71-5


PROGNOSTIC FACTORS INFLUENCING COMPLETE RESPONSE TO TREATMENT AND SURVIVAL OF PATIENTS WITH NASOPHARYNGEAL CANCER
An. Kalogera-Fountzila, P. Kosmidis, C. Bacoyiannis, A. Nicolaou, E. Samantas, E. Briassoulis, N. Pavlidis, D. Skarlos, J. Daniilidis, G. Fountzilas

Anticancer Res. 1998 Jan-Feb;18(1B):587-93


Bcl2 AND p53 PROTEIN EXPRESSION IN METASTATIC CARCINOMA OF UNKNOWN PRIMARY ORIGIN: BIOLOGICAL AND CLINICAL IMPLICATIONS. A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
E. Briassoulis, M. Tsokos, G. Fountzilas, D. Bafaloukos, P. Kosmidis, E. Samantas, D. Skarlos, C. Nicolaides, N. Pavlidis

Anticancer Res. 1998 May-Jun;18(3B):1907-14


PRIMARY EXTRANODAL NON HODGKIN’S LYMPHOMA OF THE HEAD AND NECK TO ADULTS: A CLINICOPATHOLOGICAL  COMPARISON BETWEEN TONSILLAR AND NON TONSILLAR LYMPHOMAS
T. Economopoulos, G. Fountzilas, A. Kostourou, J. Daniilidis, N. Pavlidis, H. Andreopoulou, A. Nicolaou, E. Papageorgiou, S. Mellou, J. Dervenoulas, N. Stathakis
Anticancer Res. 1998 Nov-Dec;18(6B):4655-60


P53/MDM-2 IMMUNOHISTOCHEMICAL EXPRESSION CORRELATED WITH PROLIFERATIVE  ACTIVITY IN DIFFERENT SUBTYPES OF HUMAN SARCOMAS: A TEN-YEAR FOLLOW-UP STUDY
D.G. Stefanou, A.V. Nonni, N.J. Agnantis, S.E. Athanassiadou, E. Briassoulis, N. Pavlidis
Anticancer Res. 1998 Nov-Dec;18(6B):4673-81


P53 AND BCL-2 EXPRESSION IN LOCALLY ADVANCED SQUAMOUS CELL HEAD-NECK CANCER TREATED WITH PLATINUM BASED CHEMOTHERAPY AND RADIOTHERAPY
Al. Giatromanolaki, M. Koukourakis, T. Zaramboukas, A. Skordalaki, P. Arapantoni, V. Georgoulias, G. Fountzilas
Anticancer Res. 1998 Nov-Dec;18(6B):4685-92


IMAGING OF METASTATIC MELANOMA UTILISING A TECHNETIUM-99m LABELLED RGD-CONTAINING SYNTHETIC PEPTIDE
G.B. Sivolapenko, D. Skarlos, D. Pectasides, E. Stathopoulou, A. Milonakis, G. Sirmalis, A. Stuttle, N.S. Courtenay-Luck, K. Konstantinides, A.A. Epenetos
Eur.
J Nucl. Med. 1998 Oct;25(10):1383-9


TREATMENT OF PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA AND IMPAIRED RENAL FUNCTION WITH SINGLE-AGENT DOCETAXEL
M.A. Dimopoulos, C. Deliveliotis, L.A. Moulopoulos, C. Papadimitriou, D. Mitropoulos, A. Anagnostopoulos, P. Athanassiades, C. Dimopoulos
Urology 1998 Jul;52(1):56-60


SUBCUTANEOUS LOW DOSES OF INTERLEUKIN-2 AND RECOMBINANT INTERFERON ALPHA WITH CARBOPLATIN AND VINBLASTINE IN PATIENTS WITH ADVANCED MELANOMA
D. Bafaloukos, G. Fountzilas, D. Skarlos, N. Pavlidis, C. Bakoyiannis, N. Karvounis, P. Kosmidis
Oncology. 1998 Jan-Feb;55(1):48-52


DIFFUSE LARGE CELL LYMPHOMAS: IDENTIFICATION OF PROGNOSTIC FACTORS AND VALIDATION OF THE INTERNATIONAL NON-HODGKIN’S LYMPHOMA PROGNOSTIC INDEX. A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
C. Nicolaides, G. Fountzilas, N. Zoumbos, D. Skarlos, P. Kosmidis, D. Pectasides, A. Karabelis, Th. Giannakakis, A. Symeonidis, A. Papadopoulos, F. Antoniou, N. Pavlidis
Oncology. 1998 Sep-Oct;55(5):405-15


COMBINATION REGIMEN WITH CARBOPLATIN, EPIRUBICIN AND ETOPOSIDE IN METASTATIC CARCINOMAS OF UNKNOWN PRIMARY SITE:  A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
E. Briasoulis, N. Tsavaris, G. Fountzilas, A. Athanasiadis, P. Kosmidis, D. Bafaloukos, D. Skarlos, E. Samantas, N. Pavlidis
Oncology.
1998 Sep-Oct;55(5):426-30


DOSE-DENSE ADJUVANT CHEMOTHERAPY WITH EPIRUBICIN MONOTHERAPY IN PATIENTS WITH OPERABLE BREAST CANCER AND >=10 POSITIVE AXILLARY LYMPH NODES
G. Fountzilas, C. Nicolaides, G. Aravantinos, D. Skarlos, P. Kosmidis, P. Papakostas, G.P. Stathopoulos, E. Kontostolis, D. Bafaloukos, N. Pavlidis
Oncology.
1998 Nov-Dec;55(6):508-12


A RANDOMIZED COMPARATIVE STUDY OF ANTIEMETIC PROPHYLAXIS WITH ONDASENTRON IN A SINGLE  32-mg LOADING DOSE VERSUS 8mg EVERY 6h IN PATIENTS UNDERGOING CISPLATIN-BASED CHEMOTHERAPY
N. Tsavaris, G. Fountzilas, N. Mylonakis, A. Athanassiadis, C. Kosmas, C. Karakousis, C. Bacoyiannis, P. Kosmidis
Oncology.
1998 Nov-Dec;55(6):513-6


FAVORABLE OUTCOME OF OVARIAN GERM CELL MALIGNANCIES TREATED WITH CISPLATIN OR CARBOPLATIN-BASED CHEMOTHERAPY: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
M.A. Dimopoulos, M. Papadopoulou, E. Andreopoulou, C. Papadimitriou, N. Pavlidis, G. Aravantinos, A. Aspropotamitis, A. Anagnostopoulos, G. Fountzilas, S. Michalas, D. Pectasides
Gynecol Oncol.
1998 Jul;70(1):70-4


LOCAL IMMUNE RESPONSE AFTER INTRAVESCICAL INTERFERON GAMMA IN SUPERFICIAL BLADDER CANCER
N.E. Stavropoulos, E. Ioachim, N. Pavlidis, L. Pappa, P. Kalomiris, N.J. Agnantis
Br J Urol.1998 Jun;81(6):875-9

Δημοσιεύσεις 1999

ANGIOGENESIS VS RESPONSE AFTER COMBINED  CHEMORADIOTHERAPY OF SQUAMOUS CELL  HEAD AND NECK CANCER

A.Giatromanolaki, M.I.Koukourakis, V.Georgoulias, K.C.Gatter, A.L.Harris, G.Fountzilas

Inter J Cancer. 1999 Mar 15;80(6):810-7


A PHASE II TRIAL OF PACLITAXEL AND CISPLATIN  IN METASTATIC AND RECURRENT  CARCINOMA OF THE UTERINE CERVIX

C.A.Papadimitriou, K.Sarris, L.A.Moulopoulos, G.Fountzilas, A.Anagnostopoulos, Z.Voulgaris, D.Gika, N.Giannakoulis, E.Diakomanolis, M.A.Dimopoulos

J Clin Oncol. 1999 Mar;17(3):761-6


A PHASE II STUDY WITH IDARUBICIN, VEPESIDE AND PREDNISONE (IVPP), IN  PATIENTS WITH REFRACTORY OR EARLY RELAPSED INTERMEDIATE AND HIGH GRADE NON-HODGKIN’S LYMPHOMA

N.Xiros, T.Economopoulos, G.Fountzilas, N.Pavlidis, E.Samantas, S.Raptis.

Hematologica. 1999 Feb;84(2):189-90


PACLITAXEL AND GEMCITABINE IN ADVANCED  NON-NASOPHARYNGEAL HEAD AND NECK CANCER: A PHASE II STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
G.Fountzilas, G.Stathopoulos, C.Nicolaides, A.Kalogera-Fountzila, H.Kalofonos, A.Nikolaou, C.Bacoyiannis, E.Samantas, C.Papadimitriou, P.Kosmidis, J.Daniilidis, N.Pavlidis.
Ann Oncol. 1999 Apr;10(4):475-8


WEEKLY ALTERNATING NON-CROSS RESISTANT  CHEMOTHERAPY IN GOOD PROGNOSIS SMALL CELL LUNG CANCER
D.V.Skarlos, E.Samantas, D.Pectasides, N.Pavlidis, Ch.Kalofonos, G.Klouvas, E.Panoussaki, E.Tsiakopoulos, N.Poulaki, G.Fountzilas
Am J Clin Oncol 1999 Feb;22(1):87-93


PLATINUM-BASED CHEMOTHERAPY OF PRIMARY EXTRAGONADAL GERM CELL TUMORS. THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE
D.Pectasides, G.Aravantinos, A.Visvikis, Ch.Bakoyiannis, A.Halkia, Ch.Kalofonos, P.Kosmidis, D.Skarlos, G.Fountzilas
Oncology 1999 Jul;57(1):1-9


COMBINATION CHEMOTHERAPY WITH LOW DOSES OF WEEKLY CARBOPLATIN AND ORAL ETOPOSIDE IN POOR RISK SMALL CELL LUNG CANCER
E.Samantas, D.V.Skarlos, D.Pectasides, P.Nicolaides, H.Kalofonos, N.Mylonakis, Th.Vardoulakis, P.Kosmidis, N.Pavlidis, G.Fountzilas
Lung Cancer. 1999 Feb;23(2):159-68


WEEKLY DOCETAXEL IN MINIMALLY PRETREATED  CANCER PATIENT: A DOSE-ESCALATION STUDY FOCUSED ON FEASIBILITY AND CUMULATIVE TOXICITY OF LONG-TERM ADMINISTRATION

E.Briassoulis, V.Karavasilis, D.Anastasopoulos, E.Tzamakou, G.Fountzilas, D.Rammou, V.Kostadima, N.Pavlidis
Ann Oncol. 1999 Jun;10(6):701-6


POSTOPERTIVE RADIATION AND CONCOMITANT BOLUS FLUOROURACIL WITH OR WITHOUT ADDITIONAL CHEMOTHERAPY AS ADJUVANT TREATMENT IN PATIENTS WITH HIGH RISK RECTAL CANCER. A RANDOMIZED PHASE III STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP 
G.Fountzilas, A.Zisiadis, U.Dafni, Ch.Konstantaras, G.Hatzitheoharis, A.Liaros, E.Athanassiou, N.Dombros, Ch.Dervenis, G.Basdanis, O.Gamvros, A.Souparis, E.Briassoulis, E.Samantas, A.Kappas, P.Kosmidis, D.Skarlos, N.Pavlidis
Ann Oncol 1999 Jun;10(6):671-6


EFFECTS ON BLOOD COAGULATION OF ADJUVANT CNF (CYCLOPHOSPHAMIDE, NOVANTRONE, 5-FLUOROURACIL) CHEMOTHERAPY IN STAGE II BREAST CANCER PATIENTS

D.Pectasides, D.Tsavdaridis, Ch.Aggouridaki, V.Tsavdaridou, A.Visvikis, K.Tsatalas, G.Fountzilas
Anticancer Res. 1999 Jul-Aug;19(4C):3521-6


DOCETAXEL AND CISPLATIN COMBINATION CHEMOTHERAPY IN ADVANCED CARCINOMA OF THE UROTHELIUM: A MULTICENTER PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP
M.A.Dimopoulos, C.Bacoyannis, V.Georgoulias, C.Papadimitriou, L.A.Moulopoulos, C.Deliveliotis, A.Karayannis, I.Varkarakis, G.Aravantinos, A.Zervas, D.Pantazopoulos, G.Fountzilas, A.Bamias, Z.Kyriakakis, A.Anagnostopoulos, A.Giannopoulos & P.Kosmidis
Ann Oncol. 1999 Nov;10(11):1385-8


CARBOPLATIN, METHOTREXATE AND 5-FLUOROURACIL IN COMBINATION WITH MEDROXYPROGESTERONE ACETATE (JMF- M) IN THE TREATMENT OF ADVANCED OR RECCURECT ENDOMETRIAL CARCINOMA: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

 D.Bafaloukos, G.Aravantinos, G.Samonis, G.Katsifis, C.Bacoyiannis, D.Skarlos, P.Kosmidis
Oncology 1999 Apr;56(3):198-201


RADIATION AND CONCOMITANT WEEKLY ADMINISTRATION OF PACLITAXEL IN PATIENTSWITH GLIOBLASTOMA MULTIFORME. A PHASE II STUDY

 G.Fountzilas, A.Karavelis, A.Capizzello, A.Kalogera-Fountzila, G.Karkavelas, N.Zamboglou, P.Selviaridis, G.Foroglou, Achilles Tourkantonis.

J Neuro- Oncol 1999;45(2):159-65


SQUAMOUS CELL CARCINOMA ANTIGEN, CIRCULATING IMMUNE COMPLEXES AND IMMUNOGLOBULINS IN MONITORING SQUAMOUS CELL CARCINOMA OF HEAD AND NECK. A STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)

 P.Makrantonakis, D.Pectasides, Ch.Aggouridakis, A.Visvikis, J.Daniilidis, G.Fountzilas

Am J Clin Oncol. 1999 Dec;22(6):542-9


IRINOTECAN (CPT-11) IN PATIENTS WITH ADVANCED COLORECTAL CANCER PREVIOUSLY TREATED WITH  h 5-FLUOROURACIL-BASED CHEMOTHERAPY
G.Aravantinos, D.Skarlos, P.Kosmidis, V.Georgoulias, I.Sgouros, D.Bafaloukos, N.Androlakis, S.Florou, A.Athanassiades, G.Fountzilas
Crit Rev Oncol Hematol. 1999 Dec;32(3):209-19


RADIOIMMUNOSCINTIGRAPHY IN PATIENTS WITH OVARIAN CANCER

H. P. Kalofonos, C. Giannakenas, C. Kosmas, D. Apostolopoulos, A. Onienadum, T. Petsas, D. Dimopoulos, A.A. Epenetos, P.J. Vassilakos

Acta Oncol 1999;38(5):629-34

Δημοσιεύσεις 2000

ANTHRACYCLINE-BASED CHEMOTHERAPY OF PRIMARY NON-HODGKIN’S LYMPHOMA OF THE TESTIS: THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE

D.Pectasides, Th.Economopoulos, G.Kouvatseas, A.Antoniou, Z.Zoumbos, G.Aravantinos, C.Tsatalas, A.Halkia, C.Nikolaides, Ch.Kiamouris, E.Pappa, N.Pavlidis, D.Skarlos, G.Fountzilas, M.A.Dimopoulos

Oncology 2000 May;58(4):286-92


SECOND-LINE CHEMOTHERAPY WITH WEEKLY OXALIPLATIN AND HIGH-DOSE  5-FLUOROURACIL WITH FOLINIC ACID IN  METASTATIC COLORECTAL CARCINOMA: A HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) PHASE II FEASIBILITY STUDY

J.Janinis, P.Papakostas, G.Samelis, D.Skarlos, P.Papagianopoulos, & G.Fountzilas

Ann Oncol. 2000 Feb;11(2):163-7


FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT INTERFERON ALFA-2a AS ADJUVANT TREATMENT, IN PATIENTS WITH HIGH-RISK COLON CANCER A RANDOMIZED PHASE III STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP

G.Fountzilas, A. Zisiadis, U. Dafni, C. Konstantaras, G. Hatzitheoharis, S. Papavramidis, A. Bousoulegas, G. Basdanis, E. Giannoulis, J. Dokmetzioglou, C. Katsohis, E. Nenopoulou, N. Karvounis, E. Briassoulis, G. Aravantinos, P. Kosmidis, D. Skarlos, N. Pavlidis

Oncology. 2000 Apr;58(3):227-36


IFOSFIMIDE PLUS ORAL ETOPOSIDE SALVAGE CHEMOTHERAPY FOR PLATINUM-RESISTANT PACLITAXEL-PRETREATED OVARIAN CANCER

G. Aravantinos, MA Dimopoulos, P. Kosmidis, D. Bafaloukos, Ch Papadimitriou, Ch Kiamouris, N. Pavlidis, K. Sikiotis K, P. Papakostas and DV Skarlos

Ann Oncol. 2000 May;11(5):607-12


DOCETAXEL AND GEMCITABINE IN ANTHRACYCLINE-RESISTANT ADVANCED BREAST CANCER. A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

G.Fountzilas, C.Nicolaides, D.Bafaloukos, A.Kalogera-Fountzila, H.Kalofonos, G.Samelis, G.Aravantinos, N.Pavlidis

Cancer Invest 2000;18(6):503-9


COMBINATION CHEMOTHERAPY WITH PACLITAXEL PLUS CARBOPLATIN VERSUS PACLITAXEL PLUS GEMCITABINE IN INOPERABLE NON-SMALL CELL LUNG CANCER: A PHASE III RANDOMIZED STUDY

P. Kosmidis, N. Mylonakis, A. Dimopoulos, N. Pavlidis, G. Fountzilas, E. Samantas, K. Dimitriadis, H.P. Kalofonos, D. Tsavdaridis, D. Skarlos

Semin Oncol. 2000 Feb;27(1 Suppl 2):3-8


GEMCITABINE AND VINORELBINE AS SECOND LINE TREATMENT  IN PATIENTS WITH METASTATIC BREAST CANCER PROGRESSING AFTER FIRST LINE TAXANE-BASED CHEMOTHERAPY. A PHASE II STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP

C. Nicolaides, M.A Dimopoulos, E. Samantas, D. Bafaloukos, H.P Kalofonos, G. Fountzilas, E. Razi, P. Kosmidis, N. Pavlidis

Ann Oncol 2000 Jul;11(7):873-5


CARBOPLATIN PLUS PACLITAXEL IN UNKNOWN PRIMARY CARCINOMA: A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP

E. Briassoulis, H. Kalofonos, D. Bafaloukos, E. Samantas, G. Fountzilas, N. Xiros, D. Skarlos, C. Christodoulou, P. Kosmidis, N. Pavlidis

J Clin Oncol. 2000 Sep;18(17):3101-7


A RANDOMIZED PARALLEL-GROUP, OPEN LABELED STUDY COMPARING ONDANSETRON WITH ONDANSETRON PLUS DEXAMETHASONE PATIENTS WITH METASTATIC BREAST CANCER RECEIVING HGH DOSE EPIRUBICIN AS A FIRST LINE CHEMOTHERAPY

J.Janinis, T.Giannakakis, A.Athanassiades, G.Fountzilas, D.Bafaloukos, P.Kosmidis, C.Nicolaides, N.Pavlidis, D.Skarlos

Tumori. 2000 Jan-Feb;86(1):37-41


BURKITT’S LYMPHOMA IN GREEK ADULTS. A STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP

T. Economopoulos, MA Dimopoulos, A. Foudoulakis, C. Nikolaidis, C. Tsatalas, D. Pectasides, N. Xiros, D. Rontogianni, E. Papageorgiou, G. Fountzilas

Leuk Res. 2000 Dec;24(12):993-8


PHASE II STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN: IS INACTIVE IN RECURRENT SMALL CELL LUNG CANCER

E. Samantas, H. Kalofonos, H. Linardou, C. Nikolaides, N. Mylonakis, G. Fountzilas, P. Kosmidis, D. Skarlos

Ann Oncol. 2000 Nov;11(11):1395-7


PACLITAXEL AND CISPLATIN IN ADVANCED OR RECURRENT CARCINOMA OF THE ENDOMETRIUM: LONG-TERM RESULTS OF A PHASE II MULTICENTER STUDY

MA. Dimopoulos, CA. Papadimitriou, V. Georgoulias, LA. Moulopoulos, G. Aravantinos, D. Gika, S. Karpathios, S. Stamatelopoulos

Gynecol Oncol. 2000 Jul;78(1):52-7


PACLITAXEL (175 mg/m2) PLUS CARBOPLATIN 6 AUC VERSUS PACLITAXEL (225 PLUS CARBOPLATIN 6 AUC IN ADVANCED NON-SMALL-CELL  LUNG CANCER (NSCLC): A MULTICENTER RANDOMIZED TRIAL

P.Kosmidis, N.Mylonakis, D.Skarlos, E.Samantas, M.Dimopoulos, C.Papadimitriou, C.Kalofonos, N.Pavlidis, C.Nikolaides, C.Papaconstantinou, G.Fountzilas

Ann Oncol. 2000 Jul;11(7):799-805


DOSE-DENSE SEQUENTIAL CHEMOTHERAPY WITH EPIRUBICIN AND PACLITAXEL IN ADVANCED BREAST CANCER. A PHASE II STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP

E. Razi, A.M.Dimopoulos, D. Bafaloukos, C. Papadimitriou, A. Kalogera-Fountzila, H. Kalofonos, E. Briassoulis, E. Samantas, A. Keramopoulos, N. Pavlidis, P. Kosmidis, G. Fountzilas

Cancer Invest. 2000; 19:1-8


C-erbB-2 ONCOPROTEIN IS OVEREXPRESSED IN POORLY VASCULARISED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, BUT IS NOT ASSOCIATED WITH RESPONSE TO CYTOTOXIC THERAPY OR SURVIVAL

A. Giatromanolaki, M.I. Koukourakis, E. Sivridis, G. Fountzilas

Anticancer Res. 2000 Mar-Apr;20(2A):997-1004


BRCA 1 MUTATION ANALYSIS IN BREAST CANCER/OVARIAN CANCER FAMILIES FROM GREECE

I. Konstantopoulou, C. Kroupis, A. Ladopoulou, A. Pentazidis, D. Boumba, E. Lianidou, MB. Petersen, L. Florentin, E. Chiotellis, G. Nounesis, E. Efstathiou, D. Skarlos, C. Tsionou, G. Fountzilas, D. Yannoukakos

Hum Mutat. 2000 Sep;16(3):272-3


ANGIOGENESIS, THYMIDINE PHOSPHORYLASE AND RESISTANCE OF SQUAMOUS CELL HEAD AND NECK CANCER TO CYTOTOXIC AND RADIATION THERAPY

M.I. Koukourakis, A. Giatromanolaki, G. Fountzilas, E. Sivrdis, K.C. Gatter, A.L. Harris

Clin Cancer Res. 2000 Feb;6(2):381-9


TUMOR SPECIFIC ACTIVATION OF THE VEGF/KDR ANGIOGENIC PATHWAY IN A SUBSET F LOCALLY ADVANCED SQUAMOUS CELL HEAD AND NECK CARCINOMA

A. Giatromanolaki, M.I. Koukourakis, E. Sivridis, PE. Thorpe, RA. Brekken K. Simopoulos, G. Fountzilas, KC. Gatter, AL. Harris

Clin Exp Metastasis. 2000;18(4):313-9

Δημοσιεύσεις 2001

DOSE-DENSE SEQUENTIAL CHEMOTHERAPY WITH EPIRUBICIN AND PACLITAXEL VERSUS THE COMBINATION, AS FIRST-LINE CHEMOTHERAPY, IN ADVANCED BREAST CANCER: A RANDOMIZED STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP

G. Fountzilas, C. Papadimitriou, U. Dafni, D. Bafaloukos, D. Skarlos, L.A. Moulopoulos, E. Razis, H.P. Kalofonos, G. Aravantinos, E. Briassoulis, P. Papakostas, K. Abela, E. Gogas, P. Kosmidis, N. Pavlidis and M.A. Dimopoulos

J Clin Oncol. 2001 Apr 15;19(8):2232-9


DOSE-DENSE SEQUENTIAL CHEMOTHERAPY WITH EPIRUBICIN AND PACLITAXEL IN ADVANCED BREAST CANCER

E. Razis, A.M. Dimopoulos, D. Bafaloukos, C. Papadimitriou, A. Kalogera-Fountzila, H.P. Kalofonos, E. Briassoulis, E. Samantas, A. Keramopoulos, N. Pavlidis, P. Kosmidis and G. Fountzilas

Cancer Invest. 2001;19(2):137-44


FIRST-LINE CHEMOTHERAPY WITH DOCETAXELFOR UNRESECTABLE OR METASTATIC CARCINOMA OF THE BILIARY TRACT.A MULTICENTRE PHASE II STUDY

P. Papakostas, C. Kouroussis, N. Androulakis, G. Samelis, G. Aravantinos, K. Kalbakis, E. Sarra, J. Souglakos, S. Kakolyris, V. Georgoulias

Eur J Cancer. 2001 Oct;37(15):1833-8


NUCLEAR EXPRESSION OF HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE (HAP1/REF-1) IN HEAD-AND-NECK CANCER IS ASSOCIATED WITH RESISTANCE TO CHEMORADIOTHERAPY AND POOR OUTCOME

M.I. Koukourakis, A. Giatromanolaki, S. Kakolyris, E. Sivridis, V. Georgoulias, G. Fountzilas, I.D. Hickson, K.C. Gatter and A.L. Harris

Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):27-36


PHASE II STUDY OF TEMOZOLOMIDE IN HEAVILY PRETREATED CANCER PATIENTS WITH BRAIN METASTASES

C. Christodoulou, D. Bafaloukos, P. Kosmidis, E. Samantas, A. Bamias, P. Papakostas, A. Karabelis, C. Bacoyiannis & D.V. Skarlos

Ann Oncol. 2001 Feb;12(2):249-54


AN OUT-PATIENT SECOND-LINE CHEMOTHERAPY WITH GEMCITABINE AND VINORELBINE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH CISPLATIN-BASED CHEMOTHERAPY. A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP

D. Pectasides, H.P Kalofonos, E. Samantas, C. Nicolaides, P. Papacostas, A. Onyenadum, A. Visvikis, D. Skarlos, G. Fountzilas

Anticancer Res. 2001 Jul-Aug;21(4B):3005-10


G-CSF INDUCES ELEVATION OF THE CIRCULATINGCA 15-3 IN BREAST CARCINOMA PATIENTS TREATED IN AN ADJUVANT SETTING

E. Briassoulis, E. Andreopoulou, C.F. Tolis, E. Bairaktari, A. Katsaraki, M.A. Dimopoulos, G. Fountzilas, C. Seferiadis, N. Pavlidis

Cancer. 2001 Mar 1;91(5):909-17


THALIDOMIDE AND DEXAMETHASONE COMBINATION FOR REFRACTORY MULTIPLE-MYELOMA

M.A Dimopoulos, K. Zervas, G. Kouvatseas, E. Galani, V. Grigoraki, C. Kiamouris, E. Vervessou, E. Samantas, C. Papadimitriou, O. Economou, D. Gika, P. Panayiotidis, I. Christakis, N. Anagnostopoulos

Ann Oncol. 2001 Jul;12(7):991-5


CORRELATION OF IN VITRO CYTOTOXICITY AND CLINICAL RESPONSE TO CHEMOTHERAPY IN OVARIAN AND BREAST CANCER PATIENTS

G. Agiostratidou, I. Sgouros, E. Galani, A. Voulgari, N. Chondrogianni, E. Samantas, M.A Dimopoulos , D. Skarlos, E.S Gonos

Anticancer Res. 2001 Jan-Feb;21(1A):455-9


DOSE-DENSE SEQUENTIAL ADJUVANCT CHEMOTHERAPY WITH EPIRUBICIN, PACLITAXEL AND CMF IN HIGH-RISK BREAST CANCER

G. Fountzilas, C. Papadimitriou, G. Aravantinos, C. Nicolaides, G. Stathopoulos, D. Bafaloukos, H.P. Kalofonos, T. Economopoulos, D. Skarlos, N. Pavlidis, A.M. Dimopoulos

Oncology. 2001;60(3):214-20


BAX PROTEIN EXPRESSION IN COLORECTAL CANCER: ASSOCIATION WITH p53, bcl-2 AND PATTERNS OF RELAPSE

A. Giatromanolaki, E. Sivridis, G. Stathopoulos, G. Fountzilas, H.P. Kalofonos, A. Tsamandas, E. Vrettou, C. Scopa, A. Polychronidis, K. Simopoulos and M.I. Koukourakis

Antincancer Res. 2001 Jan-Feb;21(1A):253-9


KOMBINIERTE RADIOCHEMOTHERAPIE BEI LOKAL FORTGESCHRITTENEM NASOPHARYNXKARZINOM

J. Daniilidis, J. Constantinidis, G. Fountzilas

HNO. 2001 Sep;49(9):732-8


RANDOMIZED COMPARISON OF EARLY VERSUS LATE HYPERFRACTIONATED THORACIC IRRADIATION CONCURRENTLY WITH CHEMOTHERAPY IN LIMITED DISEASE SMALL-CELL LUNG CANCER: A RANDOMIZED PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)

D.V. Skarlos, E. Samantas, E. Briassoulis, E. Panoussaki, N. Pavlidis, H.P. Kalofonos, D. Kardamakis, E. Tsiakopoulos, P. Kosmidis, D. Tsavdaridis, J. Tzitzikas, P. Tsekeris, G. Kouvatseas, N. Zamboglou & G. Fountzilas

Ann Oncol. 2001 Sep;12(9):1231-8


COMBINATION CHEMOTHERAPY WITH GEMCITABINE AND IFOSFAMIDE AS SECOND-LINE TREATMENT IN METASTATIC UROTHELIAL CANCER. A PHASE II TRIAL CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP

D. Pectasides, G. Aravantinos, H.P. Kalofonos, C. Kiamouris, D. Bafaloukos, N. Xiros, C. Nicolaides, A. Visvikis & M.A. Dimopoulos

Ann Oncol. 2001 Oct;12(10):1417-22


WEEKLY PACLITAXEL, AS FIRST LINE CHEMOTHERAPY AND TRASTUZUMAB IN PATIENTS WITH ADVANCED BREAST CANCER

G. Fountzilas, D. Tsavdaridis, A. Kalogera-Fountzilas, C. Christodoulou, E. Timotheadou, H.P. Kalofonos, P. Kosmidis, A. Adamou, P. Papakostas, H. Gogas, D. Bafaloukos, D. Skarlos

Ann Oncol. 2001 Nov;12(11):1545-51


FIRST LINE COMBINATION CHEMOTHERAPY WITH DOCETAXEL AND VINORELBINE IN ADVANCED BREAST CANCER. A PHASE II STUDY

D. Pectasides, M.A Dimopoulos, G. Aravantinos, H.P. Kalofonos, P. Papakostas, E. Briasoulis, E. Goga, C. Papadimitriou, D. Skarlos, P. Kosmidis, G. Fountzilas

Anticancer Res. 2001 Sep-Oct;21(5):3575-80


PACLITAXEL: EPIRUBICIN IN METASTATIC BREAST CANCER-A REVIEW

E.D. Razis & G. Fountzilas

Ann Oncol. 2001 May;12(5):593-8


ANGIOGENESIS AND APOPTOSIS-RELATED PROTEIN (p53, bcl-2, and bax) EXPRESSION VERSUS RESPONSE OF GASTRIC ADENOCARCINOMAS TO PACLITAXEL AND CARBOPLATIN

A. Giatromanolaki, G.P. Stathopoulos, M.I. Koukourakis, S. Rigatos, E. Vrettou, C. Kittas, G. Fountzilas and E. Sivridis

Am J Clin Oncol. 2001 Jun;24(3):222-6

Δημοσιεύσεις 2002

TEMOZOLOMIDE IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH ADVANCED MELANOMA: A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP
Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, Fountzilas G, Samantas E, Kalofonos Ch, Skarlos D, Karabelis A, Kosmidis P
J Clin Oncol. 2002 Jan 15;20(2):420-5


PACLITAXEL AND CARBOPLATIN IN PRETREATED ADVANCED GASTRIC CANCER: A PHASE II STUDY
G.P Stathopoulos, S.K Rigatos, G. Fountzilas, A. Polyzos, J.G Stathopoulos
Oncol Rep. 2002 Jan-Feb;9(1):89-92


PRIMARY TREATMENT OF LOW-GRADE NON-HODGKIN’S LYMPHOMA WITH THE COMBINATION OF FLUDARABINE AND MITOXANTRONE: A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP
M.A. Dimopoulos, G. Fountzilas, E. Papageorgiou, C. Kiamouris, G. Mantzios, A. Anagnostopoulos, C. Nicolaides and T. Economopoulos
Leuk Lymphoma. 2002 Jan;43(1):111-4


COMBINATION OF IFOSFAMIDE, PACLITAXEL, AND CICPLATIN FOR THE TREATMENT OF METASTATIC AND RECURRENT CARCINOMA OF THE UTERINE CERVIX: A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP
M.A. Dimopoulos, C.A. Papadimitriou, K. Sarris, G. Aravantinos, H.P. Kalofonos, D. Gika, G.M. Gourgoulis, E. Efstathiou, D. Skarlos and D. Bafaloukos
Gynecol Oncol. 2002 Jun;85(3):476-82


A PHASE III STUDY OF 5-FLUOROURACIL VS 5-FLUOROURACIL PLUS INTERERON ALPHA 2b VS 5-FLUOROURACIL PLUS LEUCOVORIN IN PATIENTS WITH ADVANCED COLORECTAL CANCER. A HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) STUDY
H.P. Kalofonos, C. Nicolaides, E. Samantas, N. Mylonakis, G. Aravantinos, M.A. Dimopoulos, C. Gennatas, G. Kouvatseas, E. Giannoulis, C. Dervenis, G. Basdanis, N. Pavlidis, I. Androulakis and G. Fountzilas
Am J Clin Oncol. 2002 Feb;25(1):23-30


VINBLASTINE AND INTERFERON-GAMMA COMBINATION WITH AND WITHOUT 13-Cis RETINOIC ACID FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
C. Bacoyiannis, M.A. Dimopoulos, H.P. Kalofonos, C. Nicolaides, G. Aravantinos, D. Bafaloukos, G. Samelis, A. Onyenadum, Ch. Kiamouris, D. Skarlos, N. Pavlidis, A. Triantafillidis, P. Kosmidis
Oncology. 2002;63(2):130-8


TREATMENT OF INTERMEDIATE-AND HIGH-GRADE NON-HODGKIN’S LYMPHOMA USING CEOP VERSUS CNOP. A HELLENIC COOPERATIVE ONCOLOGY GROUP
T. Economopoulos, MA Dimopoulos, S. Mellou, N. Pavlidis, E. Samantas, C. Nicolaides, C. Tsatalas, A. Papadopoulos, E. Papageorgiou, P. Papasavvas, G. Fountzilas
Eur J Haematol. 2002 Mar;68(3):135-43


PROGNOSTIC SIGNIFICANCE OF THE SEQUENTIAL DETECTION OF CIRCULATING MELANOMA CELLS BY RT-PCR IN HIGH-RISK MELANOMA PATIENTS RECEIVING ADJUVANT INTERFERON
H. Gogas, G. Kefala, D. Bafaloukos, K. Frangia, A. Polyzos, D. Pectasides, D. Tsoutsos, P. Panagiotou, J. Joannovich and D. Loukopoulos
Br J Cancer. 2002 Jul 15;87(2):181-6


INTRATUMORAL DOXORUBICIN IN PATIENTS WITH MALIGNANT BRAIN GLIOMAS
S. Voulgaris, M. Partheni, M. Karamouzis, P. Dimopoulos, N. Papadakis and H.P. Kalofonos
Am J Clin Oncol. 2002 Feb;25(1):60-4


PACLITAXEL PLUS CARBOPLATIN VERSUS GEMCITABINE PLUS PACLITAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER: A PHASE III RANDOMIZED TRIAL
P. Kosmidis, N. Mylonakis, C. Nicolaides, H.P. Kalofonos, E. Samantas, J. Boukovinas, G. Fountzilas, D. Skarlos, T. Economopoulos, D. Tsavsaridis, P. Papakostas, C. Bacoyiannis, and M. Dimopoulos
J Clin Oncol. 2002 Sep 1;20(17):3578-85


A CHANGE IN THE LAST BASE OF BRCA1 EXON 23, 5586G -> A, RESULTS IN THE ABNORMAL RNA SPLICING
A. Ladopoulou, I. Konstantopoulou, S. Armaou, E. Efstathiou, M. Mihalatos, G. Nasioulas, G. Bardi, N. Pandis, D. Yannoukakos
Cancer Genet Cytogenet. 2002 Apr 15;134(2):175-7


LYMPHOCYTE SUBPOPULATIONS AND INTERLEUKIN LEVELS IN HIGH-RISK MELANOMA PATIENTS TREATED WITH HIGH-DOSE INTERFERON A-2B
H. Gogas, G. Paterakis, K. Frangia, D. Bafaloukos, D. Pectasides, H.P. Kalofonos, D. Loukopoulos, C. Stavropoulou-Giokas, J. Joannovich and M.C. Mihm Jr
Am J Clin Oncol. 2002 Dec;25(6):591-6


PROGNOSTIC FACTORS IN GREEK PATIENTS WITH SMALL CELL LUNG CANCER (SCLC). A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
C. Christodoulou, N. Pavlidis, E. Samantas, G. Fountzilas, G. Kouvatseas, K. Pagdatoglou, F. Palamidas, C. Nicolaidis, M. Angelidou, H.P. Kalofonos, P. Kosmidis and D.V. Skarlos
Anticancer Res. 2002 Nov-Dec;22(6B):3749-57


TUMOR VOLUMETRY AS PREDICTIVE AND PROGNOSTIC FACTORS IN THE MANAGEMENT OF OVARIAN CANCER
E. Andreopoulou, D. Andreopoulos, C. Adamides, A. Kalogera-Fountzila, G. Fountzilas, M.A. Dimopoulos, G. Aravantinos, N. Zamboglou, D. Baltas, N. Pavlidis
Anticancer Res. 2002 May-Jun;22(3):1903-8


GERM LINE BRCA1 & BRCA2 MUTATION IN GREEK BREAST/OVARIAN CANCER FAMILIES: 5382insC IS THE MOST FREQUENT MUTATION OBSERVED
A.Ladopoulou, C.Kroupis, I.Konstantopoulou, L.Ioannidou-Mouzaka, A.C.Schofield, A.Pantazidis, S.Armaou, I.Tsiagas, E.Lianidou, E.Efstathiou, C.Tsionou, C.Panopoulos, M.Mihalatos, G.Nasioulas D.Skarlos, N.E.Haites G.Fountzilas, N.Pandis D.Yannoukakos
Cancer Lett. 2002 Nov 8;185(1):61-70


NEOADJUVANT CHEMOTHERAPY WITH COMBINATION OF PEGYLATED LPOSOMAL DOXORUBICIN (CAELYX) AND PACLITAXEL IN LOCALLY ADVANCED BREAST CANCER. A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)
H.Gogas, C.Papadimitriou, H.P.Kalofonos, D.Bafaloukos, G.Fountzilas, D.Tsavdaridis, A.Anagnostopoulos, A.Onyenadum, P.Papakostas, T.Economopoulos, C.Christodoulou, P.Kosmidis, C.Markopoulos.
Ann Oncol. 2002 Nov;13(11):1737-42


IRINOTECAN AND VINORELBINE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH PLATINUM-BASED CHEMOTHERAPY. A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP
D. Pectasides, G. Fountzilas, A. Rigopoulos, N.G. Bountouroglou, A. Koutras, J. Glotsos, A. Onyenadum, Th. Makatsoris, H.P. Kalofonos
Anticancer Res. 2002 Nov-Dec;22(6B):3501-6


DOCETAXEL IN COMBINATION WITH DACARBAZINE IN PATIENTS WITH ADVANCED MELANOMA
D. Bafaloukos, G. Aravantinos, G. Fountzilas, G. Stathopoulos, H. Gogas, G. Samonis, E. Briasoulis, N. Mylonakis, D.V. Skarlos, P. Kosmidis
Oncology. 2002;63(4):333-7

Δημοσιεύσεις 2003

PREVENTION OF ANEMIA IN PATIENTS WITH SOLID TUMORS RECEIVING PLATINUM BASED CHEMOTHERAPY BY RECOMBINANT HUMAN ERYTHROPOIETIN (RHUEPO): A PROSPECTIVE, OPEN LABEL, RANDOMIZED TRIAL BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
Bamias, G. Aravantinos, H.P. Kalofonos, N. Timotheadou, V. Siafaka, I. Vlahou, D. Janinis, D. Pectasides, N. Pavlidis, G. Fountzilas
Oncology. 2003;64(2):102-10


ADJUVANT CHEMOTHERAPY USING CPT-11, LEUCOVORIN PLUS BOLUS 5-FLUOROURACIL AND RADIOTHERAPY IN PATIENTS WITH RECTAL CANCER. A FEASIBILITY STUDY
H.P. Kalofonos, D. Kardamakis, A. Bamias, D. Skarlos, P. Papakostas, D. Bafaloukos, A. Sakantamis, N. Pavlidis and G. Fountzilas
Anticancer Res. 2003 Mar-Apr;23(2C):1687-91


RITUXIMAB IN COMBINATION WITH CNOP CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED INDOLENT NON-HODGKIN’S LYMPHOMA
T. Economopoulos, G. Fountzilas, N. Pavlidis, D. Kalantzis, E. Papageorgiou, C. Christodoulou, G. Hamilos, C. Nicolaides and M. Dimopoulos
Hematol J. 2003;4(2):110-5


TREATMENT OF PANCREATIC CANCER WITH A COMBINATION OF IRINOTECAN (CPT-11) AND GEMCITABINE: A MULTICENTER PHASE II STUDY BY THE GREEK COOPERATIVE GROUP FOR PANCREATIC CANCER
G.P. Stathopoulos, S.K. Rigatos, M.A.Dimopoulos, T. Giannakakis, G. Fountzilas, C. Kouroussis, D. Janninis, G. Aravantinos, N. Androulakis, S. Agelaki, J.G. Stathopoulos & V. Georgoulias
Ann Oncol. 2003 Mar;14(3):388-94


PHASE II STUDY OF DOCETAXEL-VINORELBINE IN PLATINUM-RESISTANT,PACLITAXEL-PRETREATED OVARIAN CANCER
G. Aravantinos, D. Bafaloukos, G. Fountzilas, C. Christodoulou, C. Papadimitriou, N. Pavlides, H.P. Kalofonos, H. Gogas, P. Kosmidis, M.A. Dimopoulos
Ann Oncol. 2003 Jul;14(7):1094-9


RITUXIMAB IN COMBINATION WITH VINORELBINE / GEMCITABINE CHEMOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSED T CELL RICH B CELL LYMPHOMA. A PILOT STUDY
N. Xiros, T. Economopoulos, S. Valsami, D. Rontogianni, G. Fountzilas, S. Raptis
Leuk Res. 2003 Dec;27(12):1097-9


CONTINUATION OF TRASTUZUMAB BEYOND DISEASE PROGRESSION IS SAFE AND EFFECTIVE IN PATIENTS WITH ADVANCED BREAST CANCER
G. Fountzilas, E. Razis, D. Tsavdaridis, M. Karina, S. Lambropoulos, C. Christodoulou, D. Mavroudis, H. Gogas, V. Georgoulias, D. Skarlos
Clin Breast Cancer. 2003 Jun;4(2):120-5


TREATMENT OF INTERMEDIATE AND ADVANCED STAGE HODGKIN’S DISEASE WITH MODIFIED BASELINE BEACOPP REGIMEN: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
T. Economopoulos, G. Fountzilas, M.A. Dimopoulos, S. Papageorgiou, N. Xiros, D. Kalantzis, J. Dervenoulias, S. Raptis
Eur J Hematol 2003 Oct;71(4):257-62


DOCETAXEL AND GEMCITABINE COMBINATION, AS FIRST-LINE TREATMENT, IN PATIENTS WITH EXTENSIVE DISEASE SMALL-CELL LUNG CANCER. A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP
D.V.Skarlos, A. M. Dimopoulos, P. Kosmidis, P. Papakostas, N. Pavlidis, C. Bacoyiannis, C. Kiamouris, G. Klouvas, H. Gogas, G. Fountzilas, E. Samantas
Lung Cancer. 2003 Jul;41(1):107-11


NOVEL MUTATIONS OF THE APC GENE IN FAMILIAL ADENOMATOUS POLYPOSIS IN GREEK PATIENTS
M.Mihalatos, I.Danielides, J.Belogianni, E.Harokopos, E.Papadopoulou, G.Kalimanis, M.Tsiava, J.K.Triantafillidis, P.A.Kosmidis, G.Fountzilas, G.Basdanis, N.J.Agnantis, D.Yannoukakos, G.Nasioulas

Cancer Genet Cytogenet. 2003 Feb;141(1):65-70


THE ROLE OF TAXANES AS SINGLE-AGENTS OR IN COMBINATION WITH ANTHRACYCLINES IN NEOADJUVANT CHEMOTHERAPY FOR BREAST CANCER. A REVIEW
H.Gogas, G.Fountzilas
Ann Oncol 2003; 14(5): 667-674


USEFULNESS OF TUMOR VOLUMETRY AS A PROGNOSTIC FACTOR OF SURVIVAL IN HEAD AND NECK CANCER
R.Kurek, A.Kalogera-Fountzila, K.Muskalla, U.Dafni, T.Schnabel, B.Kober, S.Roddiger, T.Martin, G.Fountzilas, N.Zamboglou
Strahlenther Onkol. 2003 May;179(5):292-7


TECHNOLOGY EVALUATION : TRIGEM, TITAN
E.Razis, G.Fountzilas
Curr Opin Mol Ther. 2003 Apr;5(2):204-7


EVALUATION OF dHPLC IN MUTATION SCREENING OF THE APC GENE IN A GREEK FAP COHORT
M.Mihalatos, A.Apessos, J.Triantafillidis, P.A.Kosmidis, G.Fountzilas, N.J.Agnantis, D.Yannoukakos, G.Nasioulas
Anticancer Res. 2003 May-Jun;23(3B):2691-5


TWO-CYCLES OF CARBOPLATIN-BASED ADJUVANT CHEMOTHERAPY FOR HIGH-RISK CLINICAL STAGE I AND STAGE IM NON-SEMINOMATOUS GERM CELL TUMOURS OF THE TESTIS: A HECOG TRIAL
D. Pectasides, D. Skarlos, A.M. Dimopoulos, D. Farmakis, M. Pectasides, G. Fountzilas, G. Aravantinos
Anticancer Res. 2003 Sep-Oct;23(5b):4239-44


GENETIC ALTERATIONS OF THE APC GENE IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS OF THE HELLENIC GROUP FOR THE STUDY OF COLORECTAL CANCER
M. Mihalatos, A. Apessos, E. Papadopoulou, N.J. Agnantis, D. Yannoukakos, G. Fountzilas, G. Nasioulas

Anticancer Res. 2003 May-Jun;23(3A):2191-3


RECOMBINANT HUMAN ERYTHROPOIETIN FOR PLATINUM-BASED CHEMOTHERAPY-INDUCED ANAEMIA: A SINGLE-CENTRE RANDOMISED STUDY
G. Aravantinos, H. Linardou, D. Makridaki, E. Laiou, A. Zafiropoulos, J. Janninis, G. Sofos, D. Gikas, E. Samantas, S. Markantoni-Kyroudi
J BUON. 2003 Apr-Jun;8(2):127-32


THE COMBINATION OF ESTRAMUSTINE AND MITOXANTRONE IN HORMONE-REFRACTORY PROSTATE CANCER: A PHASE II FEASIBILITY STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
G.F. Samelis, D. Skarlos, D. Bafaloukos, P. Kosmidis, A. Anagnostopoulos, G. Aravantinos, M.A. Dimopoulos
Urology. 2003 Jun;61(6):1211-5


A PHASE II STUDY WITH CPT-11 PLUS LEUCOVORIN AND BOLUS IV 5-FLUOROURACIL IN PATIENTS WITH ADVANCED COLORECTAL CARCINOMA
H.P. Kalofonos, D. Skarlos, D. Bafaloukos, P. Papakostas, A. Bamias, J. Janinis, E. Timotheadou, G. Kouvatseas, M. Stavropoulou, T. Economopoulos, G. Fountzilas
Cancer Invest. 2003;21(6):855-62


PROGNOSTIC SIGNIFICANCE OF CA 125, CD44 AND EPITHELIAL MEMBRANE ANTIGEN IN RENAL CELL CARCINOMA
Bamias, M. Chorti, C. Deliveliotis, N. Trakas, A. Skolarikos, B. Protogerou, S. Legaki, G. Tsakalou, N. Tamvakis and M.A. Dimopoulos
Urology. 2003 Aug;62(2):368-73

Δημοσιεύσεις 2004

ADJUVANT CYTOTOXIC AND ENDOCRINE THERAPY IN PRE- AND POST MENOPAUSAL PATIENTS WITH BREAST CANCER AND 1-9 INFILTRATED NODES: 5 YEAR RESULRS OF HeCOG RANDOMISED HE 10/92 STUDY
G.Fountzilas, G.Stathopoulos, G.Kouvatseas, A.Polychronis, G.Klouvas, E.Samantas, N.Zamboglou, K.Kyriakou, A.Adamou, D.Pectasidis, Th.Ekonomopoulos, Ch.Kalofonos, D.Bafaloukos, V.Georgoulias, E.Razi, D.Koukouras, V.Zombolas, P.Kosmidis, D.Skarlos, N.Pavlidis
Am J Clin Oncol. 2004 Feb;27(1):57-67


CONCOMITANT RADIO-CHEMOTHERAPY VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH HEAD AND NECK CANCER. A HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE III STUDY
G.Fountzilas, E.Ciuleanu, U.Dafni, G.Plataniotis, A.Kalogera-Fountzila, E.Samantas, E.Athanassiou, J.Tzitzikas, T.Ciuleanu, A.Nikolaou, P.Pantelakos, T.Zaraboukas, N.Zamboglou, J. Daniilidis, N. Ghilezan

Med Oncol. 2004;21(2):95-107


PACLITAXEL AND EPIRUBICIN VERSUS PACLITAXEL AND CARBOPLATIN, AS FIRST LINE CHEMOTHERAPY, IN PATIENTS WITH ADVANCED BREAST CANCER. A PHASE III STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
G. Fountzilas, H.P. Kalofonos, U. Dafni, C. Papadimitriou, D. Bafaloukos, P. Papakostas, A. Kalogera-Fountzila, H. Gogas, G. Aravantinos, L.A. Moulopoulos, T. Economopoulos, D. Pectasides, N. Maniadakis, V. Siafaka, E. Briasoulis, C. Christodoulou, D. Tsavdaridis, P. Makrantonakis, E. Razis, P. Kosmidis, D. Skarlos, M.A. Dimopoulos
Ann Oncol.2004 Oct;15(10):1517-26


PACLITAXEL AND GEMCITABINE, AS FIRST LINE CHEMOTHERAPY, COMBINED WITH TRASTUZUMAB IN PATIENTS WITH ADVANCED BREAST CANCER
G. Fountzilas, C. Christodoulou, D. Tsavdaridis, A. Kalogera-Fountzila, G. Aravantinos, E. Razis, J. Kostopoulos, H.P. Kalofonos, P. Papakostas, M. Karina, H. Goga, D. Skarlos.
Cancer Invest. 2004;22(5):655-62


SECOND LINE CHEMOTHERAPY WITH 5-FLUOROURACIL AND VINORELBINE IN ANTHRACYCLINE AND TAXANE PRETREATED PATIENTS WITH METASTATIC BREAST CANCER
E.Razis, P.Kosmidis, G.Aravantinos, C.Bacoyiannis, J.Janninis, H.Timotheadou, C.Christodoulou, G.Fountzilas
Cancer Invest. 2004;22(1):10-5


CONTINUATION OF TRASTUZUMAB BEYOND DISEASE PROGRESSION: MORE QUESTIONS THAN ANSWERS
E.Razis, G.Fountzilas.
Clin Br Cancer 2004;5:59-62


DOCETAXEL AND CISPLATIN WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) VERSUS M-VAC WITH G-CSF IN ADVANCED UROTHELIAL CARCINOMA: A MULTICENTER, RANDOMISED, PHASE III SUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
Α. Bamias, G. Aravantinos, Ch. Deliveliotis, D. Bafaloukos, H.P. Kalofonos, N. Xiros, A. Zervas, D. Mitropoulos, E. Samantas, D. Pectasides, P. Papakostas, D. Gika, C. Kourousis, A. Koutras, C. Papadimitriou, C. Bamias, P. Kosmidis, M.A. Dimopoulos
J. Clin Oncol. 2004 Jan 15;22(2):220-8


ADJUVANT CHEMOTHERAPY WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED CARCINOMA OF THE UPPER URINARY TRACT. A STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
A. Bamias, Ch. Deliveliotis, G. Fountzilas, D. Gika, A. Anagnostopoulos, M.P. Zorzou, E. Kastritis, C. Konstantindis, P. Kosmidis, M.A. Dimopoulos.
J Clin Oncol. 2004 Jun 1;22(11):2150-4


ADJUVANT CHEMOTHERAPY WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED BLADDER CANCER: A STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
A.Bamias, Ch.Deliveliotis, G.Aravantinos, H.P.Kalofonos, A. Karayiannis, M.A. Dimopoulos
J Urol. 2004 Apr;171(4):1467-70


INTENSIFIED BIMONTHLY CISPLATIN WITH BOLUS 5-FLUOROURACIL, CONTINUOUS 5-FLUOROURACIL AND HIGH DOSE LEUCOVORIN (LV5FU2) IN PATIENTS WITH ADVANCED GASTROINTESTINAL CARCINOMAS: A PHASE I DOSE-FINDING AND PHARMACOKINETIC STUDY
A. Bamias, K. Syrigos, G. Fountzilas, E. Tzamakou, K. Soulti, V. Karavasilis, Y. Alamanos, C. Christodoulou, N. Pavlidis
Am J Clin Oncol. 2004 Oct;27(5):465-71


SECOND-LINE CHEMOTHERAPY WITH GEMCITABINE AND CARBOPLATIN IN PACLITAXEL PRETREATED, PLATINUM-SENSITIVE OVARIAN CANCER PATIENTS
Ch.A. Papadimitriou, G. Fountzilas, G. Aravantinos, Ch. Kalofonos, L.A. Moulopoulos, E. Briassoulis, D. Gika, M-A. Dimopoulos
Gynecol Oncol. 2004 Jan;92(1):152-9


GEMCITABINE AND OXALIPLATIN (GEMOX) IN PATIENTS WITH CISPLATIN-REFRACTORY GERM CELL TUMORS. A PHASE II STUDY
D. Pectasides, M. Pectasides, D. Farmakis, G. Aravantinos, M. Nikolaou, M. Koumpou, A. Gaglia, V. Kostopoulou, N. Mylonakis, D. Skarlos
Ann Oncol. 2004 Mar;15(3):493-7


FRONT-LINE TREATMENT OF INOPERABLE OR METASTATIC PANCREATIC CANCER WITH GEMCITABINE AND CAPECITABINE: AN INTERGROUP, MULTICENTER, PHASE II STUDY
G. P. Stathopoulos, K. Syrigos, A. Polyzos, G. Fountzilas, S. K. Rigatos, N. Ziras, A. Potamiannou, I. Tsiakopoulos, N. Androulakis, G. Aravantinos, A. Athanasiadis, P. Papakotoulas, V. Georgoulias
Ann Oncol. 2004 Feb;15(2):224-9


PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE(PLD) AND PACLITAXEL IN RECURRENT OR METASTATIC HEAD AND NECK CARCINOMA: A PHASE I/II STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)
J. Janinis, G.P. Stathopoulos, P. Nikolaidis, H.P. Kalofonos, A. Kalogera-Fountzila, E. Samantas, G. Aravantinos, A. Anagnostopoulos, C. Tolis, T. Makatsoris, S.K. Rigatos, D. Bafaloukos, M.A. Dimopoulos, J. Daniilidis, G. Fountzilas
Anticancer Drugs. 2004 Jun;15(5):479-87


PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA. CLINICAL STUDY OF A DISTINCT CLINICAL ENTITY AND TREATMENT
E. Andreopoulou, D. Pectasides, M.A.D imopoulos, C. Nicolaides, G. Fountzilas, S. Valsami, T. Economopoulos

Am J Clin Oncol. 2004 Jun;27(3):312-6


THE PROGNOSTIC IMPACT OF TUMOR VOLUMENTRY IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CARCINOMAS (NON-NASOPHARYNGEAL) TREATED EITHER BY BY RADIOTHERAPY ALONE OR BY COMBINED RADIOCHEMOTHERAPY IN A RANDOMIZED TRIAL
A.G. Plataniotis, M-E. Theofanopoulou, A. Kalogera-Fountzila, A.A. Haritanti, E. Ciuleanou, N. Ghilezan, N. Zamboglou, A. Dimitriadis I. Sofroniadis, G. Fountzilas
Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1018-26


TOLERABILITY OF ADJUVANT HIGH-DOSE INTERFERON ALFA-2b: 1 MONTH VERSUS 1 YEAR. A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
H. Gogas, D. Bafaloukos, J. Ioannovich, D. karlos, A. Polyzos, G. Fountzilas, H.P. Kalofonos, G. Aravantinos, D. Tsoutsos, P. Panagiotou, K. Frangia, T. Petrakopoulou, D. Pectasides
Anticancer Res. 2004 May-Jun;24(3b):1947-52


VINORELBINE IN COMBINATION WITH INTERLEUKIN-2 AS SECOND LINE TREATMENT IN PATIENTS WITH METASTATIC MELANOMA. A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP
H.Gogas, D.Bafaloukos, G.Aravantinos, G.Fountzilas, D.Tsoutsos, P.Panagiotou, K.Frangia, H.P.Kalofonos, E.Briasoulis, O.Castana, A.Polyzos, D. Pectasides, J.Ioannovich
Cancer Invest. 2004;22(6):832-9


CAVITATING SQUAMOUS CELL LUNG CARCINOMA-DISTINCT ENTITY OR NOT? ANALYSIS OF RADIOLOGICAL, HISTOLOGICAL AND CLINICAL FEATURES
G.Pentheroudakis, L.Kostadima, G.Fountzilas, A.Kalogera-Fountzila, G.Klouvas, C.Kalofonos, N.Pavlidis
Lung Cancer. 2004 Sep;45(3):349-55


METASTATIC BREAST CARCINOMA CONFINED TO BONE: PORTRAIT OF A CLINICAL ENTITY
E. Briasoulis, V. Karavasilis, L. Kostadima, M. Ignatiadis, G. Fountzilas, N. Pavlidis
Cancer. 2004 Oct 1;101(7):1524-8


BIWEEKLY ADMINISTRATION OF 24-h INFUSION OF IRINOTECAN FOLLOWED BY A 1-h INFUSION OF DOCETAXEL: A PHASE I STUDY
E. Briasoulis, G. Pentheroudakis, H. Timotheadou, D. Rammou, N. Pavlidis, G.Fountzilas
Anticancer Drugs. 2004 Sep;15(8):747-52


COMBINATION OF PEGYLATED LIPOSOMAL DOXORUBICIN (PLD)AND PACLITAXEL IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP
D. Bafaloukos, C. Papadimitriou, H. Linardou, G. Aravantinos, P. Papakostas, D. Skarlos, P. Kosmidis, G. Fountzilas, H. Gogas, C. Kalofonos, A.M. Dimopoulos
Br J Cancer. 2004 Nov 1;91(9):1639-44


THE EFFECT OF TEMOZOLOMIDE-BASED CHEMOTHERAPY IN PATIENTS WITH CEREBRAL METASTASES FROM MELANOMA
D. Bafaloukos, D. Tsoutsos, G. Fountzilas, H. Linardou, C. Christodoulou, H.P. Kalofonos, E. Briassoulis, P. Panagiotou, H. Hatzichristou, H. Gogas
Melanoma Res. 2004 Aug;14(4):289-94


THE TREATMENT OF BRAIN METASTASES IN MELANOMA PATIENTS
D. Bafaloukos, H. Gogas
Cancer Treatment Rev. 2004 Oct;30(6):515-20


GEMCITABINE AND CARBOPLATIN COMBINATION AS FIRST-LINE TREATMENT IN ELDERLY AND UNFIT FOR CISPLATIN-BASED CHEMOTHERAPY PATIENTS WITH ADVANCED BLADDER CARCINOMA. A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP
H. Linardou, G. Aravantinos, E. Efstathiou, H. Kalofonos, A. Anagnostopoulos, C. Deliveliotis, D. Bafaloukos, M.A. Dimopoulos, A. Bamias
Urology. 2004 Sep;64(3):479-84


THE PREVALENCE OF HEPATITIS C AND HEPATITIS G VIRUS INFECTION IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN GREECE
E. Giannoulis, K. Mandraveli, K. Giannoulis, C. Nikolaides, E. Zervou, E. Papageorgiou, D. Zoulias, A. Tourkantonis, T. Economopoulos, G.Fountzilas
Acta Hematol. 2004;112(4):189-93


SERUM LEVELS OF bcl-2 IN PATIENTS WITH COLORECTAL CANCER
K. Giannoulis, G. Fountzilas, N. Angouridakis, C. Angouridaki, E. Giannoulis, O. Gamvros
Tech Coloprocto. 2004 Nov;8 Suppl 1:s56-8


SERUM CONCENTRATIONS OF SOLUBLE ICAM-1 AND VCAM-1 IN PATIENTS WITH COLORECTAL CANCER. CLINICAL IMPLICATIONS
K. Giannoulis, C. Angouridaki, G. Fountzilas, C. Papapolychroniadis, E. Giannoulis, O. Gamvros.
Tech Coloproctol. 2004 Nov;8 Suppl 1:s65-7


CHARACTERIZATION OF A NOVEL LARGE DELETION AND SINGLE POINT MUTATIONS IN THE BRCA1 GENE IN A GREEK COHORT OF FAMILIES WITH SUSPECTED HEREDITARY BREAST CANCER
Ι. Belogianni, A. Apessos, M. Mihalatos, E. Razis, S. Labropoulos, A. Petounis, V. Gaki, A. Karamopoulos, N. Pandis, K. Kyriacou, A. Hadjisavas, P. Kosmidis, D. Yannoukakos, G. Nasioulas
BMC Cancer. 2004 Sep 7;4:61


ADRIAMYCIN AND CISPLATINUM AS FIRST LINE TREATMENT IN UNRESECTABLE LOCALLY ADVANCED OR METASTATIC ADULT SOFT TISSUE SARCOMAS
H.P. Kalofonos, D. Bafaloukos, T.G. Kourelis, M.V. Karamouzis, P. Megas, G. Iconomou, E. Tsiata, D. imitropoulos, P. Kosmidis and E. Lampiris
Am J Clin Oncol. 2004 Jun;27(3):307-11

Δημοσιεύσεις 2005

TEMOZOLOMIDE (TMZ) COMBINED WITH CISPLATIN (CDDP) IN PATIENTS WITH BRAIN METASTASES FROM SOLID TUMORS: A HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) PHASE II STUDY
C. Christodoulou, D. Bafaloukos, H. Linardou, G. Aravantinos, A. Bamias, M. Carina, G. Klouvas, D. Skarlos
J Neurooncol. 2005 Jan;71(1):61-5


POSTOPERATIVE DOSE-DENSE SEQUENTIAL CHEMOTHERAPY WITH EPIRUBICIN, FOLLOWED BY CMF WITH OR WITHOUT PACLITAXEL, IN PETIENTS WITH HIGH-RISK OPERABLE BREAST CANCER: A RANDOMIZED PHASE III STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
G. Fountzilas, D. Skarlos, U. Dafni, H. Gogas, E. Briasoulis, D. Pectasides, Ch. Papadimitriou, Ch. Markopoulos, A. Polychronis, H.P. Kalofonos, V. Siafaka, P. Kosmidis, E. Timotheadou, D. Tsavdaridis, D. Bafaloukos, P. Papakostas, E. Razis, P. Makrantonakis, G. Aravantinos, Ch. Christodoulou, A. M. Dimopoulos
Ann Oncol 2005 Nov;16(11):1762-71


CHEMOTHERAPY FOR PATIENTS WITH TWO FAVOURABLE SUBSETS OF UNKNOWN PRIMARY CARCINOMA: ACTIVE, BUT HOW EFFECTIVE?
G. Pentheroudakis, E. Briassoulis, V. Karavassilis, G. Fountzilas, N. Xiros, G. Samelis, E. Samantas & N. Pavlidis
Acta Oncol. 2005;44(2):155-60


ADVANCED STAGE MUCINOUS EPITHELIAL dOVARIAN CANCER: THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE
D. Pectasides, G. Fountzilas, G. Aravantinos, H.P. Kalofonos, E. Efstathiou, E. Salamalekis, D. Farmakis, D. Skarlos, E. Briasoulis, Th. Economopoulos, M.A. Dimopoulos
Gynecol Oncol. 2005 May;97(2):436-41


NON-HODGKIN’S LYMPHOMA IN GREECE ACCORDING TO THE WHO CLASSIFICATION OF LYMPHOID NEOPLASMS. A RETROSPECTIVE ANALYSIS OF 810 CASES
T. Economopoulos, S. Papageorgiou, M.A. Dimopoulos, N. Pavlidis, C. Tsatalas, A. Symeonidis, A. Foudoulakis, D. Pectasides, D. Rontogianni, E. Rizos, P. Chalkia, A. Anagnostopoulos, M. Melachrinou, E. Papageorgiou, G. Fountzilas
Acta Haematol. 2005;113(2):97-103


TREATMENT OF NON-SMALL CELL LUNG CANCER WITH GEFITINIB (“IRESSA”, ZD1839): THE GREEK EXPERIENCE WITH A COMPASSIONATE-USE PROGRAM
E. Razis, D. Skarlos, E. Briasoulis, M. Dimopoulos, G. Fountzilas, S. Lambropoulos, S. Rigatos, P. Kopterides, H. Efstathiou, E. Tzamakou, C. Bakoyannis, D. Pectasides, T. Makatsoris, G. Varthalitis, S. Papadopoulos and P. Kosmidis
AntiCancer Drugs. 2005 Feb;16(2):191-8


IRINOTECAN OR OXALIPLATIN COMBINED WITH LEUCOVORIN AND 5-FLUOROURACIL AS FIRST-LINE TREATMENT IN ADVANCED COLORECTAL CANCER: A MULTICENTER, RANDOMIZED, PHASE II STUDY
H.P. Kalofonos, G. Aravantinos, P. Kosmidis, P. Papakostas, T. Economopoulos, M. Dimopoulos, D. Skarlos, A. Bamias, D. Pectasides, S. Chalkidou, M. Karina, A. Koutras, E. Samantas, C. Bacoyiannis, G.F. Samelis, G. Basdanis, F. Kalfarentzos and G. Fountzilas
Ann Oncol. 2005 Jun;16(6):869-77


PACLITAXEL, CISPLATIN, LEUCOVORIN, AND CONTINUOUS INFUSION FLUOROURACIL FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. A HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE II STUDY
G. Fountzilas, C. Tolis, A. Kalogera-Fountzila, D. Misailidou, P. Tsekeris, M. Karina, A. Nikolaou, E. Samantas, T. Makatsoris, E. Athanassiou, D. Skarlos, A. Bamias, N. Zamboglou, T. Economopoulos, S. Karanastassi, N. Pavlidis, and J. Daniilidis
Med Oncol. 2005;22(3):269-79


A PHASE II STUDY OF CAPECITABINE PLUS OXALIPLATIN (XELOX). A NEW FIRST-LINE OPTION IN METASTATIC COLORECTAL CANCER
T. Makatsoris, H.P. Kalofonos, G. Aravantinos, C. Papadimitriou, E. Kastritis, S. K. Rigatos, N. Xiros, T. Petsas, T. Economopoulos, A.K. Sakadamis, and G. Fountzilas
Int J Gastrointest Cancer. 2005;35(2):103-9


PROGNOSTIC FACTORS IN PATIENTS WITH COLORECTAL CANCER RECEIVING ADJUVANT CHEMOTHERAPY OR CHEMORADIOTHERAPY. A POOLED ANALYSIS OF TWO RANDOMIZED STUDIES
Bamias, G. Basdanis, I. Xanthakis, N. Pavlidis, and G. Fountzilas
Int J Gastrointest Cancer. 2005;36(1):29-38


ANGIOGENESIS IN CANCER OF UNKNOWN PRIMARY: CLINICOPATHOLOGICAL STUDY OF CD34, VEGF AND TSP-I
V. Karavasilis, V. Malamou-Mitsi, E. Briassoulis, E. Tsanou, E. Kitsou, H. P. Kalofonos, G. Fountzilas, T. Fotsis and N. Pavlidis
BMC Cancer. 2005 Mar 3;5:25


PACLITAXEL AND CARBOPLATIN AS FIRST-LINE CHEMOTHERAPY COMBINED WITH GEFITINIB (IRESSA) IN PATIENTS WITH ADVANCED BREAST CANCER: A PHASE I/II STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
G. Fountzilas, D. Pectasides, A. Kalogera-Fountzila, D. Skarlos, H.P. Kalofonos, C. Papadimitriou, D. Bafaloukos, S. Lambropoulos, S. Papadopoulos, H. Kourea, C. Markopoulos, H. Linardou, D. Mavroudis, E. Briasoulis, N. Pavlidis, E. Razis, P. Kosmidis and H. Gogas
Breast Cancer Res Treat. 2005 Jul;92(1):1-9


INDUCTION CHEMOTHERAPY WITH CISPLATIN, EPIRUBICIN, AND PACLITAXEL (CEP), FOLLOWED BY CONCOMITANT RADIOTHERAPY AND WEEKLY PACLITAXEL FOR THE MANAGEMENT OF LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA. A HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE II STUDY
G. Fountzilas, C. Tolis, A. Kalogera-Fountzila, C. Karanikiotis, M. Bai, D. Misailidou, E. Samantas, E. Athanassiou, D. Papamichael, P. Tsekeris, N. Catodritis, A. Nicolaou, G. Plataniotis, T. Makatsoris, P. Papakostas, N. Zamboglou, J. Daniilidis
Strahlentherapie Onkol. 2005 Apr;181(4):223-30


GEMCITABINE PLUS PEGYLATED LIPOSOMAL DOXORUBICIN IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER RESISTANT/REFRACTORY TO PLATINUM AND/OR TAXANES. A HeCOG PHASE II STUDY
D. Skarlos, H.P. Kalofonos, G. Fountzilas, M.A. Dimopoulos, N. Pavlidis, E. Razis, T. Economopoulos, D. Pectasides, H. Gogas, P. Kosmidis, D. Bafaloukos, G. Klouvas, G. Kyratzis and G. Aravantinos
Anticancer Res. 2005 Jul-Aug;25(4):3103-8


IRINOTECAN AND OXALIPLATIN COMBINATION, AS SECOND-LINE TREATMENT, IN FLUOROPYRIMIDINE-PRETREATED ADVANCED COLORECTAL CANCER. A PHASE II STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)
E. Timotheadou, P. Papakostas, D. Tsavdaridis, G. Basdanis, H. Kalofonos, G. Aravantinos, D. Bafaloukos and G. Fountzilas
Tumori. 2005 Jul-Aug;91(4):309-13


TEMOZOLOMIDE AND CISPLATIN VERSUS TEMOZOLOMIDE IN PATIENTS WITH ADVANCED MELANOMA: A RANDOMIZED PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP
D. Bafaloukos, D. Tsoutsos, H. Kalofonos, S. Chalkidou, P. Panagiotou, E. Linardou, E. Briassoulis, E. Efstathiou, A. Polyzos, G. Fountzilas, C. Christodoulou, C. Kouroussis, T. Iconomou, H. Gogas
Ann Oncol. 2005 Jun;16(6):950-7


THE COMBINATION OF ESTRAMUSTINE, VINORELBINE, AND MITOXANTRONE IN HORMONE-REFRACTORY PROSTATE CANCER: A PHASE II FEASIBILITY STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
G.F. Samelis, H.P. Kalofonos, A. Adamou, P. Kosmidis, D. Skarlos, G. Aravantinos, C. Kiamouris, A. Onyenadum, G. Fountzilas and A.M. Dimopoulos
Urology. 2005 Aug;66(2):382-5


MATRIX METALLOPROTEINASES IN CARCINOMA OF UNKNOWN PRIMARY
V. Karavasilis, V. Malamou-Mitsi, E. Briasoulis, E. Tsanou, E. Kitsou, H. Kalofonos, G. Fountzilas, T. Fotsis, PN. avlidis
Cancer. 2005 Nov 15;104(10):2282-7


A PHASE II STUDY OF THE DOCETAXEL-IFOSFAMIDE-CARBOPLATIN COMBINATION IN ADVANCED NON-SMALL-CELL LUNG CANCER
C. Kosmas, N. Tsavaris, A. Koutras, T. Makatsoris, N. Mylonakis, G. Tzelepis, A. Dimitrakopoulos, K. Spyropoulos, A. Polyzos, A. Karabelis, H.P. Kalofonos
Oncology. 2005;69(4):333-41


CARBOPLATIN PLUS GEMCITABINE IN PATIENTS WITH INOPERABLE OR METASTATIC PANCREATIC CANCER: A PHASE II MULTICENTER STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
N. Xiros, P. Papacostas, T. Economopoulos, G. Samelis, E. Efstathiou, E. Kastritis, H. Kalofonos, A. Onyenadum, D. Skarlos, A. Bamias, H. Gogas, D. Bafaloukos, E. Samantas, P. Kosmidis
Ann Oncol. 2005 May;16(5):773-9


PACLITAXEL PLUS CARBOPLATIN VERSUS PACLITAXEL PLUS ALTERNATING CARBOPLATIN AND CISPLATIN FOR INITIAL TREATMENT OF ADVANCED OVARIAN CANCER: LONG-TERM EFFICACY RESULTS: A HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) STUDY
G. Aravantinos, G. Fountzilas, P. Kosmidis, M.A Dimopoulos, G.P Stathopoulos, N. Pavlidis, D. Bafaloukos, C. Papadimitriou, S. Karpathios, V. Georgoulias, P. Papakostas, H.P Kalofonos, E. Grimani, D.V Skarlos
Ann Oncol. 2005 Jul;16(7):1116-22


BRAIN METASTASES FROM EPITHELIAL OVARIAN CANCER. THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) EXPERIENCE AND REVIEW OF THE LITERATURE
D. Pectasides, G. Aravantinos, G. ountzilas, C. Kalofonos, E. Efstathiou, M. Karina, N. Pavlidis, D. Farmakis, T. Economopoulos, M.A Dimopoulos
Anticancer Res. 2005 Sep-Oct;25(5):3553-8


PHASE I STUDY OF ETOPOSIDE, CISPLATIN, AND IRINOTECAN TRIPLET IN PATIENTS WITH ADVANCED-STAGE SMALL-CELL LUNG CANCER
E. Briasoulis, E. Samantas, H. Kalofonos, D. Skarlos, T. Makatsoris, C. Christodoulou, G. Fountzilas, A. Bamias, MA. Dimopoulos, P. Kosmidis, N. Pavlidis. Cancer Chemother Pharmacol. 2005 Nov;56(5):521-8


MULTIFOCAL EXTRANODAL NON-HODGKIN LYMPHOMA: A CLINICOPATHOLOGIC STUDY OF 37 CASES IN GREECE
T. Economopoulos, S. Papageorgiou, D. Rontogianni, V. Kaloutsi, G. Fountzilas, C. Tsatalas, N. Pavlidis, D. Pectasides, E. Papageorgiou, M. Dimopoulos
The Oncologist. 10(9): 734-8, 2005


hMSH2 IS THE MOST COMMONLY MUTATED MMR GENE IN A COHORT OF GREEK HNPCC PATIENTS
A Apessos, M Mihalatos, I Danielidis, G Kallimanis, NJ Agnantis, JK Triantafillidis, G Fountzilas, PA Kosmidis, E Razis, VA Georgoulias and G Nasioulas
Br J Cancer. 2005 Jan 31;92(2):396-404


CLINICAL AND MOLECULAR PROGNOSTIC FACTORS IN OPERABLE LARYNGEAL CANCER
K. Vlachtsis, A. Nikolaou, K. Markou, G. Fountzilas, I. Daniilidis
Eur Arch Otorhinolaryngol. 2005 Nov;262(11):890-8

Δημοσιεύσεις 2006

PROGNOSTIC SIGNIFICANCE OF AUTOIMMUNITY DURING TREATMENT OF MELANOMA WITH INTERFERON ALFA-2b
H. Gogas, J. Ioannovich, U. Dafni, C. Stavropoulou-Giokas, K. Frangia, D. Tsoutsos, P. Panagiotou, A. Polyzos, O. Papadopoulos, A. Stratigos, C. Markopoulos, D. Bafaloukos, D. Pectasides, G. Fountzilas, J.M. Kirkwood
N Engl J Med 2006 Feb 16;354(7):709-18


COMBINATION OF TOPOTECAN AND CISPLATIN IN RELAPSED PATIENTS WITH SMALL CELL CANCER: A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)
C. Christodoulou, H.P. Kalofonos, E. Briasoulis, D. Bafaloukos, T. Makatsoris, A. Koutras, D.V. Skarlos, E. Samantas.
Cancer Chemother Pharmacol. 2006 Jan;57(2):207-12 (Epub 2005 Jul 19)


MUTATIONS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN AND ASSOCIATIONS WITH
CLINICOPATHOLOGICAL FEATURES IN NON-SMALL CELL LUNG CANCER PATIENTS
S.Murray, E.Timotheadou, H.Linardou, AV.Vrettou, I.Kostopoulos, J.Skrickova, C.Papakostantinou, C.Christodoulou, D.Pectasides, E.Samantas, P.Papakostas, D.V.Skarlos, P.Kosmidis, G.Fountzilas.
Lung Cancer. 2006 May;52(2):225-33 (Epub 2006 Mar 29)


PACLITAXEL-CARBOPLATIN COMBINATION CHEMOTHERAPY IN ADVANCED BREAST CANCER. ACCUMULATIING EVIDENCE FOR SYNERGY, EFFICACY AND SAFETY
G. Pentheroudakis, E. Razis, A. Athanassiadis, N. Pavlidis and G. Fountzilas
Med Oncol. 2006;23(2):147-60


COMBINATION DOCETAXEL (TAXOTERE), FLUOROURACIL AND LEUCOVORIN (TFL), AS FIRST LINE CHEMOTHERAPY, IN ADVANCED GASTRIC CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE II STUDY
P. Papakostas, D. Tsavdaridis, P. Kosmidis, H.P. Kalofonos, A. Sakantamis, D. Janinis, D. Skarlos, D. Bafaloukos, A. Bamias, N. Xiros, G. Fountzilas.
Gastric Cancer. 2006;9(1):26-31


EVALUATION OF THE PROGNOSTIC VALUE OF HER-2 AND VEGF IN BREAST CANCER PATIENTS PARTICIPATING
IN A RANDOMIZED STUDY WITH DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY
I. Kostopoulos, P. Arapantoni-Dadioti, H. Gogas, S. Papadopoulos, V. Malamou-Mitsi, C.D. Scopa, S. Markaki, E. Karagianni, V. Kyriakou, A. Margariti, E. Kyrkou, K. Pavlakis, T. Zaramboukas, A. Skordalaki, A. Bourli, C. Markopoulos, D. Pectasides, M.A. Dimopoulos, D. Skarlos, G. Fountzilas
Breast Cancer Res. Treat. 2006 Apr;96(3):251-61


ELDERLY PATIENTS WITH SQUAMOUS LUNG CARCINOMA: FARING BETTER OR WORSE?
G. Pentheroudakis, K. Neanidis, L. Kostadima, G. Fountzilas, N. Pavlidis
Support Care Cancer. 2006 Aug;14(8):867-70


THE COMBINATION OF GEMCITABINE AND CARBOPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED UROTHELIAL CARCINOMA
A. Bamias, L.AA Moulopoulos, A. Koutras, G. Aravantinos, G. Fountzilas, D. Pectasides, E. Kastritis, D. Gika, D. Skarlos, H. inardou, H.P. Kalofonos, M.A. Dimopoulos
Cancer. 2006 Jan 15;106(2):297-303


EXPRESSION OF p27KIP1, p21WAF1 AND p53 DOES NOT CORRELATE WITH PROGNOSIS IN NODE-NEGATIVE INVASIVE DUCTAL CARCINOMA OF THE BREAST
H.P. Kourea, A.K. Koutras, V. Zolota, I. Grimani, E. Tzoracoeleftherakis, D. Koukouras, G. Fountzilas, H. Gogas, K. Kyriakou, A. Adamou, H.P. Kalofonos
Anticancer Res. 2006 Mar-Apr;26(2B):1657-68


ADVANCES IN THE TREATMENT OF LOCALLY ADVANCED NON-NASOPHARYNGEAL SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK REGION
Psyrri D, Fountzilas G
Med Oncol. 2006;23(1):1-15


MITOXANTRONE PLUS GEMCITABINE IN PRETREATED PATIENTS WITH METASTATIC BREAST CANCER
A. Onyenadum, H. Gogas, P. Kosmidis, G. Aravantinos, D. Bafaloukos, H. Bacoyiannis, C. Markopoulos, A. Koutras, E. Tzorakoelefterakis, T. Makatsoris, G.Fountzilas, HP. Kalofonos; Hellenic Cooperative Oncology Group
J Chemother. 2006 Apr;18(2):192-8


ADVANCED STAGE CLEAR CELL EPITHELIAL OVARIAN CANCER: THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE
D. Pectasides, G. Fountzilas, G. Aravantinos, C. Kalofonos, H. Efstathiou, D. Farmakis, D. Skarlos, N. Pavlidis, Th. Economopoulos, M.A. Dimopoulos.
Gynecol Oncol. 2006 Aug;102(2):285-91


TEMOZOLOMIDE IN COMBINATION WITH CELECOXIB IN PATIENTS WITH ADVANCED MELANOMA. A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP
H. Gogas, A. Polyzos, I. Stavrinidis, K. Frangia, D. Tsoutsos, P. Panagiotou, C. Markopoulos, O. Papadopoulos, D. Pectasides, M. Mantzourani, M. Middleton, G. Vaiopoulos, G. Fountzilas
Ann Oncol. 2006 Dec;17(12):1835-41


FOUR CYCLES OF PACLITAXEL AND CARBOPLATIN AS ADJUVANT TREATMENT IN EARLY-STAGE OVARIAN CANCER: A SIX-YEAR EXPERIENCE OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP
Α. Bamias, C. Papadimitriou, E. Efstathiou, A. Rodolakis, G. Vlahos, Z. Voulgaris, G. Bozas, G. Fountzilas, G. Aravantinos, E. Razis, D. Gika, M.A. Dimopoulos.
BMC Cancer. 2006 Sep 25;6:228


EVALUATION OF THE PROGNOSTIC AND PREDICTIVE VALUE OF p53 AND Bcl-2 IN BREAST CANCER PATIENTS PARTICIPATING IN A RANDOMIZED STUDY WITH DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY
V. Malamou-Mitsi, H. Gogas, U. Dafni, A. Bourli, T. Fillipidis, M. Sotiropoulou, D. Vlachodimitropoulos, S. Papadopoulos, O. Tzaida, G. Kafiri, V. Kyriakou, S. Markaki, I. Papaspyrou, E. Karagianni, K. Pavlakis, T. Toliou, C.D. Scopa, P. Papakostas, D. Bafaloukos, C. Christodoulou, G. Fountzilas
Ann Oncol. 2006 Oct;17(10):1504-11


PACLITAXEL AND GEMCITABINE VS PACLITAXEL AND PEGYLATED LIPOSOMAL DOXORUBICIN IN ADVANCED NON-NASOPHARYNGEAL HEAD AND NECK CANCER. AN EFFICACY AND COST ANALYSIS RANDOMIZED STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP
G. Fountzilas, P. Papakostas, U. Dafni, T. Makatsoris, M. Karina, A. Kalogera-Fountzila, N. Maniadakis, G. Aravantinos, K. Syrigos, A. Bamias, C. Christodoulou, T. Economopoulos, H.P. Kalofonos, A. Nikolaou, N. Angouridakis, G. Stathopoulos D. Bafaloukos, N. Pavlidis, J. Daniilidis
Ann Oncol. 2006 Oct;17(10):1560-7


ADJUVANT DOSE-DENSE SEQUENTIAL CHEMOTHERAPY WITH EPIRUBICIN, CMF AND WEEKLY DOCETAXEL IS FEASIBLE AND SAFE IN PATIENTS WITH OPERABLE BREAST CANCER
G. Fountzilas, D. Pectasides, C. Christodoulou, E. Timotheadou, Th. Economopoulos, P. Papakostas, Ch. Papadimitriou, H. Gogas, I. Efstratiou, D. Skarlos
Med Oncol. 2006;23(4):479-88


METASTATIC BREAST CANCER WITH LIVER METASTASES: A REGISTRY ANALYSIS OF CLINICOPATHOLOGIC, MANAGEMENT AND OUTCOME CHARACTERISTICS OFF 500 WOMEN
G. Pentheroudakis, G. Fountzilas, D. Bafaloukos, V. Koutsoukou, D. Pectasides, D. Skarlos, E. Samantas, H.P. Kalofonos, H. Gogas, N. Pavlidis
Breast Cancer Res Treat. 2006 Jun;97(3):237-44


CAN THE STANDARD CHEMOTHERAPEUTIC REGIMEN BE IMPROVED UPON FOR SMALL-CELL LUNG CANER?

A. Psyrri, G. Fountzilas
Nat Clin Pract Oncol. 2006 Jul;3(7):360-1


NON-SMALL CELL LUNG CANCER IN THE YOUNG: A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, MANAGEMENT AND OUTCOME DATA
D. Mauri, G. Pentheroudakis, D. Bafaloukos, D. Pectasides, E. Samantas, E. Efstathiou, H.P. Kalofonos, K. Syrigos, G. Klouvas, P. Papakostas, P. Kosmidis, G. Fountzilas, N. Pavlidis; Hellenic Coopeprative Oncologic Group (HeCOG).
Anticancer Res. 2006 Jul-Aug;26(4B):3175-81


PROGNOSTIC FACTORS AND SIGNIFICANCE OF THE REVISED 6TH EDITION OF THE AJCC CLASSIFICATION IN PATIENTS WITH LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA
A. Kalogera-Fountzila, D. Karanikolas, N. Katodritis, E. Samantas, A. Sarafopoulos, I. Ikonomou, N. Zamboglou, N. Tselis, A.S. Dimitriadis, G. Fountzilas; AJCC (American Joint Committee on Cancer).
Strahlenther Onkol. 2006 Aug;182(8):458-66


A MULTICENTER PHASE III TRIAL COMPARING IRINOTECAN-GEMCITABINE (IG) WITH GEMCITABINE (G) MONOTHERAPY AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER
G.P. Stathopoulos, K. Syrigos, G. ravantinos, A. Polyzos, P. Papakotoulas, G. Fountzilas, A. Potamianou, N. Ziras, J. Boukovinas, J. Varthalitis, N. Androulakis, A. Kotsakis, G. Samonis, V. Georgoulias
Br J Cancer. 2006 Sep 4;95(5):587-92 (Epub 2006 Aug 8)


THREE CASES REPORTS OF HAND-FOOT SYNDROME WITH GEFITINIB
E. Razis, M. Karina, S. Karanastassi, G. Fountzilas
Cancer Invest. 2006 Aug-Sep; 24(5): 514-6


PRIMARY GASTROINTESTINAL NON-HODKIN’S LYMPHOMA:A CLINICOPATHOLOGIC STUDY OF 128 CASES IN GREECE. A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY (HeCOG)
G. Papaxoinis, S. Papageorgiou, D. Rontogianni, V. Kaloutsi, G. Fountzilas, N. Pavlidis, M. Dimopoulos, C. Tsatalas, N. Xiros, T. Economopoulos
Leuk Lymphoma. 2006 Oct;47(10):2140-6


TWO CASES OF COMPLETE RESPONSE AFTER IMATINIB MESYLATE TREATMENT OF ADVANCED GIST
G. Papaxoinis, M. Nikolaou, E. Lianos, A. Gaglia, T. Oikonomopoulos, D. Pectasides
Anticancer Res. 2006 Nov-Dec;26(6C):4869-72


LIVER METASTASIS OF ADENOID CYSTIC CARCINOMA OF SALIVARY ORIGIN: REPORT OF A CASE PREPARED BY THIN-PREP METHOD
D. Aninos, A. Koumarianou, J. Georgoulakis, D.Pectasides, E. Brountzos, CH. Zoumpouli, T.Economopoulos, P. Karakitsos
Cytopathology. 2007 Aug;18(4):268-9


FALLOPIAN TUBE CARCINOMA: A REVIEW
D. Pectasides, E. Pectasides, T. Economopoulos
Oncologist. 2006 Sep;11(8):902-12


SYSTEMIC CHEMOTHERAPY IN LOCALLY ADVANCED AND/OR METASTATIC BLADDER CANCER
D. Pectasides, M. Pectasides, T. Economopoulos
Cancer Treat Rev. 2006 Oct;32(6):456-70 (Epub 2006 Aug 28)


MAINTENANCE OR CONSOLIDATION THERAPY IN ADVANCED OVARIAN CANCER
D. Pectasides, E. Pectasides
Oncology. 2006;70(5):315-24 (Epub 2006 Dec 12)


CISPLATIN-BASED CHEMOTHERAPY FOR MERKEL CELL CARCINOMA OF THE SKIN
D. Pectasides, M. Pectasides, A. Psyrri, A. Koumarianou, N. Xiros, E. Pectasides, A. Gaglia, E. Lianos, G. Papaxoinis, V. Lampadiari, T. Economopoulos
Cancer Invest. 2006 Dec;24(8):780-5


TREATMENT ISSUES IN CLEAR CELL CARCINOMA OF THE OVARY: DIFFERENT ENTITY?
D. Pectasides, E. Pectasides, A. Psyrri, T. Economopoulos
Oncologist. 2006 Nov-Dec;11(10):1089-94


SURVIVIN AND GLYCODELIN GLYCODELIN TRANSCRIPTIONAL ACTIVITY IN NODE-POSITIVE EARLY BREAST CANCER: mRNA EXPRESSION OF TWO KEY REGULATORS OF CELL SURVIVAL
L. Kostadima, G. Pentheroudakis, G. Fountzilas, M.A. Dimopoulos, D. Pectasides, H. Gogas, U. Stropp, Ch.Christodoulou, E. Samantas, R. Wirtz, G. Hennig, D. Bafaloukos, P. Arapantoni, H.P. Kalofonos, P.Papakostas, T. Economopoulos, A. Bamias, G. Fountzilas, N. Pavlidis
Breast Cancer Res Treat. 2006 Nov;100(2):161-7 (Epub 2006 Jul 18)


POST-OPERATIVE COMBINED RADIATION AND CHEMOTHERAPY WITH TEMOZOLOMIDE AND IRINOTECAN IN PATIENTS WITH HIGH-GRADE ASTROCYTIC TUMORS. A PHASE II STUDY WITH BIOMARKER EVALUATION
G. Fountzilas, G. Karkavelas, A. Kalogera-Fountzila, M. Karina, M. Ignatiadis, G. Koukoulis, G. Plataniotis, D. Misailidou, M. Bobos, D. Pectasides, E. Razis, A. Karavelis, P. Selviaridis
Anticancer Res. 2006 Nov-Dec;26(6C):4675-86

Δημοσιεύσεις 2008

PACLITAXEL AND GEMCITABINE VERSUS CARBOPLATIN AND GEMCITABINE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER. A PHASE III STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP

P.A Kosmidis, H.P Kalofonos, C. Christodoulou, K. Syrigos, T. Makatsoris, D. Skarlos, C. Bakogiannis, C. Nicolaides, D. Bafaloukos, A. Bamias, E. Samantas, N. Xiros, I. Boukovinas, G. Fountzilas, M.A Dimopoulos.

Ann Oncol. 2008;19(1):115-22


 GREEK BRCA1 AND BRCA2 MUTATION SPECTRUM: TWO BRCA1 MUTATIONS ACCOUNT FOR HALF THE CARRIERS FOUND AMONG HIGH-RISK BREAST/OVARIAN CANCER PATIENT

I. Konstantopoulou, T. Rampias, A. Ladopoulou, G. Koutsodontis, S. Armaou, T. Anagnostopoulos, G. Nikolopoulos, S. Kamakari, G. Nounesis, A. Stylianakis, C. Karanikiotis, E. Razis, H. Gogas, A. Keramopoulos, V. Gaki, C. Markopoulos, D. Skarlos, N. Pandis, T. Bei, I. Arzimanoglou, G. Fountzilas, D. Yannoukakos.

Breast Cancer Res Treat. 2008;107(3):431-41


 MULTICENTER PHASE-II TRIAL OF IRINOTECAN PLUS OXALIPLATIN [IROX REGIMEN] IN PATIENTS WITH POOR-PROGNOSIS CANCER OF UNKNOWN PRIMARY: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

E. Briasoulis, G. Fountzilas, A. Bamias, M.A Dimopoulos, N. Xiros, G. Aravantinos, E. Samantas, H. Kalofonos, T. Makatsoris, N. Mylonakis, P. Papakostas, D. Skarlos, I. Varthalitis, N. Pavlidis.

Cancer Chemother Pharmacol. 2008;62(2):277-84


 G1738R IS A BRCA1 FOUNDER MUTATION IN GREEK BREAST/OVARIAN CANCER PATIENTS: EVALUATION OF ITS PATHOGENICITY AND INFERENCES ON ITS GENEALOGICAL HISTORY

T. Anagnostopoulos, M. Pertesi, I. Konstantopoulou, S. Armaou, S. Kamakari, G. Nasioulas, A. Athanasiou, A. Dobrovic, MA Young, D. Goldgar, G. Fountzilas, D. Yannoukakos.

Breast Cancer Res Treat. 2008;110(2):377-85


 POSTOPERATIVE DOSE-DENSE SEQUENTIAL CHEMOTHERAPY WITH EPIRUBICIN, PACLITAXEL AND CMF IN PATIENTS WITH HIGH-RISK BREAST CANCER: SAFETY ANALYSIS OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP RANDOMIZED PHASE III TRIAL HE 10/00

G. Fountzilas, U. Dafni, H. Gogas, H. Linardou, H.P Kalofonos, E. Briasoulis, D. Pectasides, E. Samantas, D. Bafaloukos, G.P Stathopoulos, M. Karina, C. Papadimitriou, D. Skarlos, N. Pisanidis, P. Papakostas, C. Markopoulos, E. Tzorakoeleftherakis, K. Dimitrakakis, P. Makrantonakis, N. Xiros, A. Polichronis, I. Varthalitis, C. Karanikiotis, A.M Dimopoulos; Hellenic Cooperative Oncology Group.

Ann Oncol. 2008;19(5):853-60


 TARGETING c-KIT, PDGFR IN CANCER OF UNKNOWN PRIMARY: A SCREENING STUDY FOR MOLECULAR MARKERS OF BENEFIT

L. Dova, G. Pentheroudakis, V. Golfinopoulos, V. Malamou-Mitsi, I. Georgiou, G. Vartholomatos, A. Ntemou, G. Fountzilas, N. Pavlidis.

J Cancer Res Clin Oncol. 2008;134(6):697-704


 LOW-GRADE MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: A RETROSPECTIVE ANALYSIS OF 97 PATIENTS BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)

G. Papaxoinis, G. Fountzilas, D. Rontogianni, M.A Dimopoulos, N. Pavlidis, C. Tsatalas, D. Pectasides, N. Xiros, T. Economopoulos.

Ann Oncol. 2008;19(4):780-6


 PHASE II STUDY OF LOW-GRADE NON-HODGKIN LYMPHOMAS WITH FLUDARABINE AND MITOXANTRONE FOLLOWED BY RITUXIMAB CONSOLIDATION: PROMISING RESULTS IN MARGINAL ZONE LYMPHOMA

T. Economopoulos, A. Psyrri, G. Fountzilas, C. Tsatalas, A. Anagnostopoulos, S. Papageorgiou, N. Xiros, M.A Dimopoulos.

Leuk Lymphoma. 2008;49(1):68-74


 PALLIATIVE CHEMOTHERAPY IN ELDERLY PATIENTS WITH COMMON METASTATIC MALIGNANCIES: A HELLENIC COOPERATIVE ONCOLOGY GROUP REGISTRY ANALYSIS OF MANAGEMENT OUTCOME AND CLINICAL BENEFIT PREDICTORS

G. Pentheroudakis, G. Fountzilas, H.P Kalofonos, V. Golfinopoulos, G. Aravantinos, D. Bafaloukos, P. Papakostas, D. Pectasides, C. Christodoulou, K. Syrigos, T. Economopoulos, N. Pavlidis; Hellenic Cooperative Oncology Group.

Crit Rev Oncol Hematol. 2008;66(3):237-47


 CARBOPLATIN AND PACLITAXEL IN ADVANCED OR METASTATIC ENDOMETRIAL CANCER

D. Pectasides, N. Xiros, G. Papaxoinis, E. Pectasides, C. Sykiotis, A. Koumarianou, A. Psyrri, A. Gaglia, D. Kassanos, P. Gouveris, J. Panayiotidis, G. Fountzilas, T. Economopoulos.

Gynecol Oncol. 2008;109(2):250-4


 PACLITAXEL, EPIRUBICIN, AND CARBOPLATIN IN ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA: A HELLENIC CO-OPERATIVE ONCOLOGY GROUP (HeCOG) STUDY

C.A Papadimitriou, D. Bafaloukos, G. Bozas, H. Kalofonos, P. Kosmidis, G. Aravantinos, G. Fountzilas, M.A Dimopoulos; Hellenic Co-operative Oncology Group.

Gynecol Oncol. 2008;110(1):87-92


 ADULT GRANULOSA CELL TUMORS OF THE OVARY: A CLINICOPATHOLOGICAL STUDY OF 34 PATIENTS BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)

D. Pectasides, G. Papaxoinis, G. Fountzilas, G. Aravantinos, E. Pectasides, D. Mouratidou, T. Economopoulos, Ch. Andreadis.

Anticancer Res. 2008 Mar-Apr;28(2B):1421-7


 HLA CLASS II ALLELES AND THE PRESENCE OF CIRCULATING EPSTEIN-BARR VIRUS DNA IN GREEK PATIENTS WITH NASOPHARYNGEAL CARCINOMA

C. Karanikiotis, M. Daniilidis, N. Karyotis, C. Bakogiannis, T. Economopoulos, S. Murray, D. Papamichael, E. Samantas, A. Nikolaou, L. Skoura, N. Tselis, N. Zamboglou, G. Fountzilas.

Strahlenther Onkol. 2008;184(6):325-31


 ADJUVANT DOSE-DENSE SEQUENTIAL CHEMOTHERAPY WITH EPIRUBICIN, CMF AND WEEKLY PACLITAXEL IN PATIENTS WITH RESECTED HIGH-RISK BREAST CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) STUDY

C.A Papadimitriou, P. Papakostas, E. Timotheadou, G. Aravantinos, A. Bamias, G. Fountzilas.

Cancer Invest. 2008;26(5):491-8


 PERSONALITY FACTORS ASSOCIATED WITH PSYCHOLOGICAL DISTRESS IN TESTICULAR CANCER SURVIVORS

V. Siafaka, T.N Hyphantis, I. Alamanos, G. Fountzilas, D. Skarlos, D. Pectasides, V. Mavreas, N. Pavlidis.

J Pers Assess. 2008;90(4):348-55


 LIVER METASTASES FROM CANCER OF UNKNOWN PRIMARY (CUPL): A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND PROGNOSIS IN 49 PATIENTS AND SYSTEMATIC REVIEW OF THE LITERATURE

G. Lazaridis, G. Pentheroudakis, G. Fountzilas, N. Pavlidis.

Cancer Treat Rev. 2008;34(8):693-700


 TRASTUZUMAB IN THE ADJUVANT TREATMENT OF EARLY-STAGE BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

IJ. Dahabreh, H. Linardou, F. Siannis, G. Fountzilas, S. Murray.

Oncologist. 2008 Jun;13(6):620-30


 DOCETAXEL AND CARBOPLATIN COMBINATION CHEMOTHERAPY AS OUTPATIENT PALLIATIVE THERAPY IN CARCINOMA OF UNKNOWN PRIMARY: A MULTICENTRE HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE II STUDY

G. Pentheroudakis, E. Briasoulis, H.P Kalofonos, G. Fountzilas, T. Economopoulos, G. Samelis, A. Koutras, M. Karina, N. Xiros, E. Samantas, A. Bamias, N. Pavlidis;Hellenic Cooperative Oncology Group.

Acta Oncol. 2008;47(6):1148-55


 A RANDOMISED PHASE III TRIAL OF ADJUVANT RADIO-CHEMOTHERAPY COMPARING IRINOTECAN, 5FU and LEUCOVORIN TO 5FU AND LEUCOVORIN IN PATIENTS WITH RECTAL CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

H.P Kalofonos, A. Bamias, A. Koutras, P. Papakostas, G. Basdanis, E. Samantas, M. Karina, D. Misailidou, N. Pisanidis, G. Pentheroudakis, T. Economopoulos, C. Papadimitriou, D.V Skarlos, D. Pectasides, M. Stavropoulos, D. Bafaloukos, D. Kardamakis, C. Karanikiotis, G. Vourli, G. Fountzilas; Hellenic Cooperative Oncology Group Study.

Eur J Cancer. 2008 Aug;44(12):1693-700


 PACLITAXEL, TOPOTECAN, AND CARBOPLATIN IN METASTATIC ENDOMETRIAL CARCINOMA: A HELLENIC CO-OPERATIVE ONCOLOGY GROUP (HeCOG) STUDY

C.A Papadimitriou, G. Fountzilas, D. Bafaloukos, G. Bozas, H. Kalofonos, D. Pectasides, G. Aravantinos, A. Bamias, M.A Dimopoulos; Hellenic Co-operative Oncology Group.

Gynecol Oncol. 2008 Oct;111(1):27-34


 CARBOPLATIN AND PACLITAXEL VERSUS CISPLATIN, PACLITAXEL AND DOXORUBICIN FOR FIRST-LINE CHEMOTHERAPY OF ADVANCED OVARIAN CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) STUDY

G. Aravantinos, G. Fountzilas, A. Bamias, I. Grimani, S. Rizos, H.P Kalofonos, D.V Skarlos, T. Economopoulos, P.A Kosmidis, G.P Stathopoulos, E. Briasoulis, D. Pectasides, E. Samantas, E. Timotheadou, C. Papadimitriou, A. Papanikolaou, A. Onyenadum, P. Papakostas, D. Bafaloukos, M.A Dimopoulos; Hellenic Cooperative Oncology Group study.

Eur J Cancer. 2008 Oct;44(15):2169-77


 POTENTIAL VALUE OF PTEN IN PREDICTING CETUXIMAB RESPONSE IN COLORECTAL CANCER: AN EXPLORATORY STUDY

E. Razis, E. Briasoulis, E. Vrettou, D.V Skarlos, D. Papamichael, I. Kostopoulos, E. Samantas, I. Xanthakis, M. Bobos, E. Galanidi, M. Bai, I. Gikonti, A. Koukouma, G. Kafiri, P. Papakostas, K.T Kalogeras, P. Kosmidis, G. Fountzilas.

BMC Cancer. 2008 Aug 13;8: 234


 SOMATIC MUTATIONS OF THE TYROSINE KINASE DOMAIN OF EPIDERMAL GROWTH FACTOR RECEPTOR AND TYROSINE KINASE INHIBITOR RESPONSE TO TKIs IN NON-SMALL CELL LUNG CANCER: AN ANALYTICAL DATABASE

Murray S, Dahabreh IJ, Linardou H, Manoloukos M, Bafaloukos D, Kosmidis P.

J Thorac Oncol. 2008 Aug;3(8):832-9


 MYELOTOXICITY AS A PROGNOSTIC FACTOR IN PATIENTS WITH ADVANCED BREAST CANCER TREATED WITH CHEMOTHERAPY: A POOLED ANALYSIS OF TWO RANDOMISED TRIALS CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP

Koutras AK, Fountzilas G, Dafni U, Dimopoulos MA, Pectasides D, Klouvas G, Papakostas P, Kosmidis P, Samantas E, Gogas H, Briasoulis E, Vourli G, Petsas T, Xiros N, Kalofonos HP; Hellenic Cooperative Oncology Group.

Anticancer Res. 2008 Sep-Oct;28(5B):2913-20


 EVALUATION OF THE PROGNOSTIC AND PREDICTIVE VALUE OF HER FAMILY mRNA EXPRESSION IN HIGH-RISK EARLY BREAST CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) STUDY

Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G; Hellenic Cooperative Oncology Group (HeCOG).

Br J Cancer. 2008 Dec 2;99(11):1775-85


 GEMCITABINE COMBINED WITH GEFITINIB IN PATIENTS WITH INOPERABLE OR METASTATIC PANCREATIC CANCER: A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP WITH BIOMARKER EVALUATION

Fountzilas G, Bobos M, Kalogera-Fountzila A, Xiros N, Murray S, Linardou H, Karayannopoulou G, Koutras AK, Bafaloukos D, Samantas E, Christodoulou C, Economopoulos T, Kalogeras KT, Kosmidis P.

Cancer Invest. 2008 Oct;26(8):784-93


 ASSESSMENT OF SOMATIC k-RAS MUTATIONS AS A MECHANISM ASSOCIATED WITH RESISTANCE TO EGFR-TARGETED AGENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF STUDIES IN ADVANCED NON-SMALL-CELL LUNG CANCER AND METASTATIC COLORECTAL CANCER

Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S.

Lancet Oncol. 2008 Oct;9(10):962-72


 MICROVESSEL DENSITY (MVD) AND CYCLOOXYGENASE-2 (COX-2)/ β-CATENIN INTERACTION ARE ASSOCIATED WITH RELAPSE IN PATIENTS WITH TRANSITIONAL CARCINOMA RECEIVING ADJUVANT

Chemotherapy with Paclitaxel/Carboplatin: a Hellenic Cooperative Oncology Group (HECOG) Study

A.Bamias, F.Kyriakou, M.Chorti, N.Kavantzas, A.Noni, A.Kyroudi-Voulgari, D.Rontoyianni, E.Kastritis, N.Xiros, E.S.Patsouris, S.Murray, N.Tamvakis, M.A.Dimopoulos

Anticancer Res. 2008 Jul-Aug;28(4C):2479-86


 DCC AND TS PROTEIN EXPRESSION IN RESECTED GASTRIC CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

A. Bamias, G. Fountzilas, M. Michael, C. Konstantaras, E. Vrettou, E. Eleftheriadis, P. Papakostas, K. Papadimitriou, N. Pavlidis, N. Xiros, M. Bai

Cent Eur J Med. 2008 ; 3(1) : 29-39


 THE ROLE OF TAXANES IN THE MANAGEMENT OF PATIENTS WITH EARLY BREAST CANCER: A REVIEW OF THE CLINICAL EVIDENCE AND MOLECULAR MECHANISMS OF RESISTANCE

H. Gogas, G. Pentheroudakis, A. Antoniadis, S. Murray, G. Fountzilas

Cancer and Chemotherapy Rev. 2008; 3


 GEMCITABINE AND PEGYLATED LIPOSOMAL DOXORUBICIN ALTERNATING WITH CISPLATIN PLUS CYCLOPHOSPHAMIDE IN PLATINUM REFRACTORY/RESISTANT, PACLITAXEL-PRETREATED, OVARIAN CARCINOMA

D. Pectasides, N. Xiros, G. Papaxoinis, G. Aravantinos, C. Sykiotis, E. Pectasides, A. Psyrri, A. Koumarianou, A. Gaglia, P. Gouveris, T. Economopoulos

Gynecol Oncol 2008; 108 (1): 47-52

Δημοσιεύσεις 2009

EPITHELIAL OVARIAN CANCER IN GREECE: A RETROSPECTIVE STUDY OF 1791 PATIENTS BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG)

D. Pectasides, G. Papaxoinis, G. Fountzilas, G. Aravantinos, A. Bamias, N. Pavlidis, H.P. Kalofonos, E. Timotheadou, E. Samantas, E. Briasoulis, D.V. Skarlos, T. Economopoulos, M.A. Dimopoulos

Anticancer Research 2009 Feb;29(2):745-5


 ECONOMIC EVALUATION OF TAXANE-BASED FIRST-LINE CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER IN GREECE: AN ANALYSIS ALONGSIDE A MULTICENTER, RANDOMIZED PHASE III CLINICAL TRIAL

N. Maniadakis, U. Dafni, V. Fragoulakis, I. Grimani, E. Galani, A. Fragkoulidi, G. Fountzilas

Annals of Oncology 2009 Feb;20(2):278-85 [Epub 2008 Oct]


 GENE EXPRESSION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND MICROTUBULE-ASSOCIATED PROTEIN TAU IN HIGH-RISK EARLY BREAST CANCER: A QUEST FOR MOLECULAR PREDICTORS OF TREATMENT BENEFIT IN THE CONTEXT OF A HELLENIC COOPERATIVE ONCOLOGY GROUP TRIAL

G. Pentheroudakis, KT Kalogeras, RM Wirtz, I. Grimani, G. Zografos, H. Gogas, U. Stropp, D. Pectasides, D. Skarlos, G. Hennig, E. Samantas, D. Bafaloukos, P. Papakostas, H.P Kalofonos, N. Pavlidis, G. Fountzilas

Breast Cancer Research and Treatment 2009 Jul;116(1):131-43 [Epub 2008 Jul 31]


 A RANDOMIZED PHASE III STUDY COMPARING THREE ANTHRACYCLINE-FREE TAXANE-BASED REGIMENS, AS FIRST LINE CHEMOTHERAPY, IN METASTATIC BREAST CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

G. Fountzilas, U. Dafni, M.A Dimopoulos, A. Koutras, D. Skarlos, P. Papakostas, H. Gogas, D. Bafaloukos, A. Kalogera-Fountzila, E. Samantas, E. Briasoulis, D. Pectasides, N. Maniadakis, F. Matsiakou, G. Aravantinos, C. Papadimitriou, M. Karina, C. Christodoulou, P. Kosmidis, H.P Kalofonos

Breast Cancer Research and Treatment 2009 May;115(1):87-99 [Epub 2008 May 16]


 EFFECTS OF EPOETIN ALFA ON QUALITY OF LIFE OF CANCER PATIENTS WITH SOLID TUMORS RECEIVING CHEMOTHERAPY. A PROSPECTIVE, OPEN LABEL, RANDOMIZED TRIAL OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG)

C. Christodoulou, U. Dafni, G. Aravantinos, A. Koutras, E. Samantas, M. Karina, J. Janinis, P. Papakostas, D. Skarlos, H. Kalofonos, G. Fountzilas

Anticancer Research 2009 Feb;29(2):693-702


 INDUCTION CHEMOTHERAPY WITH DOCETAXEL AND CISPLATIN FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY IN PATIENTS WITH INOPERABLE NON-NASOPHARYNGEAL CARCINOMA OF THE HEAD AND NECK

G. Fountzilas, A. Bamias, A. Kalogera-Fountzila, G. Karayannopoulou, M. Bobos, E. Athanassiou, K.T. Kalogeras, C. Tolis, P. Tsekeris, P. Papakostas, C. Vamvouka, T. Zaramboukas, P. Kosmidis, N. Zamboglou, D. Misailidou

Anticancer Research 2009 Feb;29(2):529-38


 TRASTUZUMAB COMBINED WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN PATIENTS WITH METASTATIC BREAST CANCER. A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) WITH BIOMARKER EVALUATION

C. Christodoulou, I. Kostopoulos, H.P. Kalofonos, E. Lianos, M. Bobos, E. Briasoulis, H. Gogas, E. Razis, D.V. Skarlos, G. Fountzilas

Oncology 2009;76(4):275-85 [Epub 2009 Mar 5]


 ANALYSIS OF 7 IMMUNOHISTOCHEMICAL MARKERS IN MALE GERM CELL TUMORS DEMONSTRATES THE PROGNOSTIC SIGNIFICANCE OF P53 AND MIB-1

D. Pectasides, G. Papaxoinis, M. Nikolaou, C. Valavanis, G. Aravantinos, G. Fountzilas, N. Tamvakis, E. Pectasides, I. Lekka, P. Arapantoni-Dadioti, A. Zizi, I. Ghiconti, T. Economopoulos

Anticancer Research 2009 Feb;29(2):737-44


 TOPOISOMERASE I BUT NOT THYMIDYLATE SYNTHASE IS ASSOCIATED WITH IMPROVED OUTCOME IN PATIENTS WITH RESECTED COLORECTAL CANCER TREATED WITH IRINOTECAN CONTAINING ADJUVANT CHEMOTHERAPY

I. Kostopoulos, V. Karavasilis, M. Karina, M. Bobos, N. Xiros, G. Pentheroudakis, G. Kafiri, P. Papakostas, E. Vrettou, G. Fountzilas

BMC Cancer 2009 Sep 24;9:339


 TARGETED KRAS MUTATION ASSESSMENT ON PATIENT TUMOR HISTOLOGIC MATERIAL IN REAL TIME DIAGNOSTICS

V. Kotoula, E. Charalambous, B. Biesmans, A. Malousi, E. Vrettou, G. Fountzilas, G. Karkavelas

PLoS One 2009 Nov 4;4(11):e7746


 CONTRIBUTION OF BRCA1 GERM-LINE MUTATIONS TO BREAST CANCER IN GREECE: A HOSPITAL-BASED STUDY OF 987 UNSELECTED BREAST CANCER CASES

S. Armaou, M. Pertesi, F. Fostira, G. Thodi, P.S Athanasopoulos, S. Kamakari, A. Athanasiou, H. Gogas, D. Yannoukakos, G .Fountzilas and I. Konstantopoulou

British Journal of Cancer 2009 Jul 7;101(1):32-7 [Epub 2009 Jun 2]


 PHASE II STUDY OF NEOADJUVANT IMATINIB IN GLIOBLASTOMA: EVALUATION OF CLINICAL AND MOLECULAR EFFECTS OF THE TREATMENT

E. Razis, P. Selviaridis, S. Labropoulos, J.L. Norris, M.J Zhu, D.D. Song, T. Kalebic, M. Torrens, A. Kalogera-Fountzila, G. Karkavelas, S. Karanastasi, J.A. Fletcher, and G. Fountzilas

Clinical Cancer Research 2009 Oct 1;15(19):6258-66 [Epub 2009 Sep 29]


 RANDOMIZED MULTICENTER PHASE II TRIAL OF CISPLATIN AND IFOSFAMIDE WITH OR WITHOUT PACLITAXEL IN RECURRENT OR METASTATIC CARCINOMA OF THE UTERINE CERVIX: A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY

G. Mountzios, M. A. Dimopoulos, A. Bamias, G. Vourli, H. Kalofonos, G. Aravantinos, G. Fountzilas & C. A. Papadimitriou

Annals of Oncology 2009 Aug;20(8):1362-8 [Epub 2009 May 20]


 TRANSCRIPTIONAL ACTIVITY OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER) FAMILY AND ANGIOGENESIS EFFECTORS IN LOCOREGIONALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) AND CORRELATION WITH PATIENT OUTCOME

G. Pentheroudakis, N. Angouridakis, R.M. Wirtz, A. Nikolaou, K.T. Kalogeras, N. Pavlidis, G. Fountzilas

Journal of Oncology 2009;2009:854127 [Epub 2009 Oct 7]


 DOSE-RANGING STUDY OF METRONOMIC ORAL VINORELBINE IN PATIENTS WITH ADVANCED REFRACTORY CANCER

E. Briasoulis, P. Pappas, C. Puozzo, C. Tolis, G. Fountzilas, U. Dafni, M. Marselos, and N. Pavlidis

Clinical Cancer Research 2009 Oct 15;15(20):6454-61 [Epub 2009 Oct 6]


 PEGFILGRASTIM ADMINISTERED ON THE SAME DAY WITH DOSE-DENSE ADJUVANT CHEMOTHERAPY FOR BREAST CANCER IS ASSOCIATED WITH HIGHER INCIDENCE OF FEBRILE NEUTROPENIA AS COMPARED TO CONVENTIONAL GROWTH FACTOR SUPPORT. A MATCHED CASE-CONTROL STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG)

D.V. Skarlos, E. Timotheadou, E. Galani, E. Samantas, I. Grimani, E. Lianos, G. Aravantinos, I. Xanthakis, G. Pentheroudakis, D. Pectasides, G. Fountzilas.

Oncology 2009;77(2):107-12 [Epub 2009 Jul 21]


 MANAGEMENT OF ADVANCED STAGE UTERINE SARCOMAS: A BONE OF CONTENTION

F. Zagouri, H. Linardou, A.M Dimopoulos, C.A Papadimitriou

European Journal of Gynaecologic Oncology 2009;30(5):483-92


 SOMATIC EGFR MUTATIONS AND EFFICACY OF TYROSINE KINASE INHIBITORS IN NSCLC

H. Linardou, I.J Dahabreh, D. Bafaloukos, P. Kosmidis, S. Murray

Nature Reviews Clinical Oncology 2009 Jun;6(6):352-66


 RANDOMIZED PHASE III STUDY OF ONE MONTH VERSUS ONE YEAR ADJUVANT HIGH-DOSE INTERFERON-&[ALPHA] 2B IN PATIENTS WITH RESECTED HIGH-RISK MELANOMA

D. Pectasides, U. Dafni, D. Bafaloukos, D. Skarlos, A. Polyzos, D. Tsoutsos, H. Kalofonos, G. Fountzilas, P. Panagiotou, G. Kokkalis, O. Papadopoulos, O. Castana, S. Papadopoulos, E. Stavrinidis, G. Vourli, J. Ioannovich†, H.G ogas

Journal of Clinical Oncology 2009 Feb 20;27(6):939-44 [Epub 2009 Jan 12]


 PRIMARY FALLOPIAN TUBE CARCINOMA: RESULTS OF A RETROSPECTIVE ANALYSIS OF 64 PATIENTS

D. Pectasides, E. Pectasides, G. Papaxoinis, C. Andreadis, G. Papatsibas, G. Fountzilas, K. Pliarchopoulou, A. Macheras, G. Aravantinos, T. Economopoulos

Gynecol Oncol 2009 Oct;115(1):97-101 [Epub 2009 Jul 16]


 XELOX versus FOLFOX6 AS AN ADJUVANT TREATMENT IN COLORECTAL CANCER: AN ECONOMIC ANALYSIS

N. Maniadakis, V. Fragoulakis, D. Pectasides, G. Fountzilas

Curr Med Res Opin 2009 Mar;25(3):797-805


 CARBOPLATIN AND PACLITAXEL IN METASTATIC OR RECURRENT CERVICAL CANCER

D. Pectasides D, Fountzilas G, Papaxoinis G, Pectasides E, Xiros N, Sykiotis C, Koumarianou A, Psyrri A, Panayiotides J, Economopoulos T.

Int J Gynecol Cancer 2009 May;19(4):777-81


 GASTRIC METASTASES ORIGINATING FROM BREAST CANCER: REPORT OF 8 CASES AND REVIEW OF THE LITERATURE

D. Pectasides, A. Psyrri, K. Pliarchopoulou, T. Floros, G. Papaxoinis, M. Skondra, G. Papatsibas, A. Macheras, G. Athanasas, P. Arapantoni-Datioti, T. Economopoulos

Anticancer Res 2009 Nov;29(11):4759-63


 NON-SMALL CELL LUNG CANCER IN THE ELDERLY: CLINICO-PATHOLOGIC, MANAGEMENT AND OUTCOME CHARACTERISTICS IN COMPARISON TO YOUNGER PATIENTS

A. Koumarianou, G. Fountzilas, P. Kosmidis, G. Klouvas, E. Samantas, C. Kalofonos, G. Pentheroudakis, T. Economopoulos, D. Pectasides

J Chemother 2009 Nov;21(5):573-83


 SUNITINIB TREATMENT IN PATIENTS WITH SEVERE RENAL FUNCTION IMPAIRMENT: A REPORT OF FOUR CASES BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP

G. Lainakis, A. Bamias, E. Psimenou, G. Fountzilas, M.A. Dimopoulos

Clin Nephrology 2009 Jul;72(1):73-8


 THE IMPORTANCE OF TUMOR VOLUME IN THE PROGNOSIS OF PATIENTS WITH GLIOBLASTOMA. COMPARISON OF COMPUTERIZED VOLUMETRY AND GEOMETRIC MODELS

G. Iliadis, P. Selviaridis, A. Kalogera-Fountzila, A. Fragkoulidi, D. Baltas, N. Tselis, A. Chatzisotiriou, D. Misailidou, N. Zamboglou, G. Fountzilas

Strahlentherapie und Onkologie 2009 Nov;185(11):743-50 [Epub 2009 Nov 10]


 STAGE I TESTICULAR SEMINOMA: MANAGEMENT AND CONTROVERSIES

D. Pectasides, E. Pectasides, A. Constantinidou, G. Aravantinos

Critical Reviews in Oncology/Hematology 2009 Jul;71(1):22-8 [Epub 2008 Nov 28]


 CURRENT MANAGEMENT OF STAGE I TESTICULAR NON-SEMINOMATOUS GERM CELL TUMOURS

D. Pectasides, E. Pectasides, A. Constantinidou, G. Aravantinos

Crit Rev Oncol Hematol 2009 May;70(2):114-23. Epub 2008 Sep 19


 WEEKLY DOCETAXEL WITH OR WITHOUT GEMCITABINE AS SECOND LINE CHEMOTHERAPY IN PACLITAXEL PRETREATED PATIENTS WITH METASTATIC BREAST CANCER: A RANDOMISED PHASE II STUDY CONDUCTED BY THE HELLENIC CO-OPERATIVE ONCOLOGY GROUP (HECOG)

C.A Papadimitriou, H. Kalofonos, F. Zagouri, P. Papakostas, G. Bozas, T. Makatsoris, M.A Dimopoulos, G. Fountzilas

Oncology 2009;77(3-4):212-6 [Epub 2009 Sep 4]


 MMP9 BUT NOT EGFR, MET, ERCC1, P16, AND P-53 IS ASSOCIATED WITH RESPONSE TO CONCOMITANT RADIOTHERAPY, CETUXIMAB AND WEEKLY CISPLATIN IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CANCER

G. Fountzilas, A. Kalogera-Fountzila, S. Lambaki, R.M. Wirtz, A. Nikolaou, G. Karayannopoulou, M. Bobos, V. Kotoula, S. Murray, A. Lambropoulos, G. Aravantinos, K. Markou, E. Athanassiou, D. Misailidou, K.T. Kalogeras, D. Skarlos

J Oncol 2009;2009:305908 [Epub 2009 Dec 29]


 ELUCIDATION OF THE TRANSMISSION OF A NOVEL MUTATION IN BRCA1 [1125DELCT] IN A FAMILY WITH MULTIPLE CASES OF BREAST CANCER

E. Razis, I. Belogianni, V. Siamanta, A. Apessos, V. Kyriakopoulou, E. Papadopoulou, M. Sariyanni, D. Theofilopoulos, S. Labropoulos, G. Nasioulas

Cancer Genomics Proteomics 2009 Jul-Aug;6(4):215-7

Δημοσιεύσεις 2010

A TWISTED KISS: IN VITRO AND IN VIVO EVIDENCE OF GENETIC VARIATION AND SUPPRESSED TRANSCRIPTION OF THE METASTASIS-SUPPRESSOR GENE KISS1 IN EARLY BREAST CANCER

G. Pentheroudakis, L. Kostadima, L. Dova, I. Georgiou, T. Tzavaras, G. Vartholomatos, R. M.Wirtz, G. Fountzilas, V. Malamou-Mitsi, N. Pavlidis

Neoplasma 2010;57(1):47-54


 A RANDOMIZED PHASE II STUDY OF CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS CARBOPLATIN PLUS PACLITAXEL IN PLATINUM SENSITIVE OVARIAN CANCER PATIENTS: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

D. Bafaloukos, H. Linardou, G. Aravantinos, C. Papadimitriou, A. Bamias, G. Fountzilas, H.P Kalofonos, P. Kosmidis, E. Timotheadou, T. Makatsoris, E. Samantas, E. Briasoulis, C. Christodoulou, P. Papakostas, D. Pectasides, A.M Dimopoulos

BMC Med 2010 Jan 7;8:3.


 SOMATIC EGFR MUTATION AND GENE COPY GAIN AS PREDICTIVE BIOMARKERS FOR RESPONSE TO TYROSINE KINASE INHIBITORS IN NON-SMALL CELL LUNG CANCER

IJ Dahabreh, H. Linardou, F. Siannis, P. Kosmidis, D. Bafaloukos, S. Murray

Clinical Cancer Research 2010 Jan 1;16(1):291-303


 PROGNOSTIC STRATIFICATION OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH SUNITINIB. COMPARISON WITH THE MEMORIAL SLOAN-KETTERING PROGNOSTIC FACTORS MODEL

A. Bamias, A. Karadimou, S. Lampaki, G. Lainakis, L. Malettou, E. Timotheadou, K. Papazisis, Ch. Andraeadis, L. Kontovinis, I. Anastasiou, K. Stravodimos, I. Xanthakis, A. Skolarikos, Ch. Christodoulou, K. Syrigos, Ch. Papandreou, E. Razi, U. Dafni, G. Fountzilas and M.A Dimopoulos

BMC Cancer 2010 Feb 18;10:45


 PACLITAXEL AND CARBOPLATIN AS NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED BREAST CANCER: A PHASE II TRIAL OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP

H. Gogas, D. Pectasides, I. Kostopoulos, E. Lianos, D. Skarlos, G. Papaxoinis, M. Bobos, H.P. Kalofonos, K. Petraki, K. Pavlakis, D. Bafaloukos, G. Fountzilas

Clinical Breast Cancer 2010 Jun;10(3):230-7


 A LOCUS ON 19p13 MODIFIES RISK OF BREAST CANCER IN BRCA1 MUTATION CARRIERS AND IS ASSOCIATED WITH HORMONE RECEPTOR-NEGATIVE BREAST CANCER IN THE GENERAL POPULATION

A.C. Antoniou….D. Yannoukakos, G. Fountzilas… et al

Nature Genetics 2010 Oct;42(10):885-92 [Epub 2010 Sep 19]


 NUCLEAR LOCALIZATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 IN HEAD AND NECK SQUAMOUS CELL CARCINOMA IS ASSOCIATED WITH A BETTER PROGNOSIS

E.Pectasides, A.M.Egloff, C.Sasaki, P.Kountourakis, B.Burtness, G.Fountzilas, U.Dafni, T.Zaramboukas, T.Rampias, D.Rimm, J.Grandis, A.Psyrri

Clin Cancer Res 2010 Apr 15;16(8):2427-34 [Epub 2010 Apr 6]


 A PHASE II STUDY OF SUNITINIB IN PATIENTS WITH RECURRENT AND/OR METASTATIC NON-NASOPHARYNGEAL HEAD AND NECK CANCER

G.Fountzilas, A.Fragkoulidi, A.Kalogera-Fountzila, M.Nikolaidou, M. Bobos, J.Calderaro, F.Andreiuolo, M.Marselos

Cancer Chemother Pharmacol 2010 Mar;65(4):649-60 [Epub 2009 Aug 5]


 CARBOPLATIN PLUS PEMETREXED AS FIRST-LINE TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA: A PHASE II STUDY

N. Katirtzoglou, I. Gkiozos, N. Makrilia, E. Tsaroucha, A. Rapti, G. Stratakos, G. Fountzilas, KN. Syrigos

Clin Lung Cancer 2010 Jan;11(1):30-5


 FIFTEEN-YEAR TRENDS IN METASTATIC BREAST CANCER SURVIVAL IN GREECE

U.Dafni, I.Grimani, A.Xyrafas, AG.Eleftheraki, G.Fountzilas

Breast Cancer Res Treat 2010 Feb;119(3):621-31


 A RANDOMISED PHASE III STUDY OF ADJUVANT PLATINUM/DOCETAXEL CHEMOTHERAPY WITH OR WITHOUT RADIATION THERAPY IN PATIENTS WITH GASTRIC CANCER

A. Bamias, M. Karina, P. Papakostas, I. Kostopoulos, M. Bobos, G. Vourli, E. Samantas, Ch. Christodoulou, G. Pentheroudakis, D. Pectasides, M.A. Dimopoulos, G. Fountzilas

Cancer Chemotherapy and Pharmacology 2010 May;65(6):1009-21


 BEVACIZUMAB IN THE TREATMENT OF BREAST CANCER

A.K.Koutras, G.Fountzilas, T.Makatsoris, S.Peroukides, H.P.Kalofonos

Cancer Treat Rev 2010 Feb;36(1):75-82


 EFFECTS OF KRAS, BRAF, NRAS, AND PIK3CA MUTATIONS ON THE EFFICACY OF CETUXIMAB PLUS CHEMOTHERAPY IN CHEMOTHERAPY-REFRACTORY METASTATIC COLORECTAL CANCER: A RETROSPECTIVE CONSORTIUM ANALYSIS

W. De Roock, B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas, KT Kalogeras, V. Kotoula, D. Papamichael, P. Laurent-Puig, F. Penault-Llorca, P. Rougier, B. Vincenzi, D. Santini, G. Tonini, F. Cappuzzo, M. Frattini, F. Molinari, P. Saletti, S. De Dosso, M. Martini, A. Bardelli, S. Siena, A. Sartore-Bianchi, J. Tabernero, T. Macarulla, F. Di Fiore, AO Gangloff, F. Ciardiello, P. Pfeiffer, C. Qvortrup, TP Hansen, E. Van Cutsem, H. Piessevaux, D. Lambrechts, M. Delorenzi, S. Tejpar

Lancet Oncol 2010 Aug;11(8):753-62 [Epub 2010 Jul 8]


 SCREENING OF THE DNA MISMATCH REPAIR GENES MLH1, MSH2 AND MSH6 IN GREEK COHORT OF LYNCH SYNDROME SUSPECTED FAMILIES

G. Thodi, F. Fostira, R. Sandaltzopoulos, G. Nasioulas, A.A. Grivas, I. Boukovinas, M. Mylonaki, C. Panopoulos, M. Brankovic Magic, G. Fountzilas, D. Yannoukakos

BMC Cancer 2010 Oct 11;10:544


 THE UPGRADED ROLE OF HER3 AND HER4 RECEPTORS IN BREAST CANCER

AK. Koutras, G. Fountzilas, KT. Kalogeras, I. Starakis, G. Iconomou, HP. Kalofonos

Crit Rev Oncol Hematol 2010 May;74(2):73-8 [Epub 2009 May 30]


 COMBINATION OF OSTEOPONTIN AND ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE AS POTENT PROGNOSTIC DISCRIMINATORS IN HER2 AND ER NEGATIVE BREAST CANCER

M. Ihnen, R.M. Wirtz, K.T. Kalogeras, K. Milde-Langosch, M. Schmidt, I. Witzel, A.G. Eleftheraki, C. Papadimitriou, F. Jänicke, E. Briassoulis, D. Pectasides, A. Rody, G. Fountzilas and V. Müller

Brit J Cancer 2010 Sep 28;103(7):1048-56 [Epub 2010 Aug 24]


 TP53 ARG72PRO POLYMORPHISM AND COLORECTAL CANCER RISK: A SYSTEMATIC REVIEW AND META-ANALYSIS

IJ Dahabreh, H. Linardou, P. Bouzika, V. Varvarigou, S. Murray

Cancer Epidemiol Biomarkers Prev 2010 Jul;19(7):1840-7


 LOW FREQUENCY OF SOMATIC MUTATIONS IN UTERINE SARCOMAS: A MOLECULAR ANALYSIS AND REVIEW OF THE LITERATURE

S. Murray, H. Linardou, G. Mountzios, M. Manoloukos, S. Markaki, E. Eleutherakis-Papaiakovou, MA Dimopoulos, CA Papadimitriou

Mutat Res 2010 Apr 1;686(1-2):68-73 [Epub 2010 Feb 1]


 MUTATIONAL SPECTRUM OF APC AND GENOTYPE-PHENOTYPE CORRELATIONS IN GREEK FAP PATIENTS

F. Fostira, G. Thodi, R. Sandaltzopoulos, G. Fountzilas and D. Yannoukakos

BMC Cancer 2010 Jul 22;10:389


 PHASE I TRIAL OF WEEKLY IRINOTECAN AND PACLITAXEL COMBINED WITH CARBOPLATIN IN PATIENTS WITH ADVANCED CANCER. A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

E. Briasoulis, V. Golfinopoulos, M.Karina, P. Papakostas, N. Pavlidis, G. Fountzilas

Anticancer Drugs 2010 Sep;21(8):785-9


 CARBOPLATIN/GEMCITABINE ALTERNATING WITH CARBOPLATIN/PEGYLATED LIPOSOMAL DOXORUBICIN AND CARBOPLATIN/CYCLOPHOSPHAMIDE IN PLATINUM REFRACTORY/RESISTANT PACLITAXEL – PRETREATED OVARIAN CARCINOMA

D. Pectasides, E. Pectasides, G. Papaxoinis, A. Psyrri, K. Pliarchopoulou, A. Koumarianou, A. Macheras, G. Athanasas, N. Xiros, T. Economopoulos

Gynecologic Oncology 2010 Jul;118(1):52-7 [Epub 2010 Apr 20]


 CORRELATION OF MOLECULAR HLA TYPING AND OUTCOME IN HIGH-RISK MELANOMA PATIENTS RECEIVING ADJUVANT INTERFERON

H. Gogas, J.M Kirkwood, C.S. Falk, U. Dafni, V.K. Sondak, D. Tsoutsos, A. Stratigos, C. Markopoulos, D. Pectasides, M. Spyropoulou-Vlachou

Cancer 2010 Sep 15;116(18):4326-33


 IRINOTECAN/FLUOROURACIL/LEUCOVORIN OR THE SAME REGIMEN FOLLOWED BY OXALIPLATIN/FLUOROURACIL/LEUCOVORIN IN METASTATIC COLORECTAL CANCER

H. P. Kalofonos, P. Papakostas, T. Makatsoris, D. Papamichael, G. Vourli, I. Xanthakis, G. Aravantinos, C. Papadimitriou, G. Pentheroudakis, I. Varthalitis, G. Samelis, K.N. Syrigos, N. Xiros, M. Stavropoulos, P. Kosmidis, C. Christodoulou, H. Linardou, M. Skondra, D. Pectasides, T. Economopoulos, G. Fountzilas

Anticancer Res 2010 Oct;30(10):4325-33


 EVALUATION OF SIX CTLA-4 POLYMORPHISMS IN HIGH-RISK MELANOMA PATIENTS RECEIVING ADJUVANT INTERFERON THERAPY IN THE HE13A/98 MULTICENTER TRIAL

H. Gogas, U. Dafni, H. Koon, M. Spyropoulou-Vlachou, Y. Metaxas, E. Buchbinder, E. Pectasides, D. Tsoutsos, A. Polyzos, A. Stratigos, C. Markopoulos, P. Panagiotou, G. Fountzilas, O. Castana, P. Skarlos, M.B. Atkins, J.M. Kirkwood

J Transl Med 2010 Nov 3;8:108


 SCREENING FOR EGFR MUTATIONS IN PATIENTS WITH HEAD AND NECK CANCER TREATED WITH GEFITINIB ON A COMPASSIONATE-USE PROGRAM: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

S. Murray, M. Bobos, N. Angouridakis, A. Nikolaou, H. Linardou, E. Razis, G. Fountzilas

Journal of Oncology 2010;2010:709678 [Epub 2011 Jan 3]

Δημοσιεύσεις 2011

A RANDOMIZED PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH IRINOTECAN, LEUCOVORIN AND FLUOROURACIL VERSUS LEUCOVORIN AND FLUOROURACIL FOR STAGE II AND III COLON CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

C.A. Papadimitriou, P. Papakostas, M. Karina, L. Malettou, M.A. Dimopoulos, G. Pentheroudakis, E. Samantas, A. Bamias, D. Miliaras, G. Basdanis, N. Xiros, G. Klouvas, D. Bafaloukos, G. Kafiri, I. Papaspirou, D. Pectasides, C. Karanikiotis, T. Economopoulos, I. Efstratiou, I. Korantzis, N. Pisanidis, T. Makatsoris, F. Matsiakou, G. Aravantinos, H. P. Kalofonos, G. Fountzilas

BMC Med 2011 Jan 31;9:10


ALL ABOUT KRAS FOR CLINICAL ONCOLOGY PRACTICE: GENE PROFILE, CLINICAL IMPLICATIONS AND LABORATORY RECOMMENDATIONS FOR SOMATIC MUTATIONAL TESTING IN COLORECTAL CANCER

H. Linardou, E. Briasoulis, I.J. Dahabreh, G. Mountzios, C. Papadimitriou, S. Papadopoulos, D. Bafaloukos, P. Kosmidis, S. MurrayCancer

Cancer Treat Rev 2011 May;37(3):221-33 [Epub 2010 Sep 29]


STAT RELATED PROFILES ARE ASSOCIATED WITH PATIENT RESPONSE TO TARGETED TREATMENTS IN LOCALLY ADVANCED SCCHN

V. Kotoula, S. Lambaki, D. Televantou, A. Kalogera-Fountzila, A. Nikolaou, K. Markou, D. Misailidou, K.N. Syrigos, G. Fountzilas

Transl Oncol 2011 Feb 1;4(1):47-58


COMPARATIVE PROGNOSTIC VALUE OF EPIDERMAL GROWTH FACTOR QUANTITATIVE PROTEIN EXPRESSION COMPARED WITH FISH FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA

E. Pectasides, T. Rampias, P. Kountourakis, C. Sasaki, D. Kowalski, G. Fountzilas, T. Zaramboukas, D. Rimm, B. Burtness, A. Psyrri

Clin Cancer Res 2011 May 1;17(9):2947-54 [Epub 2011 Feb 25]


PACLITAXEL AND GEMCITABINE VERSUS PACLITAXEL AND VINORELBINE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER. A PHASE III STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG)

P.A. Kosmidis, G. Fountzilas, A.G. Eleftheraki, H.P. Kalofonos, G. Pentheroudakis, D. Skarlos, M.A. Dimopoulos, D. Bafaloukos, D. Pectasides, E. Samantas, I. Boukovinas, S. Lambaki, N. Katirtzoglou, C. Bakogiannis & K.N. Syrigos

Annals of Oncology 2011 Apr;22(4):827-34 [Epub 2010 Sep 29]


 EGFR GENE COPY NUMBER AS A PREDICTIVE BIOMARKER FOR PATIENTS RECEIVING TYROSINE KINASE INHIBITOR TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS IN NON-SMALL CELL LUNG CANCER

I.J. Dahabreh, H. Linardou, P. Kosmidis, D. Bafaloukos, S. Murray

Annals of Oncology 2011 Mar;22(3):545-52. [Epub 2010 Sep 8]


 MECHANISMS OF RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: CLINICAL AND MOLECULAR CONSIDERATIONS

A. Pallis, E. Briasoulis, H. Linardou, C. Papadimitriou, D. Bafaloukos, P. Kosmidis, S. Murray

Current Medicinal Chemistry 2011;18(11):1613-28


 PROGNOSTIC UTILITY OF Β-TUBULIN ISOTYPE III AND CORRELATIONS WITH OTHER MOLECULAR AND CLINICOPATHOLOGICAL VARIABLES IN PATIENTS WITH EARLY BREAST CANCER: A TRANSLATIONAL HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY

G. Pentheroudakis, A. Batistatou, K.T. Kalogeras, R. Kronenwett, R.M. Wirtz, E. Bournakis, A.G. Eleftheraki, D. Pectasides, M. Bobos, D. Miliaras, I. Papaspirou, S. Kamina, H. Gogas, A.K. Koutras, N. Pavlidis, G. Fountzilas

Breast Cancer Research and Treatment 2011 May;127(1):179-93. [Epub 2011 Mar 9]


REPORT OF THE LONG-TERM EFFICACY OF TWO CYCLES OF ADJUVANT BLEOMYCIN/ETOPOSIDE/CISPLATIN IN PATIENTS WITH STAGE I TESTICULAR NONSEMINOMATOUS GERM-CELL TUMORS (NSGCT): A RISK ADAPTED PROTOCOL OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP

A. Bamias, G. Aravantinos, I. Kastriotis, G. Alivizatos, I. Anastasiou, C. Christodoulou, R. Gyftaki, H.P Kalofonos, M.A Dimopoulos

Urologic Oncology 2011 Mar-Apr;29(2):189-93. [Epub 2009 Apr 11]


PACLITAXEL AND BEVACIZUMAB, AS FIRST LINE COMBINED TREATMENT, IN PATIENTS WITH METASTATIC BREAST CANCER.THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE WITH BIOLOGICAL MARKER EVALUATION

G. Fountzilas, H.P. Kourea, M. Bobos, D. Televantou, V. Kotoula, C. Papadimitriou, K.T. Papazisis, E. Timotheadou, I. Efstratiou, A. Koutras, G. Pentheroudakis, C. Christodoulou, G. Aravantinos, D. Miliaras, K. Petraki, C.N. Papandreou, P. Papakostas, D. Bafaloukos, D. Repana, E. Razis, D. Pectasides, A.M. Dimopoulos

Anticancer Research 2011 Sep;31(9):3007-18


RELEVANCE OF HER2 AND TOP2A PARAMETERS AS PROGNOSTIC FACTORS IN HIGH-RISK EARLY BREAST CANCER PATIENTS TREATED WITH ADJUVANT EPIRUBICIN-BASED DOSE-DENSE SEQUENTIAL TREATMENT IN THE CONTEXT OF HELLENIC COOPERATIVE ONCOLOGY GROUP RANDOMIZED TRIAL

G. Fountzilas, Ch. Valavanis, V. Kotoula, A.G. Eleftheraki, K.T. Kalogeras, O. Tzaida, A. Batistatou, R. Kronenwett, R.M. Wirtz, M. Bobos, E.Timotheadou, N. Soupos, G. Pentheroudakis, H. Gogas, D. Vlachodimitropoulos, G. Polychronidou, G. Aravantinos, A. Koutras, Ch. Christodoulou, D. Pectasides, and P. Arapantoni

Journal of Translational Medicine, On line


VASCULAR ENDOTHELIAL GROWTH FACTOR POLYMORPHISMS AND CLINICAL OUTCOME IN COLORECTAL CANCER PATIENTS TREATED WITH IRINOTECAN-BASED CHEMOTHERAPY AND BEVACIZUMAB IN THE FIRST-LINE SETTING

A.K. Koutras, A. Antonacopoulou, A.G. Eleftheraki, A. Koumarianou, I. Varthalitis, F. Fostira, I. Sgouros, E. Briasoulis, E. Bournakis, D. Bafaloukos, I. Bombolaki, E. Galani, D. Pectasides, G. Foutzilas, H.P. Kalofonos

Pharmacogenomics J. 2012 Dec;12(6):468-75. doi: 10.1038/tpj.2011.37. [Epub 2011 Aug 16]


INDUCTION CHEMOTHERAPY FOLLOWED BY CONCOMITANT RADIOTHERAPY AND WEEKLY CISPLATIN VERSUS THE SAME CONCOMITANT CHEMORADIOTHERAPY IN PATIENTS WITH NASOPHARYNGEAL CARCINOMA: A RANDOMIZED PHASE II STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) WITH BIOMARKER EVALUATION

G. Fountzilas, E. Ciuleanu, M. Bobos, A. Kalogera-Fountzila, A.G Eleftheraki, G. Karayannopoulou, T. Zaramboukas, A. Nikolaou, K. Markou, L. Resiga, D. Dionysopoulos, E. Samantas, H. Athanassiou, D. Misailidou, D. Skarlos, T. Ciuleanu

Annals of Oncology, 2012 Feb;23(2):427-35. [Epub 2011 Apr 27]


EVALUATION OF THE ASSOCIATION OF PIK3CA MUTATIONS AND PTEN LOSS WITH EFFICACY OF TRASTUZUMAB THERAPY IN METASTATIC BREAST CANCER

E.Razis, M. Bobos, V. Kotoula, A.G. Eleftheraki, H.P. Kalofonos, K. Pavlakis, P. Papakostas, G. Aravantinos, G. Rigakos, I. Efstratiou, K. Petraki, D. Bafaloukos, I. Kostopoulos, D. Pectasides, K.T. Kalogeras, D. Skarlos, G. Fountzilas

Breast Cancer Research and Treatment 2011 Jul;128(2):447-56. [Epub 2011 May 19]


COMMON BREAST CANCER SUSCEPTIBILITY LOCI ARE ASSOCIATED WITH TRIPLE NEGATIVE BREAST CANCER

K.N Stevens, C.M Vachon, A.M Lee, S. Slager, T. Lesnick, C. Olswold, P.A Fasching, P. Miron, D. Eccles, J.E Carpenter, A.K Godwin, C. Ambrosone, R. Winqvist, H. Brauch H; GENICA consortium, M.K Schmidt, A. Cox, S.S Cross, E. Sawyer, A. Hartmann, M.W Beckmann, R. Schulz-Wendtland, A.B Ekici, W.J Tapper, S.M Gerty, L. Durcan, N. Graham, R. Hein, S. Nickels, D. Flesch-Janys, J. Heinz, H.P Sinn, I. Konstantopoulou, F. Fostira, D. Pectasides, A.M Dimopoulos, G. Fountzilas, C.L Clarke, R. Balleine, J.E Olson, Z. Fredericksen, R.B Diasio, H. Pathak, E. Ross, J. Weaver, T. Rüdiger, A. Försti, T. Dünnebier, F. Ademuyiwa, S. Kulkarni, K. Pylkäs, A. Jukkola-Vuorinen,Y.D Ko, E. Van Limbergen, H. Janssen, J. Peto, O. Fletcher, G.G Giles, L. Baglietto, S. Verhoef, I. Tomlinson, V.M Kosma, J. Beesley, D. Greco, C. Blomqvist, A. Irwanto, J. Liu, F.M Blows, S.J Dawson, S. Margolin, A. Mannermaa, N.G Martin, G.W Montgomery, D. Lambrechts, I. dos Santos Silva, G. Severi, U. Hamann, P. Pharoah, D.F Easton, J. Chang-Claude, D. Yannoukakos, H. Nevanlinna, X. Wang, F.J Couch

Cancer Research, 2011 Oct 1;71(19):6240-9. [Epub 2011 Aug 15]


A COMMON VARIANT AT THE TERT/CLPTM1L LOCUS IS ASSOCIATED WITH ESTROGEN RECEPTOR-NEGATIVE BREAST CANCER

C.A Haiman, G.K Chen, C.M Vachon, F. Canzian, A. Dunning, R.C Millikan, X. Wang, F. Ademuyiwa, S. Ahmed, C.B Ambrosone, L. Baglietto, R. Balleine, E.V Bandera, M.W Beckmann, C.D Berg, L. Bernstein, C. Blomqvist, W.J Blot, H. Brauch, J.E Buring, L.A Carey, J.E Carpenter, J. Chang-Claude, S.J Chanock, D.I Chasman, C.L Clarke, A. Cox, S.S Cross, S.L Deming, R.B Diasio, A.M Dimopoulos, W.R Driver, T. Dünnebier, L. Durcan, D. Eccles, C.K Edlund, A.B Ekici, P.A Fasching, H.S Feigelson, D. Flesch-Janys, F. Fostira, A. Försti, G. Fountzilas, S.M Gerty; Gene Environment Interaction and Breast Cancer in Germany (GENICA) Consortium, G.G Giles, A.K Godwin, P. Goodfellow, N. Graham, D. Greco, U. Hamann, S.E Hankinson, A. Hartmann, R. Hein, J. Heinz, A. Holbrook, R.N Hoover, J.J Hu, D.J Hunter, S.A Ingles, A. Irwanto, J. Ivanovich, E.M John, N. Johnson, A. Jukkola-Vuorinen, R. Kaaks, Y.D Ko, L.N Kolonel, I. Konstantopoulou, V.M Kosma, S. Kulkarni, D. Lambrechts, A.M Lee, L.L Marchand, T. Lesnick, J. Liu, S. Lindstrom, A. Mannermaa, S. Margolin, N.G Martin, P. Miron, G.W Montgomery, H. Nevanlinna, S. Nickels, S. Nyante, C. Olswold, J. Palmer, H. Pathak, D. Pectasides, C.M Perou, J. Peto, P.D Pharoah, L.C Pooler, M.F Press, K. Pylkäs, T.R Rebbeck, J.L Rodriguez-Gil, L. Rosenberg, E. Ross, T. Rüdiger, S. Silva Idos, E. Sawyer, M.K Schmidt, R. Schulz-Wendtland, F. Schumacher, G. Severi, X. Sheng, L.B Signorello, H.P Sinn, K.N Stevens, M.C Southey, W.J Tapper, I. Tomlinson, F.B Hogervorst, E. Wauters, J. Weaver, H. Wildiers, R. Winqvist, D. Van Den Berg, P. Wan, L.Y Xia , D. Yannoukakos, W. Zheng, R.G Ziegler, A. Siddiq, S.L Slager, D.O Stram, D. Easton, P. Kraft, B.E Henderson, F.J Couch

Nature Genetics, 2011 Oct 30;43(12):1210-4. doi: 10.1038/ng.985


TRIPLE-NEGATIVE PHENOTYPE IS OF ADVERSE PROGNOSTIC VALUE IN PATIENTS TREATED WITH DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY: A TRANSLATIONAL RESEARCH ANALYSIS IN THE CONTEXT OF A HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) RANDOMIZED PHASE III TRIAL

P. Skarlos, C. Christodoulou, K.T Kalogeras, A.G Eleftheraki, M. Bobos, A. Batistatou, C. Valavanis, O. Tzaida, E. Timotheadou, R. Kronenwett, R.M Wirtz, I. Kostopoulos, D. Televantou, E. Koutselini, I. Papaspirou, C.A Papadimitriou, D. Pectasides, H. Gogas, G. Aravantinos, N. Pavlidis, P. Arapantoni, D.V Skarlos, G. Fountzilas

Cancer Chemotherapy Pharmacology [Epub 2011 Sep 8]


POSTOPERATIVE DOSE-DENSE SEQUENTIAL VERSUS CONCOMITANT ADMINISTRATION OF EPIRUBICIN AND PACLITAXEL IN PATIENTS WITH NODE-POSITIVE BREAST CANCER: 5-YEAR RESULTS OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP. HE 10/00 PHASE III TRIAL

H. Gogas, U. Dafni, M. Karina, C. Papadimitriou, A. Batistatou, M. Bobos, H.P Kalofonos, A.G Eleftheraki, E. Timotheadou, D. Bafaloukos, C. Christodoulou, C. Markopoulos, E. Briasoulis, P. Papakostas, E. Samantas, P. Kosmidis, G.P Stathopoulos, C. Karanikiotis, D. Pectasides, M.A Dimopoulos, G. Fountzilas

Breast Cancer Research and Treatment [Epub 2011 Dec 21]


EXPRESSION OF ANGIOGENIC MARKERS IN THE PERIPHERAL BLOOD OF DOCETAXEL-TREATED ADVANCED BREAST CANCER PATIENTS. A HELLENIC ONCOLOGY GROUP (HECOG) STUDY

D. Pectasides, G. Papaxoinis, V. Kotoula, H. Fountzilas, I. Korantzis, A. Koutras, A.M. Dimopoulos, P. Papakostas, G. Aravantinos, I. Varthalitis, P. Kosmidis, D. Skarlos, E. Bournakis, D. Bafaloukos, H.P. Kalofonos, K.T. Kalogeras, G.Fountzilas

Oncology Reports, doi: 10.3892/or.2011.1504. [Epub 2011 Oct 13]

Δημοσιεύσεις 2012

VOLUMETRIC AND MGMT PARAMETERS IN GLIOBLASTOMA PATIENTS: SURVIVAL ANALYSIS

G. Iliadis, V. Kotoula, A.Chatzisotiriou, D. Televantou, A.G. Eleftheraki, S. Lambaki, D. Misailidou, P. Selviaridis, G. Fountzilas

BMC Cancer 2012 Jan 3;12:3


POSTOPERATIVE DOSE-DENSE SEQUENTIAL VERSUS CONCOMITANT ADMINISTRATION OF EPIRUBICIN AND PACLITAXEL IN PATIENTS WITH NODE-POSITIVE BREAST CANCER: 5-YEAR RESULTS OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP. HE 10/00 PHASE III TRIAL

H. Gogas, U. Dafni, M. Karina, C. Papadimitriou, A. Batistatou, M. Bobos, H.P Kalofonos, A.G Eleftheraki, E. Timotheadou, D. Bafaloukos, C. Christodoulou, C. Markopoulos, E. Briasoulis, P. Papakostas, E. Samantas, P. Kosmidis, G.P Stathopoulos, C. Karanikiotis, D. Pectasides, M.A Dimopoulos, G. Fountzilas

Breast Cancer Res Treat  2012 Apr;132(2):609-19. doi: 10.1007/s10549-011-1913-4 (Epub 2011 Dec 21)


PROGNOSTIC SIGNIFICANCE OF UBE2C MRNA EXPRESSION IN HIGH-RISK EARLY BREAST CANCER. HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY

A. Psyrri, K.T. Kalogeras, R. Kronenwett, R.M. Wirtz, A. Batistatou, E. Bournakis, E. Timotheadou, H. Gogas, G. Aravantinos, C. ChristodoulouT. Makatsoris, H. Linardou, D. Pectasides, N. Pavlidis, T. Economopoulos, G. Fountzilas

Ann Oncol 2012 Jun;23(6):1422-7. doi: 10.1093/annonc/mdr527 (Epub 2011 Nov 4)


EXPRESSION OF ANGIOGENIC MARKERS IN THE PERIPHERAL BLOOD OF DOCETAXEL-TREATED ADVANCED BREAST CANCER PATIENTS. A HELLENIC ONCOLOGY GROUP (HECOG) STUDY

D. Pectasides, G. Papaxoinis, V. Kotoula, H. Fountzilas, I. Korantzis, A. Koutras, A.M. Dimopoulos, P. Papakostas, G. Aravantinos, I. Varthalitis, P. Kosmidis, D. Skarlos, E. Bournakis, D. Bafaloukos, H.P. Kalofonos, K.T. Kalogeras, G. Fountzilas

Oncology Reports 2012 Jan;27(1):216-24. doi: 10.3892/or.2011.1504


HER2 AND TOP2A IN HIGH-RISK EARLY BREAST CANCER PATIENTS TREATED WITH ADJUVANT EPIRUBICIN-BASED DOSE-DENSE SEQUENTIAL CHEMOTHERAPY
G. Fountzilas, Ch. Valavanis, V. Kotoula, A.G. Eleftheraki, K.T. Kalogeras, O. Tzaida, A. Batistatou, R. Kronenwett, R.M. Wirtz, M. Bobos, E. Timotheadou, N. Soupos, G. Pentheroudakis, H. Gogas, D. Vlachodimitropoulos, G. Polychronidou, G. Aravantinos, A. Koutras, Ch. Christodoulou, D. Pectasides and P.Arapantoni
J Trans Med. 2012 Jan 12;10:10. doi: 10.1186/1479-5876-10-10


IDENTIFICATION AND VALIDATION OF GENE EXPRESSION MODELS THAT PREDICT CLINICAL OUTCOME IN PATIENTS WITH EARLY-STAGE LARYNGEAL CANCER
E. Fountzilas, K. Markou, K. Vlachtsis, A. Nikolaou, P. Arapantoni-Dadioti, E. Ntoula, G. Tassopoulos, M. Bobos, P. Konstatninopoulos, G. Fountzilas & D. Spentzos
Ann Oncol.2012 Aug;23(8):2146-53. doi: 10.1093/annonc/mdr576


VINORELBINE VERSUS PACLITAXEL FOR PATIENTS WITH ADVANCED NON–SMALL CELL LUNG CANCER (NSCLC) AND A PERFORMANCE STATUS OF 2
P.A. Kosmidis, K. Syrigos, H.P. Kalofonos, M.A Dimopoulos, D. Skarlos, N. Pavlidis, I. Boukovinas, D. Bafaloukos, D. Pectasides, Ch. Bacoyiannis and G. Fountzilas
Anticancer Res. 2012 Jan;32(1):175-81


PROGNOSTIC UTILITY OF ANGIOGENESIS AND HYPOXIA EFFECTORS IN PATIENTS WITH OPERABLE SQUAMOUS CELL CANCER OF THE LARYNX
G. Pentheroudakis, I. Nicolaou, V. Kotoula, H. Fountzilas, K. Markou, A.G. Eleftheraki, A. Fragkoulidi, I. Karasmanis, A. Tsigka, N. Angouridakis, K. Vlachtsis, A. Nikolaou, N. Pavlidis, G. Fountzilas
Oral Oncol.
2012 Aug;48(8):709-16. doi: 10.1016/j.oraloncology.2012.02.002 (Epub 2012 Feb 25)


THE PROGNOSTIC AND PREDICTIVE VALUE OF MRNA EXPRESSION OF VEGF FAMILY MEMBERS IN BREAST CANCER: A STUDY IN PRIMARY TUMORS OF HIGH-RISK EARLY BREAST CANCER PATIENTS PARTICIPATING IN A RANDOMIZED HELLENIC COOPERATIVE ONCOLOGY GROUP TRIAL
H. Linardou, , K.T. Kalogeras, R. Kronenwett, G. Kouvatseas, R.M. Wirtz, F. Zagouri, H. Gogas, Ch. Christodoulou, A.K. Koutras, E. Samantas, D. Pectasides, D. Bafaloukos, G. Fountzilas
Breast Cancer Res. 2012 Nov 12;14(6):R145


DIFFERENTIAL RESPONSE OF IMMUNOHISTOCHEMICALLY DEFINED BREAST CANCER SUBTYPES TO DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY
G. Fountzilas, U. Dafni, M. Bobos, A. Batistatou, V. Kotoula, H. Trihia, V. Malamou-Mitsi, S. Miliaras, S. Chrisafi, S. Papadopoulos, M. Sotiropoulou, Th. Fillipidis, H. Gogas, T. Koletsa, D. Bafaloukos, D. Televantou, K.T. Kalogeras, D. Pectasides, D.V. Skarlos, A. Koutras, M.A. Dimopoulos
PloS One. 2012;7(6):e37946. doi: 10.1371/journal.pone.0037946 (Epub 2012 Jun 5)


IMPROVED OUTCOME OF HIGH-RISK EARLY HER2-POSITIVE BREAST CANCER WITH HIGH CXCL13/CXCR5 MRNA EXPRESSION
E. Razis, K.T. Kalogeras, V. Kotoula, A.G. Eleftheraki, N. Nikitas, R. Kronenwett, E. Timotheadou, Ch. Christodoulou, D. Pectasides, H. Gogas, R.M. Wirtz, Th.Makatsoris, Di. Bafaloukos, G. Aravantinos, D. Televantou, N. Pavlidis, G. Fountzilas
Clin Breast Cancer.
2012 Jun;12(3):183-93. doi: 10.1016/j.clbc.2012.03.006


IMMUNOHISTOCHEMICAL STUDY OF THE EPITHELIAL MESENCHYMAL TRANSITION PHENOTYPE IN CANCER OF UNKNOWN PRIMARY: INCIDENCE, CORRELATIONS AND PROGNOSTIC UTILITY
A. Stoyianni, A. Goussia, G. Pentheroudakis, V.Siozopoulou, E. Ioachim, D. Krikelis, V. Golfinopoulos, A. Cervantes, M. Bobos, Th. Fotsis, S. Bellou, G. Fountzilas, V. Malamou-Mitsi, N. Pavlidis
Anticancer Res. 2012 Apr;32(4):1273-81


INTRACELLULAR SIGNALLING VIA THE AKT AXIS AND DOWNSTREAM EFFECTORS IS ACTIVE AND PROGNOSTICALLY SIGNIFICANT IN CARCINOMAS OF UNKNOWN PRIMARY (CUP): A STUDY OF 100 CUP CASES
V. Golfinopoulos, G. Pentheroudakis, A. Goussia, V. Siozopoulou, M. Bobos, D. Krikelis, A. Cervantes, T. Ciuleanu, M. Marsellos, G. Fountzilas, V. Malamou-Mitsi, N. Pavlidis
Ann Oncol. 2012 Oct;23(10):2725-30 (Epub 2012 May 6)


PROFILING IMMUNOHISTOCHEMICAL EXPRESSION OF NOTCH1-3, JAGGED1, CMET, PHOSPHO-MAPK IN 100 CARCINOMAS OF UNKNOWN PRIMARY
D. Krikelis, G. Pentheroudakis, A.Goussia, V.Siozopoulou, M. Bobos, D. Petrakis, A. Stoyianni, V. Golfinopoulos, A. Cervantes, T. Ciuleanu, G. Fountzilas, V. Malamou-Mitsi, N. Pavlidis
Clin Exp Metastasis.
2012 Aug;29(6):603-14. doi: 10.1007/s10585-012-9474-4 (Epub 2012 Apr 19)


INDUCTION CHEMOTHERAPY FOLLOWED BY CONCOMITANT RADIOTHERAPY AND WEEKLY CISPLATIN VERSUS THE SAME CONCOMITANT CHEMORADIOTHERAPY IN PATIENTS WITH NASOPHARYNGEAL CARCINOMA: A RANDOMIZED PHASE II STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) WITH BIOMARKER EVALUATION
G. Fountzilas, E. Ciuleanu, M. Bobos, A. Kalogera-Fountzila, A.G. Eleftheraki, G. Karayannopoulou, T. Zaramboukas, A. Nikolaou, K. Markou, L. Resiga, D. Dionysopoulos, E. Samantas, H. Athanassiou, D. Misailidou, D. Skarlos, T. Ciuleanu
Ann Oncol.
2012 Feb;23(2):427-35. doi: 10.1093/annonc/mdr116 (Epub 2011 Apr 27)


TRIPLE-NEGATIVE PHENOTYPE IS OF ADVERSE PROGNOSTIC VALUE IN PATIENTS TREATED WITH DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY: A TRANSLATIONAL RESEARCH ANALYSIS IN THE CONTEXT OF A HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) RANDOMIZED PHASE III TRIAL
P. Skarlos, C. Christodoulou, K.T. Kalogeras, A.G. Eleftheraki, M. Bobos, A. Batistatou, C. Valavanis, O. Tzaida, E. Timotheadou, R. Kronenwett, R.M Wirtz, I. Kostopoulos, D. Televantou, E. Koutselini, I. Papaspirou, C.A Papadimitriou, D. Pectasides, H. Gogas, G. Aravantinos, N. Pavlidis, P. Arapantoni, D.V. Skarlos, G. Fountzilas
Cancer Chemother Pharmacol.
2012 Feb;69(2):533-46. doi: 10.1007/s00280-011-1730-9 (Epub 2011 Sep 8)


XELΙRI-BEVACIZUMAB VERSUS FOLFIRI-BEVACIZUMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE III TRIAL WITH COLLATERAL BIOMARKER ANALYSIS
D. Pectasides, G. Papaxoinis, K.T. Kalogeras, A.G. Eleftheraki, I. Xanthakis, Th. Makatsoris, E. Samantas, I. Varthalitis, P. Papakostas, N. Nikitas, C.N. Papandreou, G. Pentheroudakis, E. Timotheadou, A. Koutras, J. Sgouros, D. Bafaloukos, G. Klouvas, Th. Economopoulos, K.N. Syrigos, G. Fountzilas
BMC Cancer. 2012 Jun 29;12:271. doi: 10.1186/1471-2407-12-271


TOPOISOMERASE II alpha GENE AMPLIFICATION IS A FAVORABLE PROGNOSTIC FACTOR IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER TREATED WITH TRASTUZUMAB
G. Fountzilas, Ch. Christodoulou, M. Bobos, V. Kotoula, A.G. Eleftheraki, I. Xanthakis, A. Batistatou, G. Pentheroudakis, N. Xiros, I. Papaspirou, A. Koumarianou, P. Papakostas, D. Bafaloukos, D.V. Skarlos, K.T. Kalogeras
J Transl Med. 2012 Oct 23;10:212. doi: 10.1186/1479-5876-10-212


PREVALENCE OF BRCA1 MUTATIONS AMONG 403 WOMEN WITH TRIPLE-NEGATIVE BREAST CANCER: IMPLICATIONS FOR GENETIC SCREENING SELECTION CRITERIA: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
F. Fostira, M. Tsitlaidou, C. Papadimitriou, M. Pertesi, E. Timotheadou, A.V. Stavropoulou, S. Glentis, E. Bournakis, M. Bobos, D. Pectasides, P. Papakostas, G. Pentheroudakis, H. Gogas, P. Skarlos, E. Samantas, D. Bafaloukos, P.A. Kosmidis, A. Koutras, D. Yannoukakos, I. Konstantopoulou, G. Fountzilas
Breast Cancer Res. Treat. 2012 Jul;134(1):353-62. doi: 10.1007/s10549-012-2021-9 (Epub 2012 Mar 21)


PROGNOSTIC SIGNIFICANCE OF RACGAP1 MRNA EXPRESSION IN HIGH-RISK EARLY BREAST CANCER.A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY
K. Pliarchopoulou, K.T. Kalogeras, R. Kronenwett, R.M. Wirtz, A.G. Eleftheraki, A. Batistatou, M. Bobos, N. Soupos, G. Polychronidou, H. Gogas, E. Samantas, C. Christodoulou, T. Makatsoris, N. Pavlidis, D. Pectasides, G. Fountzilas
Cancer Chemother Pharmacol. 2013 Jan;71(1):245-55. doi: 10.1007/s00280-012-2002-z (Epub 2012 Oct 25.)


LAPATINIB AND CAPECITABINE COMBINATION FOR HER2 POSITIVE METASTATIC BREAST CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
H. Linardou, D.V. Skarlos, C. Christodoulou, A. Koutras, D. Bafaloukos, P. Papakostas, E. Kostouras, I. Grossi, E. Galani, D. Pectasides, G. Fountzilas
Mediterranean Oncology Journal (MOJ). 2012;1:40-44


COMBINATION TREATMENT WITH METRONOMIC TEMOZOLOMIDE, BEVACIZUMAB AND LONG-ACTING OCTREOTIDE FOR MALIGNANT NEUROENDOCRINE TUMOURS
A. Koumarianou, S. Antoniou, G. Kanakis, N. Economopoulos, D. Rontogianni, A. Ntavatzikos, N. Tsavaris, D. Pectasides, G. Dimitriadis, G. Kaltsas
Endocr Relat Cancer. 2012 Jan 9;19(1):L1-4. doi: 10.1530/ERC-11-0287. Print 2012 Feb


EXPRESSION OF DNA REPAIR AND REPLICATION GENES IN NON-SMALL CELL LUNG CANCER (NSCLC): A ROLE FOR THYMIDYLATE SYNTHETASE (TYMS)
V. Kotoula, D. Krikelis, V. Karavasilis, T. Koletsa, A.G. Eleftheraki, D. Televantou, Ch. Christodoulou, S. Dimoudis, I. Korantzis, D. Pectasides, K.N. Syrigos, P. A Kosmidis, G. Fountzilas
BMC Cancer.
2012 Aug 6;12:342. doi: 10.1186/1471-2407-12-342


MOLECULAR PREDICTORS OF RESPONSE TO TYROSINE KINASE INHIBITORS IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER
S. Murray, V. Karavasilis, M. Bobos, E. Razis, S. Papadopoulos, Ch. Christodoulou, P. Kosmidis, G. Fountzilas
J Exp Clin Cancer Res. 2012 Sep 19;31(1):77. doi: 10.1186/1756-9966-31-77


COST-MINIMIZATION ANALYSIS OF THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER IN GREECE
V. Fragoulakis, V. Papagiannopoulou, G. Kourlaba, N. Maniadakis and G. Fountzilas
Clin Ther. 2012 Oct;34(10):2132-42. doi: 10.1016/j.clinthera.2012.09.005


ASSOCIATION OF ERCC1SNPs WITH OUTCOME IN PLATINUM-TREATED PATIENTS WITH ADVANCED UROTHELIAL CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY
N. Nikitas, A. Karadimou, E. Tsitoura, N. Soupos, M. Tsiatas, V. Karavasilis, D. Pectasides, N. Pavlidis, M. Chrisofos, I. Adamakis, S. Murray, G. Fountzilas, M.A. Dimopoulos, A. Bamias
Pharmacogenomics.
2012 Nov;13(14):1595-607. doi: 10.2217/pgs.12.162


PROSPECTIVE, OPEN-LABEL, RANDOMIZED, PHASE III STUDY OF TWO DOSE-DENSE REGIMENS MVAC VERSUS GEMCITABINE/CISPLATIN IN PATIENTS WITH INOPERABLE, METASTATIC OR RELAPSED UROTHELIAL CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY (HE1603)
A. Bamias, U. Dafni, A. Karadimou, E. Timotheadou, G. Aravantinos, A. Psyrri, I. Xanthakis, M. Tsiatas, M. Koutoulidis, C. Constantinidis, C. Hatzimouratidis, E. Samantas, A. Visvikis, M. Chrisophos, K. Stravodimos, C. Deliveliotis, A. Eleftheraki, D. Pectasides, G. Fountzilas, M.A. Dimopoulos
Ann Oncol.
2013 Apr;24(4):1011-7. doi: 10.1093/annonc/mds583. (Epub 2012 Nov 7)


SURVIVAL FROM BREAST CANCER IN RELATION TO ACCESS TO TERTIARY HEALTHCARE, BODY MASS INDEX, TUMOR CHARACTERISTICS AND TREATMENT: A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY
P. Panagopoulou, H. Gogas, N. Dessypris, N. Maniadakis, G. Fountzilas, E.T. Petridou
Eur J Epidemiol.
2012 Nov;27(11):857-66. doi: 10.1007/s10654-012-9737-z. (Epub 2012 Oct 20)


GLOBAL MICRORNA PROFILING IN FAVORABLE PROGNOSIS SUBGROUPS OF CANCER OF UNKNOWN PRIMARY (CUP) DEMONSTRATES NO SIGNIFICANT EXPRESSION DIFFERENCES WITH METASTASES OF MATCHED KNOWN PRIMARY TUMORS
G. Pentheroudakis, Y. Spector, D. Krikelis, V. Kotoula, E. Meiri, V. Malamou-Mitsi, G. Fountzilas, M. Sanden, N. Pavlidis, H. Benjamin, R. Aharonov
Clin Exp Metastasis.
2013 Apr;30(4):431-9. doi: 10.1007/s10585-012-9548-3. (Epub 2012 Nov 4)


DARPP32, STAT5 AND STAT3 MRNA EXPRESSION RATIOS IN GLIOBLASTOMAS ARE ASSOCIATED WITH PATIENT OUTCOME
D. Televantou, G. Karkavelas, P. Hytiroglou, S. Lampaki, G. Iliadis, P. Selviaridis, K.S. Polyzoidis, G. Fountzilas, V. Kotoula
Pathol Oncol Res. 2013 Apr;19(2):329-43. doi: 10.1007/s12253-012-9588-7.
(Epub 2012 Dec 20)


SAMPLE PARAMETERS AFFECTING THE CLINICAL RELEVANCE OF RNA BIOMARKERS IN TRANSLATIONAL BREAST CANCER RESEARCH
V. Kotoula, K.T. Kalogeras, G. Kouvatseas, D. Televantou, R. Kronenwett, R.M. Wirtz, G. Fountzilas
Virchows Arch. 2013 Feb;462(2):141-54. doi: 10.1007/s00428-012-1357-1.
(Epub 2012 Dec 20)


EXPRESSION OF ANGIOGENIC MARKERS IN THE PERIPHERAL BLOOD OF PATIENTS WITH ADVANCED BREAST CANCER TREATED WITH WEEKLY DOCETAXEL
I. Korantzis, K.T Kalogeras, G. Papaxoinis, V. Kotoula, A. Koutras, N. Soupos, P. Papakostas, D. Dionysopoulos, E. Samantas, Ch. Christodoulou, H. Linardou, D. Pectasides, G. Fountzilas
Anticancer Res. 2012 Oct;32(10):4569-80

Δημοσιεύσεις 2013

TMA CONSTRUCTION AND IMMUNOHISTOCHEMISTRY {additional file 1}


RNA EXTRACTION AND RT‐PCR METHODOLOGY {additional file 2}


DESCRIPTIVES OF PROTEIN AND mRNA EXPRESSION {Supplementary Table 1, additional file 3}


ASSOCIATIONS BETWEEN CLINICOPATHOLOGICAL VARIABLES AND NOTCH PATHWAY COMPONENTS AT THE mRNA AND PROTEIN LEVELS (pvalues) {Supplementary Table 2, additional file 4}


PROGNOSTIC SIGNIFICANCE OF CLINICOPATHOLOGICAL CHARACTERISTICS CHARACTERISTICS {Supplementary Table 3, additional file 5}


PROGNOSTIC SIGNIFICANCE OF mRNA PROTEIN EXPRESSION ON DISEASE-FREE SURVIVAL {Supplementary Table 4, additional file 6}



PROGNOSTIC SIGNIFICANCE OF RACGAP1 mRNA EXPRESSION IN HIGH-RISK EARLY BREAST CANCER: A STUDY IN PRIMARY TUMORS OF BREAST CANCER PATIENTS PARTICIPATING IN A RANDOMIZED HELLENIC COOPERATIVE ONCOLOGY GROUP TRIAL

K. Pliarchopoulou, K.T. Kalogeras, R. Kronenwett, R.M. Wirtz, A.G. Eleftheraki, A. Batistatou, M. Bobos, N. Soupos, G. Polychronidou, H. Gogas, E. Samantas, C. Christodoulou, T. Makatsoris, N. Pavlidis, D. Pectasides, G. Fountzilas
Cancer Chemother Pharmacol. 2013 Jan;71(1):245-55. doi: 10.1007/s00280-012-2002-z (Epub 2012 Oct 25)


 A PHASE I STUDY OF TEMOZOLOMIDE AND LAPATINIB COMBINATION IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS
V. Karavasilis, V. Kotoula, G. Pentheroudakis, D.Televantou, S. Lambaki, S. Chrisafi,M. Bobos, G. Fountzilas
J Neurol. 2013 Jun;260(6):1469-80. doi: 10.1007/s00415-012-6812-z.


INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF1R) EXPRESSION AND SURVIVAL IN OPERABLE SQUAMOUS-CELL LARYNGEAL CANCER
G. Mountzios, I. Kostopoulos, V. Kotoula, I. Sfakianaki, E. Fountzilas, K. Markou, I. Karasmanis, S. Levva, N. Angouridakis, K. Vlachtsis, A. Nikolaou, J. Constantinidis, G. Fountzilas
PLoS One. 2013;8(1):e54048. doi: 10.1371/journal.pone.0054048 (Epub 2013 Jan 24)


EXPRESSION PROFILING OF 21 BIOMOLECULES IN LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMAS OF CAUCASIAN PATIENTS
D. Krikelis, M. Bobos, G. Karayannopoulou, L. Resiga, S. Chrysafi, E. Samantas, D. Andreopoulos, V. Vassiliou, E. Ciuleanu, G. Fountzilas G
BMC Clin Pathol. 2013 Jan 29;13:1. doi: 10.1186/1472-6890-13-1


PSYCHIATRIC MANIFESTATIONS, PERSONALITY TRAITS AND HEALTH-RELATED QUALITY OF LIFE IN CANCER OF UNKNOWN PRIMARY SITE
T. Hyphantis, I. Papadimitriou, D. Petrakis, G. Fountzilas, D. Repana, K. Assimakopoulos, A.F. Carvalho, N. Pavlidis
Psychooncology.
2013 Jan 29. doi: 10.1002/pon.3244. [Epub ahead of print]


SAMPLE PARAMETERS AFFECTING THE CLINICAL RELEVANCE OF RNA BIOMARKERS IN TRANSLATIONAL BREAST CANCER RESEACH
V. Kotoula, K.T Kalogeras, G. Kouvatseas, D. Televantou, R. Kronenwett, R.M Wirtz, G. Fountzilas
Virchows Arch. 2013 Feb;462(2):141-54. doi: 10.1007/s00428-012-1357-1.
(Epub 2012 Dec 20)


BIOMARKERS OF BENEFIT FROM CETUXIMAB-BASED THERAPY IN METASTATIC COLORECTAL CANCER: INTERACTION OF EGFR LIGAND EXPRESSION WITH RAS/RAF, PIK3CA GENOTYPES
G. Pentheroudakis, V. Kotoula, W. De Roock, G. Kouvatseas, P. Papakostas, T. Makatsoris, D. Papamichael, I. Xanthakis, J. Sgouros, D. Televantou, G. Kafiri, A.C. Tsamandas, E. Razis, E. Galani, D. Bafaloukos, I. Efstratiou, I. Bompolaki, D. Pectasides, N. Pavlidis, S. Tejpar, G. Fountzilas
BMC Cancer.
2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49


CYCLIN D1, EGFR, AND Akt/mTOR PATHWAY. POTENTIAL PROGNOSTIC MARKERS IN LOCALIZED LARYNGEAL SQUAMOUS CELL CARCINOMA
D. Dionysopoulos, K. Pavlakis, V. Kotoula, E. Fountzilas, K. Markou, I. Karasmanis, N. Angouridakis, A. Nikolaou, K.T Kalogeras, G. Fountzilas
Strahlenther Onkol. 2013 Mar;189(3):202-14. doi: 10.1007/s00066-012-0275-0 (Epub 2013 Feb 13)


HER2 GENE COPY NUMBER STATUS MAY INFLUENCE CLINICAL EFFICACY TO ANTI-EGFR MONOCLONAL ANTIBODIES IN METASTATIC COLORECTAL CANCER PATIENTS
V. Martin, L. Landi, F. Molinari, G. Fountzilas G, R. Geva, A. Riva, P. Saletti, S. De Dosso, A. Spitale, S. Tejpar, K.T Kalogeras, L. Mazzucchelli, M. Frattini, F. Cappuzzo
Br J Cancer. 2013 Feb 19;108(3):668-75. doi: 10.1038/bjc.2013.4 (Epub 2013 Jan 24)


DOSE SELECTION TRIAL OF METRONOMIC ORAL VINORELBINE MONOTHERAPY IN PATIENTS WITH METASTATIC CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP CLINICALTRANSLATIONAL STUDY
E. Briasoulis, G. Aravantinos, G. Kouvatseas, P. Pappas, E. Biziota, I. Sainis, T. Makatsoris, I. Varthalitis, I. Xanthakis, A. Vassias, G. Klouvas, I. Boukovinas, G. Fountzilas, K.N Syrigos, H. Kalofonos, E. Samantas
BMC Cancer. 2013 May 29;13(1):263 (Epub ahead of print)


MOLECULAR PROFILE OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS BEARING p16 HIGH PHENOTYPE
T. Rampias, E. Pectasides, M. Prasad, C. Sasaki, P. Gouveris, A. Dimou, P. Kountourakis, C. Perisanidis,
B. Burtness, T. Zaramboukas, D. Rimm, G. Fountzilas, A. Psyrri
Ann Oncol. 2013 Aug;24(8):2124-31. doi: 10.1093/annonc/mdt013 (Epub 2013 Feb 13)


EVALUATION OF THE PROGNOSTIC ROLE OF CENTROMERE 17 GAIN AND HER2/TOPOISOMERASE II ALPHA GENE STATUS AND PROTEIN EXPRESSION IN PATIENTS WITH BREAST CANCER TREATED WITH ANTHRACYCLINE-CONTAINING ADJUVANT CHEMOTHERAPY: POOLED ANALYSIS OF TWO HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) PHASE III TRIALS
G. Fountzilas, U. Dafni, M. Bobos, V. Kotoula, A. Batistatou, I. Xanthakis, C. Papadimitriou,
I. Kostopoulos, T. Koletsa, E. Tsolaki, D. Televantou, E. Timotheadou, A. Koutras, G. Klouvas, E. Samantas, N. Pisanidis, C. Karanikiotis, I. Sfakianaki, N. Pavlidis, H. Gogas, H. Linardou, K.T Kalogeras KT, D. Pectasides, M.A Dimopoulos
BMC Cancer. 2013 Mar 28;13:163. doi: 10.1186/1471-2407-13-163


PREVALENCE OF BRCA1 MUTATIONS IN FAMILIAL AND SPORADIC GREEK OVARIAN CANCER CASES

A.V Stavropoulou, F. Fostira, M. Pertesi, M. Tsitlaidou, G.E Voutsinas, O. Triantafyllidou, A. Bamias, M.A Dimopoulos, E. Timotheadou, D. Pectasides, C. Christodoulou, G. Klouvas, C. Papadimitriou, T. Makatsoris, G. Pentheroudakis, G. Aravantinos, V. Karydakis, D. Yannoukakos, G. Fountzilas, I. Konstantopoulou
PLoS One. 2013;8(3):e58182. doi: 10.1371/journal.pone.0058182 (Epub 2013 Mar 11)


DARPP32, STAT5 AND STAT3 mRNA EXPRESSION RATIOS IN GLIOBLASTOMAS ARE ASSOCIATED WITH PATIENT OUTCOME
D. Televantou, G. Karkavelas, P. Hytiroglou, S. Lampaki, Iliadis G, Selviaridis P, Polyzoidis KS,
G. Fountzilas, V. Kotoula
Pathol Oncol Res. 2013 Apr;19(2):329-43. doi: 10.1007/s12253-012-9588-7 (Epub 2012 Dec 20)


GLOBAL microRNA PROFILING IN FAVORABLE PROGNOSIS SUBGROUPS OF CANCER OF UNKNOWN PRIMARY (CUP) DEMONSTRATES NO SIGNIFICANT EXPRESSION DIFFERENCES WITH METASTASES OF MATCHED KNOWN PRIMARY TUMORS
G. Pentheroudakis, Y. Spector, D. Krikelis, V. Kotoula, E. Meiri, V. Malamou-Mitsi, G. Fountzilas, M. Sanden, N. Pavlidis, H. Benjamin, R. Aharonov
Clin Exp Metastasis. 2013 Apr;30(4):431-9. doi: 10.1007/s10585-012-9548-3. (Epub 2012 Nov 4)


EVALUATION OF CURRENT PROGNOSTIC AND PREDICTIVE MARKERS IN BREAST CANCER: A VALIDATION STUDY OF TISSUE MICROARRAYS
A. Batistatou, D. Televantou, M. Bobos, A.G Eleftheraki, E. Kouvaras, S. Chrisafi, G.K Koukoulis, V. Malamou-Mitsi, G. Fountzilas
Anticancer Res. 2013 May;33(5):2139-45


IXABEPILONE ADMINISTERED WEEKLY OR EVERY THREE WEEKS IN HER2-NEGATIVE METASTATIC BREAST CANCER PATIENTS; A RANDOMIZED NON-COMPARATIVE PHASE II TRIAL
G. Fountzilas, V. Kotoula, D. Pectasides, G. Kouvatseas, E. Timotheadou, M. Bobos, X. Mavropoulou, C. Papadimitriou, E. Vrettou, G. Raptou, A. Koutras, E. Razis, D. Bafaloukos, E. Samantas, G. Pentheroudakis, D.V. Skarlos

PLoS One. 2013 Jul 23;8(7):e69256. doi: 10.1371/journal.pone.0069256. Print 2013


DEVELOPMENT AND VALIDATION OF A PROGNOSTIC MODEL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH SUNITINIB: A EUROPEAN COLLABORATION
A. Bamias, K. Tzannis, B. Beuselinck, S. Oudard, B. Escudier, D. Diosynopoulos, K. Papazisis, H. Lang, P. Wolter, E. de Guillebon, K. Stravodimos, M. Chrisofos, G. Fountzilas, R.T. Elaidi, M.A. Dimopoulos, C. Bamia

Br J Cancer. 2013 Jul 23;109(2):332-41. doi: 10.1038/bjc.2013.341. Epub 2013 Jun 27


PROGNOSTIC SIGNIFICANCE OF ESR1 GENE AMPLIFICATION, mRNA/PROTEIN EXPRESSION AND FUNCTIONAL PROFILES IN HIGH-RISK EARLY BREAST CANCER: A TRANSLATIONAL STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)
G. Pentheroudakis, V. Kotoula, A.G. Eleftheraki, E. Tsolaki, R.M. Wirtz, K.T. Kalogeras, A. Batistatou, M. Bobos, M.A. Dimopoulos, E. Timotheadou, H. Gogas, C. Christodoulou, K. Papadopoulou, I. Efstratiou, C.D Scopa, I. Papaspyrou, D. Vlachodimitropoulos, H. Linardou, E. Samantas, D. Pectasides, N. Pavlidis, G. Fountzilas

PLoS One. 2013 Jul 29;8(7):e70634. doi: 10.1371/journal.pone.0070634. Print 2013


THE PROGNOSTIC ROLE OF EPHRIN A2 AND ENDOTHELIAL GROWTH FACTOR RECEPTOR PATHWAY MEDIATORS IN PATIENTS WITH ADVANCED COLORECTAL CANCER TREATED WITH CETUXIMAB
A. Strimpakos, G. Pentheroudakis, V. Kotoula, W. De Roock, G. Kouvatseas, P. Papakostas,T. Makatsoris, D. Papamichael, A. Andreadou, J. Sgouros, A. Zizi-Sermpetzoglou, A. Kominea, D. Televantou, E. Razis, E. Galani, D. Pectasides, S. Tejpar, K. Syrigos, G. Fountzilas

Clin Colorectal Cancer. 2013 Dec;12(4):267-274.e2. doi: 10.1016/j.clcc.2013.07.001.


THE PROGNOSTIC SIGNIFICANCE OF WNT PATHWAY IN SURGICALLY-TREATED COLORECTAL CANCER: β-CATENIN EXPRESSION PREDICTS FOR DISEASE-FREE SURVIVAL
K. Kamposioras, A. Konstantara, V. Kotoula, S. Lakis, G. Kouvatseas, E. Akriviadis, E. Vrettou, D. Dionysopoulos, D. Krikelis, K. Papadopoulou, E. Charalambous, S. Chrisafi, C. Konstantaras, G. Fountzilas

Anticancer Res. 2013 Oct;33(10):4573-84


MULTIPLE INDEPENDENT VARIANTS AT THE TERT LOCUS ARE ASSOCIATED WITH TELOMERE LENGTH AND RISKS OF BREAST AND OVARIAN CANCER
S.E.Bojesen … D. Yannoukakos … G. Fountzilas et al

Nat Genet. 2013 Apr;45(4):371-84, 384e1-2. doi: 10.1038/ng.2566


VASCULAR ENDOTHELIAL GROWTH FACTOR POLYMORPHISMS AND CLINICAL OUTCOME IN PATIENTS WITH METASTATIC BREAST CANCER TREATED WITH WEEKLY DOCETAXEL
A.K. Koutras, V. Kotoula, C. Papadimitriou, D. Dionysopoulos, F. Zagouri, H.P. Kalofonos,H.P. Kourea, D.V. Skarlos, E. Samantas, K. Papadopoulou, P. Kosmidis, D. Pectasides, G. Fountzilas

Pharmacogenomics J. 2013 Sep 24. doi: 10.1038/tpj.2013.36. [Epub ahead of print]


IDENTIFICATION AND VALIDATION OF A MULTIGENE PREDICTOR OF RECURRENCE IN PRIMARY LARYNGEAL CANCER
E. Fountzilas, V. Kotoula, N. Angouridakis, I. Karasmanis, R.M. Wirtz, A.G. Eleftheraki, E. Veltrup, K. Markou, A. Nikolaou, D. Pectasides, G. Fountzilas
PLoS One. 2013 Aug 9;8(8):e70429. doi: 10.1371/journal.pone.0070429.
(eCollection 2013)


NOVEL microRNA-BASED ASSAY DEMONSTRATES 92% AGREEMENT WITH DIAGNOSIS BASED ON CLINICOPATHOLOGIC AND MANAGEMENT DATA IN A COHORT OF PATIENTS WITH CARCINOMA OF UNKNOWN PRIMARY
G. Pentheroudakis, N. Pavlidis, G. Fountzilas, D. Krikelis, A. Goussia, A. Stoyianni, M. Sanden, B. St Cyr, N. Yerushalmi, H. Benjamin, E. Meiri, A. Chajut, S. Rosenwald, R. Aharonov, Y. Spector
Mol Cancer.
2013 Jun 10;12:57. doi: 10.1186/1476-4598-12-57


BEVACIZUMAB AND MICROMETASTASES: REVISITING THE PRECLINICAL AND CLINICAL ROLLERCOASTER
G. Mountzios, G. Pentheroudakis, P. Carmeliet
Pharmacol Ther. 2013 Sep 27. pii: S0163-7258(13)00192-7. doi: 10.1016/j.pharmthera.2013.09.003. [Epub ahead of print]


INSIGHTS INTO THE EPITHELIAL MESENCHYMAL TRANSITION PHENOTYPE IN CANCER OF UNKNOWN PRIMARY FROM A GLOBAL MICRORNA PROFILING STUDY”, HAS BEEN ACCEPTED FOR PUBLICATION IN CLINICAL AND TRANSLATIONAL ONCOLOGY
A. Stoyianni, G. Pentheroudakis, H. Benjamin, A. Cervantes, K. Ashkenazi, G. Lazaridis, N. Pavlidis, Y Spector
Clin Transl Oncol.
2013 Nov 27. [Epub ahead of print]


EXPLORING THE BIOLOGY OF CANCER OF UNKNOWN PRIMARY: BREAKTHROUGHS AND DRAWBACKS
K. Kamposioras, G. Pentheroudakis, N. Pavlidis
Eur J Clin Invest 2013 May;43(5):491-500. doi: 10.1111/eci.12062.
Epub 2013 Mar 11. Review


NOVEL APPROACHES FOR CONCURRENT IRRADIATION IN LOCALLY ADVANCED CERVICAL CANCER: PLATINUM COMBINATIONS, NON-PLATINUM-CONTAINING REGIMENS, AND MOLECULAR TARGETED AGENTS
G. Mountzios, A. Soultati, D. Pectasides, M.A dimopoulos and Ch. Papadimitriou
Obstet Gynecol Int. 2013;2013:536765. doi: 10.1155/2013/536765. Epub 2013 May 21

Δημοσιεύσεις 2014

A STUDY OF GENE EXPRESSION MARKERS FOR PREDICTIVE SIGNIFICANCE FOR BEVACIZUMAB BENEFIT IN PATIENTS WITH METASTATIC COLON CANCER: A TRANSLATIONAL RESEARCH STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)
G. Pentheroudakis, V. Kotoula, E. Fountzilas, G. Kouvatseas, G. Basdanis, I. Xanthakis, T. Makatsoris, E. Charalambous, PD. apamichael, E. Samantas, P. Papakostas, D. Bafaloukos, E. Razis, C. Christodoulou, I. Varthalitis, N. Pavlidis, G. Fountzilas
BMC Cancer. 2014 Feb 20;14(1):111. doi: 10.1186/1471-2407-14-111


HIGH PREVALENCE OF BRCA1 FOUNDER MUTATIONS IN GREEK BREAST/OVARIAN FAMILIES
I. Konstantopoulou, M. Tsitlaidou, F. Fostira, M. Pertesi, A.V Stavropoulou, O. Triantafyllidou, E. Tsotra, A. Tsiftsoglou, C. Tsionou, S. Droufakou, C. Dimitrakakis, G. Fountzilas, D. Yannoukakos
Clin Genet. 2014 Jan;85(1):36-42. doi: 10.1111/cge.12274. Epub 2013 Oct 20


VASCULAR ENDOTHELIAL GROWTH FACTOR POLYMORPHISMS AND CLINICAL OUTCOME IN PATIENTS WITH METASTATIC BREAST CANCER
AK. Koutras, V. Kotoula, C. Papadimitriou, D. Dionysopoulos, F. Zagouri, HP. Kalofonos, HP. Kourea, DV. Skarlos , E. Samantas , K. Papadopoulou , P. Kosmidis, D. Pectasides, G. Fountzilas
Pharmacogenomics J. 2014 Jun;14(3):248-55. doi: 10.1038/tpj.2013.36. Epub 2013 Sep 24


MARKERS OF EPITHELIAL TO MESENCHYMAL TRANSITIONS IN ASSOCIATION ASSOCIATION WITH SURVIVAL IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
E. Pectasides, T. Rampias, C. Sasaki, C. Perisanidis, V. Kouloulias, B. Burtness, T. Zaramboukas, D. Rimm, G. Fountzilas, A. Psyrri
PLoS One. 2014 Apr 10;9(4):e94273. doi: 10.1371/journal.pone.0094273. eCollection 2014


A NEW MATHEMATICAL MODEL FOR THE INTERPRETATION OF TRANSLATIONAL RESEARCH EVALUATING SIX CTLA-4 POLYMORPHISMS IN HIGH-RISK MELANOMA PATIENTS RECEIVING ADJUVANT INTERFERON
P. Pancoska, JM. Kirkwood, S. Bouros, M. Spyropoulou-Vlachou, E. Pectasides, D. Tsoutsos, A. Polyzos, C. Markopoulos, P. Panagiotou, O. Castana, D. Bafaloukos, G. Fountzilas, H. Gogas
PLoS One. 2014 Jan 27;9(1):e86375. doi: 10.1371/journal.pone.0086375. eCollection 2014


PROGNOSTIC SIGNIFICANCE OF THE WNT PATHWAY IN SQUAMOUS CELL LARYNGEAL CANCER
A. Psyrri, V. Kotoula, E. Fountzilas, Z. Alexopoulou, M. Bobos , D. Televantou, G. Karayannopoulou, D. Krikelis, K. Markou, I. Karasmanis, N. Angouridakis, KT. Kalogeras, A. Nikolaou, G. Fountzilas
Oral Oncol. 2014 Apr;50(4):298-305. doi: 10.1016/j.oraloncology.2014.01.005. Epub 2014 Jan 21


EGFR GENE GAIN AND PTEN PROTEIN EXPRESSION ARE FAVORABLE PROGNOSTIC FACTORS IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER TREATED WITH CETUXIMAB
E. Razis, G. Pentheroudakis, G. Rigakos, M. Bobos, G. Kouvatseas, O. Tzaida, T. Makatsoris, P. Papakostas, M. Bai, A. Goussia, E. Samantas, D. Papamichael, O. Romanidou, I. Efstratiou, E. Tsolaki, A. Psyrri, W. De Roock, D. Bafaloukos, G. Klouvas, S. Tejpar, KT. Kalogeras, D. Pectasides, G. Fountzilas
J Cancer Res Clin Oncol. 2014 May;140(5):737-48. doi: 10.1007/s00432-014-1626-2. Epub 2014 Mar 5


DIFFERENTIAL EXPRESSION OF THE INSULIN-LIKE GROWTH FACTOR RECEPTOR AMONG EARLY BREAST CANCER SUBTYPES
G. Mountzios, D. Aivazi, I. Kostopoulos, HP. Kourea, G. Kouvatseas, E. Timotheadou, P. Zebekakis, I. Efstratiou, H. Gogas, C. Vamvouka, S. Chrisafi, A. Stofas, G. Pentheroudakis, A. Koutras, E. Galani, D. Bafaloukos, G. Fountzilas
PLoS One. 2014 Mar 17;9(3):e91407. doi: 10.1371/journal.pone.0091407. eCollection 2014


ASSOCIATION OF VEGF-A SPLICE VARIANT mRNA EXPRESSION WITH OUTCOME IN BEVACIZUMAB-TREATED PATIENTS WITH METASTATIC BREAST CANCER
G. Pentheroudakis, V. Kotoula, G. Kouvatseas, E. Charalambous, D. Dionysopoulos, F. Zagouri, A. Koutras, K. Papazisis, D. Pectasides, E. Samantas, MA. Dimopoulos, CN. Papandreou, G. Fountzilas
Clin Breast Cancer. 2014 Mar 1. pii: 1526-8209(14)00034-2. doi: 10.1016/j.clbc.2014.02.009. [Epub ahead of print]


GENOME-WIDE ASSOCIATION STUDY IDENTIFIES 25 KNOWN BREAST CANCER SUSCEPTIBILITY LOCI AT RISK FACTORS FOR TRIPLE-NEGATIVE BREAST CANCER
KS. Purrington , S. Slager, D. Eccles, D. Yannoukakos, PA. Fasching, … D. Yannoukakos, I. Konstantopoulou, F. Fostira, A. Vratimos,P. Apostolou, I. Konstanta, V. Kotoula, S. Lakis, MA. Dimopoulos, D. Skarlos, D. Pectasides, G. Fountzilas
Carcinogenesis. 2014 May;35(5):1012-9. doi: 10.1093/carcin/bgt404. Epub 2013 Dec 9


LACK OF ASSOCIATION BETWEEN KRAS MUTATIONS AND 18F-FDG PET/CT IN CAUCASIAN METASTATIC COLORECTAL CANCER PATIENTS
D. Krikelis, E. Skoura, V. Kotoula, P. Rondogianni, N. Pianou, A. Samartzis, I. Xanthakis, G. Fountzilas, IE. Datseris
Anticancer Res. 2014 May;34(5):2571-9


THE ANDROGEN RECEPTOR AS A SURROGATE MARKER FOR MOLECULAR APOCRINE BREAST CANCER SUBTYPING
S. Lakis, V. Kotoula, AG. Eleftheraki, A. Batistatou, M. Bobos, T. Koletsa, E. Timotheadou, S. Chrisafi, G. Pentheroudakis, A. Koutras, F. Zagouri, H. Linardou, G. Fountzilas
Breast. 2014 Jun;23(3):234-43. doi: 10.1016/j.breast.2014.02.013. Epub 2014 Apr 3


p85 PROTEIN EXPRESSION IS ASSOCIATED WITH POOR SURVIVAL IN HER2-POSITIVE PATIENTS WITH ADVANCED BREAST CANCER TREATED WITH TRASTUZUMAB
K. Pavlakis, M. Bobos, A. Batistatou, V. Kotoula, AG. Eleftheraki, A. Stofas, E. Timotheadou, G. Pentheroudakis, A. Psyrri, A. Koutras, D. Pectasides, P. Papakostas, E. Razis, C. Christodoulou, KT. Kalogeras, G. Fountzilas
Pathol Oncol Res. 2014 Aug 8. [Epub ahead of print]


PROGNOSTIC AND PREDICTIVE VALUE OF p-Akt, EGFR, AND p-mTOR IN EARLY BREAST CANCER
G. Lazaridis, S. Lambaki, G. Karayannopoulou, AG. Eleftheraki, I. Papaspirou, M. Bobos, I. Efstratiou, G. Pentheroudakis, N. Zamboglou, G. Fountzilas
Strahlenther Onkol. 2014 Jul;190(7):636-8, 640-5


IN SITU QUANTITATIVE MEASUREMENT OF HER2mRNA PREDICTS BENEFIT FROM TRASTUZUMAB-CONTAINING CHEMOTHERAPY IN A COHORT OF METASTATIC BREAST CANCER PATIENTS
M. Vassilakopoulou, T. Togun, U. Dafni, H. Cheng, J. Bordeaux, VM. Neumeister, M. Bobos, G. Pentheroudakis, DV. Skarlos, D. Pectasides, V. Kotoula, G. Fountzilas,DL. Rimm, A. Psyrri
PLoS One. 2014 Jun 26;9(6):e99131. doi: 10.1371/journal.pone.0099131. eCollection 2014


ADJUSTING BREAST CANCER PATIENT PROGNOSIS WITH NON-HER2-GENE PATTERNS ON CHROMOSOME 17
V. Kotoula, M. Bobos, Z. Alexopoulou, C. Papadimitriou, K. Papadopoulou, E. Charalambous, E. Tsolaki, G. Xepapadakis, I. Nicolaou, I. Papaspirou, G. Aravantinos, C. Christodoulou, I. Efstratiou, H. Gogas, G. Fountzilas
PLoS One. 2014 Aug 6;9(8):e103707. doi: 10.1371/journal.pone.0103707. eCollection 2014


GENETIC VARIATION IN MITOTIC REGULATORY PATHWAY GENES IS ASSOCIATED WITH BREAST TUMOR GRADE

K.S. Purrington…. D. Yannoukakos…. F. Fostira, G. Fountzilas, I. Konstantopoulou….

Hum Mol Genet. 2014 Nov 15;23(22):6034-46. doi: 10.1093/hmg/ddu300. Epub 2014 Jun 13.


alphaB-CRYSTALLIN IS A MARKER OF AGGRESSIVE BREAST CANCER BEHAVIOR BUT DOES NOT INDEPENDENTLY PREDICT FOR PATIENT OUTCOME: A COMBINED ANALYSIS OF TWO RANDOMIZED STUDIES

T. Koletsa, F. Stavridi, M. Bobos, I. Kostopoulos, V. Kotoula, A.G. Eleftheraki, I.Konstantopoulou, Ch. Papadimitriou, A. Batistatou, H. Gogas, A. Koutras, D.V. Skarlos, G. Pentheroudakis, I. Efstratiou, D. Pectasides, G. Fountzilas

BMC Clin Pathol. 2014 Jun 23;14:28. doi: 10.1186/1472-6890-14-28. eCollection 2014.


EGFR EXPRESSION IS ASSOCIATED WITH DECREASED BENEFIT FROM TRASTUZUMAB IN THE NCCTG N9831 (ALLIANCE) TRIAL

H. Cheng, K.V Ballman, M. Vassilakopoulou, A.C Dueck, M. M Reinholz, K. Tenner, J. Gralow, C. Hudis, N.E Davidson, G. Fountzilas, A.E McCullough, B. Chen, A. Psyrri, D.L Rimm, E.A Perez

Br J Cancer. 2014 Sep 9;111(6):1065-71. doi: 10.1038/bjc.2014.442. Epub 2014 Aug 12.


DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY FOLLOWED, AS INDICATED, BY TRASTUZUMAB FOR ONE YEAR IN PATIENTS WITH EARLY BREAST CANCER: FIRST REPORT AT 5-YEAR MEDIAN FOLLOW-UP OF A HELLENIC COOPERATIVE ONCOLOGY GROUP RANDOMIZED PHASE III TRIAL
G. Fountzilas, U. Dafni, C. Papadimitriou, E. Timotheadou, H. Gogas, A.G. Eleftheraki, I. Xanthakis, C.Christodoulou, A. Koutras, C.N. Papandreou, P. Papakostas, S. Miliaras, C. Markopoulos, C. Dimitrakakis, P.Korantzopoulos, C. Karanikiotis, D. Bafaloukos, P. Kosmidis, E. Samantas, I. Varthalitis, N. Pavlidis, D.Pectasides, M.A. Dimopoulos
BMC Cancer, 2014 Jul 15;14:515. doi: 10.1186/1471-2407-14-515


A STUDY OF GENE EXPRESSION MARKERS FOR PREDICTIVE SIGNIFICANCE FOR BEVACIZUMAB BENEFIT IN PATIENTS WITH METASTATIC COLON CANCER: A TRANSLATIONAL RESEARCH STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG)

G. Pentheroudakis, V. Kotoula, E. Fountzilas, G.Kouvatseas, G. Basdanis, I. Xanthakis, Th. Makatsoris, E. Charalambous, D. Papamichael, E. Samantas, P. Papakostas, D. Bafaloukos, E. Razis, Ch. Christodoulou, I. Varthalitis, N. Pavlidis and G. Fountzilas

BMC Cancer. 2014 Feb 20;14:111. doi: 10.1186/1471-2407-14-111.


BEVACIZUMAB AND MICROMETASTASES: REVISITING THE PRECLINICAL AND CLINICAL ROLLERCOASTER

G. Mountzios, G. Pentheroudakis, P. Carmeliet

Pharmacol Ther. 2014 Feb; 141(2):117-24. doi:10.1016/j.pharmthera.2013.09.003. Epub 2013 Sep 27.


PROGNOSTIC MARKERS IN EARLY STAGE COLORECTAL CANCER: SIGNIFICANCE OF TYMS rnRNA EXPRESSION

A. Koumarianou, I. Tzeveleki, D. Mekras, A.G. Eleftheraki, M. Bobos, R. Wirtz, E. Fountzilas, Ch. Valavanis, I. Xanthakis, K.T. Kalogeras, G. Basdanis, G. Pentheroudakis, V. Kotoula, G. Fountzilas

Anticancer Research, 2014 Sep;34(9):4949-62.

Δημοσιεύσεις 2015

PROGNOSTIC AND PREDICTIVE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR POLYMORPHISMS IN BREAST CANCER

Koutras A, Kotoula V, Fountzilas G.

Pharmacogenomics. 2015 Jan;16(1):79-94. doi: 10.2217/pgs.14.148


IMPACT OF TUMOR ANGIOGENIC PROFILE ON THE OUTCOME OF PATIENTS WITH METASTATIC BREAST CARCINOMA TREATED WITH WEEKLY DOCETAXEL. A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY

H.P. Kourea, V. Kotoula, A. Koutras, Z. Alexopoulou, I. Papaspirou, D.V. Skarlos, I. Efstratiou, M. Bobos, F. Zagouri, P. Papakostas, D. Pectasides, S. Chrisafi, I. Varthalitis, G. Aravantinos, P. Kosmidis, D. Bafaloukos, C.D. Scopa and G. Fountzilas

Histol Histopathol (2015) 30: 1129-1141


INHERITED MUTATIONS IN 17 BREAST CANCER SUSCEPTIBILITY GENES AMONG A LARGE TRIPLE-NEGATIVE BREAST CANCER COHORT UNSELECTED FOR FAMILY HISTORY OF BREAST CANCER

F.J. Couch, S.N. Hart, …….I. Konstantopoulou, F. Fostira, A. Vratimos, G. Fountzilas, …..D. Yannoukakos, S.L. Slager, C.M. Vachon, D.M. Eccles, and P.A. Fasching

Journal of Clinical Oncology, 33(4), 304-311, 2015


MEASUREMENT OF DOMAIN-SPECIFIC HER2 (ERBB2) EXPRESSION MAY CLASSIFY BENEFIT FROM TRASTUZUMAB IN BREAST CANCER

D.E Carvajal-Hausdorf, K.A Schalper, Pusztai L, A. Psyrri, K.T Kalogeras, V. Kotoula, G. Fountzilas, D.L Rimm

J Natl Cancer Inst. 2015 May 19;107(8). pii: djv136. doi: 10.1093/jnci/djv136. Print 2015 Aug


EVALUATION OF TWO HIGHLY-MULTIPLEXED CUSTOM PANELS FOR MASSIVELY PARALLEL SEMICONDUCTOR SEQUENCING ON PARAFFIN DNA

V. Kotoula, A. Lyberopoulou, K. Papadopoulou, E. Charalambous, Z. Alexopoulou, C. Gakou, S. Lakis, E. Tsolaki, K. Lilakos, G. Fountzilas

PLoS One. 2015 Jun 3;10(6):e0128818. doi: 10.1371/journal.pone.0128818. eCollection 2015


PAI-1 AND HER2 INTERACTION IN METASTATIC BREAST CANCER DISEASE: EVIDENCE FOR ADDED BENEFIT FROM TRASTUZUMAB IN HER2-NEGATIVE PATIENTS

A. Koumarianou, G. Karayannopoulou, G. Gourgioti, A. Batistatou, M. Bobos, I. Efstratiou, D. Miliaras, E. Galani, G. Pentheroudakis, D. Pectasides, G. Aravantinos, D. Bafaloukos, P. Papakostas, E. Razis, H. P. Kalofonos, Kalliopi Petraki, Maria Sotiropoulou, Konstantine T. Kalogeras, George Fountzilas

Cancer Chemother Pharmacol. 2015 Jun;75(6):1289-301. doi: 10.1007/s00280-015-2762-3. Epub 2015 May 7.


CHEK2 c.1100delC ALLELE IS RARELY IDENTIFIED IN GREEK BREAST CANCER CASES

P. Apostolou, F. Fostira, M. Papamentzelopoulou, M. Michelli, C. Panopoulos, G. Fountzilas, I. Konstantopoulou, G.E Voutsinas, D. Yannoukakos

Cancer Genet. 2015 Apr;208(4):129-34. doi: 10.1016/j.cancergen.2015.02.006. Epub 2015 Feb 20


PROGNOSTIC SIGNIFICANCE OF VEGFC AND VEGFR1 MRNA EXPRESSION ACCORDING TO HER2 STATUS IN BREAST CANCER: A STUDY OF PRIMARY TUMORS FROM PATIENTS WITH HIGH-RISK EARLY BREAST CANCER PARTICIPATING IN A RANDOMIZED HELLENIC COOPERATIVE ONCOLOGY GROUP TRIAL

H. Linardou, K.T Kalogeras, R. Kronenwett, Z. Alexopoulou, R.M Wirt, F. Zagouri, C.D. Scopa, H. Gogas, K. Petraki, Ch. Christodoulou, K.Pavlakis, A.K Koutras, E. Samantas, H. Patsea, D. Pectasides, D. Bafaloukos, G. Fountzilas

Anticancer Res. 2015 Jul; 35 (7): 4023-36.


COMPARISON OF FILGRASTIM AND PEGFILGRASTIM TO PREVENT NEUTROPENIA AND MAINTAIN DOSE INTENSITY OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER

G . Kourlaba, M.A Dimopoulos, D. Pectasides, D.V Skarlos, H. Gogas, G. Pentheroudakis, A. Koutras, G. Fountzilas, N. Maniadakis

Support Care Cancer. 2015 Jul; 23 (7): 2045-51. doi: 10.1007/s00520-014-2555-y.


p85 PROTEIN EXPRESSION IS ASSOCIATED WITH POOR SURVIVAL IN HER2-POSITIVE PATIENTS WITH ADVANCED BREAST CANCER TREATED WITH TRASTUZUMAB

K. Pavlakis, M. Bobos, A. Batistatou, V. Kotoula, A.G Eleftheraki, A. Stofas, E. Timotheadou, G. Pentheroudakis, A. Psyrri, A. Koutras, D. Pectasides, P. Papakostas, E. Razis, C. Christodoulou, K.T Kalogeras, G. Fountzilas

Pathol Oncol Res. 2015 Apr;21(2):273-82. doi: 10.1007/s12253-014-9818-2.


SIGNIFICANCE OF THE TYPE OF PIK3CA MUTATIONS IN PATIENTS WITH EARLY BREAST CANCER TREATED WITH ADJUVANT CHEMOTHERAPY: A Hellenic Cooperative Oncology Group (HeCOG) study

G.Papaxoinis, V. Kotoula, Z. Alexopoulou, K.T. Kalogeras, F. Zagouri, E. Timotheadou, H. Gogas, G. Pentheroudakis, Ch. Christodoulou, A. Koutras, D. Bafaloukos, G. Aravantinos, P. Papakostas, E. Charalambous, K. Papadopoulou, I. Varthalitis, I. Efstratiou, Th. Zaramboukas, H. Patsea, C. D. Scopa, M. Skondra, P. Kosmidis, D. Pectasides, G. Fountzilas 

PLoS One. 2015 Oct 9;10(10):e0140293. doi: 10.1371/journal.pone.0140293. eCollection 2015.


TUMORS WITH HIGH-DENSITY TUMOR INFILTRATING LYMPHOCYTES CONSTITUTE A FAVORABLE ENTITY IN BREAST CANCER: A POOLED ANALYSIS OF FOUR PROSPECTIVE ADJUVANT TRIALS

V. Kotoula, K. Chatzopoulos, S. Lakis, Z. Alexopoulou, E. Timotheadou, F. Zagouri, G. Pentheroudakis, H. Gogas, E. Galani, I. Efstratiou, Th. Zaramboukas, A. Koutras, G. Aravantinos, E. Samantas, A. Psyrri, H. Kourea, M. Bobos, P. Papakostas, P. Kosmidis, D. Pectasides, G. Fountzilas

Oncotarget. 2015 Oct 25. doi: 10.18632/oncotarget.6231. [Epub ahead of print]


PREDICTIVE BIOMARKERS TO CHEMOTHERAPY IN PATIENTS WITH ADVANCED MELANOMA RECEIVING THE COMBINATION OF CISPLATIN-VINBLASTINE-TEMOZOLOMIDE (PVT) AS FIRST-LINE TREATMENT: A STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)

H. Linardou, G. Pentheroudakis, I. Varthalitis, H. Gogas, D. Pectasides, T. Makatsoris, G. Fountzilas, D. Bafaloukos

Anticancer Res. 2015 Feb;35(2):1105-13


INTRAVENOUS HIGH DOSE INTERFERON WITH OR WITHOUT MAINTENANCE TREATMENT IN MELANOMA AT HIGH RISK OF RECURRENCE: META-ANALYSIS OF 3 TRIALS

A. Malczewski,….D. Pectasides, G. Fountzilas, H. Gogas, …et al.

Cancer Med. 2015 Dec 8. doi: 10.1002/cam4.563. [Epub ahead of print]


IMMUNE RESPONSE GENE EXPRESSION IN COLORECTAL CANCER CARRIES DISTINCT PROGNOSTIC IMPLICATIONS ACCORDING TO TISSUE, STAGE AND SITE: A PROSPECTIVE RETROSPECTIVE TRANSLATIONAL STUDY IN THE CONTEXT OF A HELLENIC COOPERATIVE ONCOLOGY GROUP RANDOMISED TRIAL

Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, Gourgioti G, Gakou C, Syrigos KN, Bournakis E, Rallis G, Varthalitis I, Galani E, Lazaridis G, Papaxoinis G, Pectasides D, Aravantinos G, Makatsoris T, Kalogeras KT, Fountzilas G.

PLoS One. 2015 May 13;10(5):e0124612. doi: 10.1371/journal.pone.0124612. eCollection 2015


RANDOMIZED PHASE III CLINICAL TRIAL COMPARING THE COMBINATION OF CAPECITABINE AND OXALIPLATIN (CAPOX) WITH THE COMBINATION OF 5-FLUOROURACIL, LEUCOVORIN AND OXALIPLATIN (MODIFIED FOLFOX6) AS ADJUVANT THERAPY IN PATIENTS WITH OPERATED HIGH-RISK STAGE II OR STAGE III COLORECTAL CANCER

D. Pectasides, V. Karavasilis, G. Papaxoinis, G. Gourgioti, T. Makatsoris, G. Raptou, E. Vrettou, J. Sgouros, E. Samantas, G. Basdanis, P. Papakostas, D. Bafaloukos, V. Kotoula, H.P Kalofonos, C.D Scopa, G. Pentheroudakis, G. Fountzilas

BMC Cancer. 2015 May 10;15:384. doi: 10.1186/s12885-015-1406-7.


PHASE III, RANDOMIZED, DOUBLE-BLIND MULTICENTER TRIAL COMPARING ORTERONEL (TAK-700) PLUS PREDNISONE WITH PLACEBO PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT HAS PROGRESSED DURING OR AFTER DOCETAXEL-BASED THERAPY: ELM-PC5

K. Fizazi, R. Jones, S. Oudard, E. Efstathiou, F. Saad, R. de Wit, J. De Bono, F.M Cruz, G. Fountzilas, A. Ulys, F. Carcano, N. Agarwal, D. Agus, J. Bellmunt, D.P Petrylak, S.Y Lee, I.J Webb, B. Tejura, N. Borgstein, R. Dreicer

J Clin Oncol. 2015 Mar 1;33(7):723-31. doi: 10.1200/JCO.2014.56.5119. Epub 2015 Jan 26


TWO CYCLES OF ADJUVANT CARBOPLATIN IN STAGE I SEMINOMA: 8-YEAR EXPERIENCE BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)

K. Koutsoukos, K. Tzannis, C. Christodoulou, V. Karavasilis, C. Bakoyiannis, T. Makatsoris, C.N Papandreou, D. Pectasides, M.A Dimopoulos, A. Bamias

World J Urol, 2015, DOI 10.1007/s00345-015-1695-0


PROGNOSTIC SIGNIFICANCE OF WNT AND HEDGEHOG PATHWAY ACTIVATION MARKERS IN CANCER OF UNKNOWN PRIMARY

G .Fotopoulos, A. Gousia, E. Bareta, E. Koumpis, S. Xrysafi, M. Bobos, V. Malamou-Mitsi, G. Fountzilas, N. Pavlidis, G. Pentheroudakis

Eur J Clin Invest. 2015 Aug 13. doi: 10.1111/eci.12518. Epub 2015 Sep 13.


CHEMOTHERAPY AND RADIOTHERAPY IN NASOPHARYNGEAL CARCINOMA: AN UPDATE OF THE MAC-NPC META-ANALYSIS

Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lu TX, Bourhis J, Pignon JP; MAC-NPC Collaborative Group.

Lancet Oncol. 2015 Jun;16(6):645-55. doi: 10.1016/S1470-2045(15)70126-9. Epub 2015 May 6. PMID:25957714


PROTEIN AND MRNA EXPRESSION OF NOTCH PATHWAY COMPONENTS IN OPERABLE TUMORS OF PATIENTS WITH LARYNGEAL CANCER

D. Krikelis, V. Kotoula, M. Bobos, E. Fountzilas, K. Markou, I. Karasmanis, N. Angouridakis, K. Vlachtsis, K.T Kalogeras, A. Nikolaou, G. Fountzilas

Anticancer Res. 2014 Nov;34(11):6495-503


EVALUATION OF PD-L1 EXPRESSION AND ASSOCIATED TUMOR-INFILTRATING LYMPHOCYTES IN LARYNGEAL SQUAMOUS CELL CARCINOMA

A. Psyrri et al

Clin Cancer Res. 2015 Sep 25. [Epub ahead of print]


INTACT OR BROKEN-APART RNA: AN ALTERNATIVE CONCEPT FOR ALK FUSION SCREENING IN NON-SMALL CELL LUNG CANCER (NSCLC)

V. Kotoula, M. Bobos, M. Vassilakopoulou, E. Tsolaki, S. Chrisafi, A. Psyrri, G. Lazaridis, K. Papadopoulou, I. Efstratiou, C. Michail-Strantzia, L.V Debelenko, P. Kosmidis, G. Fountzilas

Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):60-70. doi: 10.1097/PAI.0000000000000028.


FCGR POLYMORPHISMS AND CETUXIMAB EFFICACY IN CHEMO-REFRACTORY METASTATIC COLORECTAL CANCER: AN INTERNATIONAL CONSORTIUM STUDY

R. Geva, L. Vecchione, K.T. Kalogeras, B. Vittrup Jensen, H.J Lenz , T. Yoshino, D. Paez, C. Montagut, J. Souglakos, F. Cappuzzo, A. Cervantes, M. Frattini, G. Fountzilas, J.S. Johansen, E.V Høgdall , W. Zhang, D. Yang, K. Yamazaki, T. Nishina, D. Papamichael, B. Vincenzi, T. Macarulla, F. Loupakis , J. De Schutter, K.L Garm Spindler, P. Pfeiffer, F. Ciardiello, H. Piessevaux, S. Tejpar

Gut. 2015 Jun;64(6):921-8. doi: 10.1136/gutjnl-2014-307234. Epub 2014 Jul 10.

Δημοσιεύσεις 2016

INTERACTION BETWEEN BETA-CATENIN AND EGFR EXPRESSION BY IMMUNOHISTOCHEMISTRY IDENTIFIES PROGNOSTIC SUBGROUPS IN EARLY HIGH-RISK TRIPLE NEGATIVE BREAST CANCER.  

Sotirios Lakis, Stefanos Dimoudis, Vassiliki Kotoula, Zoi Alexopoulou, Ioannis Kostopoulos, Triantafyllia Koletsa, Mattheos Bobos, Eleni Timotheadou, Irene Papaspirou, Ioannis Efstratiou, Gerasimos Aravantinos, Vasilios Karavasilis, Flora Zagouri, Helen Gogas, Evangelia Razis, George Pentheroudakis, Christos Christodoulou, Dimitrios Pectasides, George Fountzilas

Anticancer Res. 2016 May;36(5):2365-78.


SAFETY AND TOLERABILITY OF ANTHRACYCLINE-CONTAINING ADJUVANT CHEMOTHERAPY IN ELDERLY HIGH-RISK BREAST CANCER PATIENTS

Vasilios Karavasilis, Christos Papadimitriou, Helen Gogas, George Kouvatseas, George Pentheroudakis, Angelos Koutras, Christos Christodoulou, Dimitrios Bafaloukos, Epaminontas Samantas, Nikolaos Pisanidis, Pavlos Papakostas, Gerasimos Aravantinos, Charisios Karanikiotis, Paris Kosmidis, Dimitrios Pectasides, Meletios-Athanassios Dimopoulos, George Fountzilas

Clin Breast Cancer. 2016 Aug;16(4):291-298.e3. doi: 10.1016/j.clbc.2015.12.001. Epub 2015 Dec 17.


GENES ASSOCIATED WITH HISTOPATHOLOGIC FEATURES OF TRIPLE NEGATIVE BREAST TUMORS PREDICT MOLECULAR SUBTYPES

Purrington KS, Visscher DW, Wang C, Yannoukakos D, Hamann U, Nevanlinna H, Cox A, Giles GG, Eckel-Passow JE, Lakis S, Kotoula V, Fountzilas G, Kabisch M, Rüdiger T, Heikkilä P, Blomqvist C, Cross SS, Southey MC, Olson JE, Gilbert J, Deming-Halverson S, Kosma VM, Clarke C, Scott R, Jones JL, Zheng W, Mannermaa A; Jane Carpenter for ABCTC Investigators, Eccles DM, Vachon CM, Couch FJ.

Breast Cancer Res Treat. 2016 May;157(1):117-31. doi: 10.1007/s10549-016-3775-2. Epub 2016 Apr 15.


COMPARISON OF THE ABILITY OF DIFFERENT CLINICAL TREATMENT SCORES TO ESTIMATE PROGNOSIS IN HIGH-RISK EARLY BREAST CANCER PATIENTS: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

Flora Stavridi, Konstantine T. Kalogeras, Kyriaki Pliarchopoulou, Ralph M. Wirtz, Zoi Alexopoulou, Flora Zagouri, Elke Veltrup, Eleni Timotheadou, Helen Gogas, Angelos Koutras, Georgios Lazaridis, Christos Christodoulou, George Pentheroudakis, Apostolos Laskarakis, Petroula Arapantoni-Dadioti, Anna Batistatou, Maria Sotiropoulou, Gerasimos Aravantinos, Pavlos Papakostas, Paris Kosmidis, Dimitrios Pectasides, George Fountzilas

PLoS One. 2016 Oct 3;11(10):e0164013. doi: 10.1371/journal.pone.0164013.


MYC COPY GAIN, CHROMOSOMAL INSTABILITY AND PI3K ACTIVATION AS POTENTIAL MARKERS OF UNFAVOURABLE OUTCOME IN TRASTUZUMAB-TREATED PATIENTS WITH METASTATIC BREAST CANCER

Helen Gogas, Vassiliki Kotoula, Zoi Alexopoulou, Christos Christodoulou, Ioannis Kostopoulos, Mattheos Bobos, Georgia Raptou, Elpida Charalambous, Eleftheria Tsolaki, Ioannis Xanthakis, George Pentheroudakis, Angelos Koutras, Dimitrios Bafaloukos, Pavlos Papakostas, Gerasimos Aravantinos, Amanda Psyrri, Kalliopi Petraki, Dimitrios Pectasides, George Fountzilas

J Transl Med. 2016 May 17;14(1):136. doi: 10.1186/s12967-016-0883-z.


TP53 MUTATIONS AND PROTEIN IMMUNOPOSITIVITY MAY PREDICT FOR POOR OUTCOME BUT ALSO FOR TRASTUZUMAB BENEFIT IN PATIENTS WITH EARLY BREAST CANCER TREATED IN THE ADJUVANT SETTING

Fountzilas G, Giannoulatou E, Alexopoulou Z, Zagouri F, Timotheadou E, Papadopoulou K, Lakis S, Bobos M, Poulios C, Sotiropoulou M, Lyberopoulou A, Gogas H, Pentheroudakis G, Pectasides D, Koutras A, Christodoulou C, Papandreou C, Samantas E, Papakostas P, Kosmidis P, Bafaloukos D, Karanikiotis C, Dimopoulos MA, Kotoula V.

Oncotarget. 2016 May 31;7(22):32731-53. doi: 10.18632/oncotarget.9022.


TUMORS WITH HIGH-DENSITY TUMOR INFILTRATING LYMPHOCYTES CONSTITUTE A FAVORABLE ENTITY IN BREAST CANCER: A POOLED ANALYSIS OF FOUR PROSPECTIVE ADJUVANT TRIALS.

Kotoula VChatzopoulos KLakis SAlexopoulou ZTimotheadou EZagouri FPentheroudakis GGogas HGalani EEfstratiou IZaramboukas TKoutras AAravantinos GSamantas EPsyrri AKourea HBobos MPapakostas PKosmidis PPectasides DFountzilas G

Oncotarget. 2016 Jan 26;7(4):5074-87. doi: 10.18632/oncotarget.6231.


EFFECTS OF TP53 AND PIK3CA MUTATIONS IN EARLY BREAST CANCER: A MATTER OF CO-MUTATION AND TUMOR INFILTRATING LYMPHOCYTES

Vassiliki Kotoula, Vasilios Karavasilis, Flora Zagouri, George Kouvatseas, Eleni Giannoulatou, Helen Gogas, Sotiris Lakis, George Pentheroudakis, Mattheos Bobos, Kyriaki Papadopoulou, Eleftheria Tsolaki, Dimitrios Pectasides, Georgios Lazaridis, Angelos Koutras, Gerasimos Aravantinos, Christos Christodoulou, Pavlos Papakostas, Christos Markopoulos, George Zografos, Christos Papandreou, George Fountzilas

Breast Cancer Res Treat. 2016 Jul;158(2):307-21. doi: 10.1007/s10549-016-3883-z.


MALE BREAST CANCER IN BRCA1 AND BRCA2 MUTATION CARRIERS: PATHOLOGY DATA FROM THE CONSORTIUM OF INVESTIGATORS OF MODIFIERS OF BRCA1/2.

Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL,….Garber J, Fostira F, Fountzilas G, Chenevix-Trench G, Antoniou AC, Ottini L.

Breast Cancer Res. 2016 Feb 9;18(1):15. doi: 10.1186/s13058-016-0671-y.


TUMOR INFILTRATING LYMPHOCYTES AFFECT THE OUTCOME OF PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER IN COMBINATION WITH MUTATED AMINO ACID CLASSES.

Kotoula V, Lakis S, Vlachos IS, Giannoulatou E, Zagouri F, Alexopoulou Z, Gogas H, Pectasides D, Aravantinos G, Efstratiou I, Pentheroudakis G, Papadopoulou K, Chatzopoulos K, Papakostas P, Sotiropoulou M, Nicolaou I, Razis E, Psyrri A, Kosmidis P, Papadimitriou C, Fountzilas G.

PLoS One. 2016 Sep 29;11(9):e0163138. doi: 10.1371/journal.pone.0163138. eCollection 2016.


HAPLOTYPE ANALYSIS REVEALS THAT THE RECURRENT BRCA1 DELETION OF EXONS 23 AND 24 IS A GREEK FOUNDER MUTATION.

Apostolou P, Pertesi M, Aleporou-Marinou V, Dimitrakakis C, Papadimitriou C, Razis E, Christodoulou C, Fountzilas G, Yannoukakos D, Konstantopoulou I, Fostira F.

Clin Genet. 2017 Mar;91(3):482-487.doi: 10.1111/cge.12824. Epub 2016 Aug 22.


DISEASE EVOLUTION AND HETEROGENEITY IN BILATERAL BREAST CANCER.

Fountzilas E, Kotoula V, Zagouri F, Giannoulatou E, Kouvatseas G, Pentheroudakis G, Koletsa T, Bobos M, Papadopoulou K, Samantas E, Demiri E, Miliaras S, Christodoulou C, Chrisafi S, Razis E, Fostira F, Pectasides D, Zografos G, Fountzilas G.

Am J Cancer Res. 2016 Nov 1;6(11):2611-2630


HER FAMILY PROTEIN EXPRESSION IN A GREEK POPULATION WITH GASTRIC CANCER. A RETROSPECTIVE HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

T. Makatsoris, A.C. Tsamandas, A. Strimpakos, Z. Alexopoulou, D. Dionysopoulos, S. Pervana, A. Konstantara, P. Papakostas, E. Samantas, G. Rallis, A. Dimou, G. Pentheroudakis, K. Papaparaskeva, A. Psyrri, K.T. Kalogeras, K. Syrigos, C.D. Scopa, G. Fountzilas

Anticancer Research 36: 1581-1590 (2016)


EVALUATION OF CPG ISLAND METHYLATOR PHENOTYPE AS A BIOMARKER IN COLORECTAL CANCER TREATED WITH ADJUVANT OXALIPLATIN

Cohen SA, Wu C, Yu M, Gourgioti G, Wirtz R, Raptou G, Gkakou C, Kotoula V, Pentheroudakis G, Papaxoinis G, Karavasilis V, Pectasides D, Kalogeras KT, Fountzilas G, Grady WM.

Clin Colorectal Cancer. 2016 Jun;15(2):164-9. doi: 10.1016/j.clcc.2015.10.005.


EXPRESSION PATTERNS OF GROWTH AND SURVIVAL GENES WITH PROGNOSTIC IMPLICATIONS IN ADVANCED PANCREATIC CANCER.

Pectasides D, Kotoula V, Papaxoinis G, Alexopoulou Z, Dervenis C, Samantas E, Papaparaskeva K, Charalambous E, Gkakou C, Agalianos C, Kalogeras KT, Pentheroudakis G, Fountzilas G.

Anticancer Res. 2016 Dec;36(12):6347-6356.


EVALUATION OF PD-L1 EXPRESSION AND ASSOCIATED TUMOR-INFILTRATING LYMPHOCYTES IN LARYNGEAL SQUAMOUS CELL CARCINOMA

Vassilakopoulou MAvgeris MVelcheti VKotoula VRampias T4Chatzopoulos KPerisanidis CKontos CKGiotakis AIScorilas ARimm DSasaki CFountzilas GPsyrri A

Clin Cancer Res. 2016 Feb 1;22(3):704-13. doi: 10.1158/1078-0432.CCR-15-1543.


LESSONS FROM THE PAST: LONG-TERM SAFETY AND SURVIVAL OUTCOMES OF A PREMATURELY TERMINATED RANDOMIZED CONTROLLED TRIAL OF PROPHYLACTIC VERSUS HEMOGLOBIN-BASED ERYTHROPOIETIN ADMINISTRATION IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA.

Giannis Mountzios, Gerasimos Aravantinos, Zoi Alexopoulou, Eleni Timotheadou, Fotini Matsiakou, Christos Christodoulou, Konstantinos Laschos, Eleni Galani, Angelos Koutras, Dimitrios Bafaloukos, Helena Linardou, Dimitrios Pectasides, Ioannis Varthalitis, Pavlos Papakostas, Haralambos P. Kalofonos and George Fountzilas

Mol Clin Oncol. 2016 Feb;4(2):211-220.


NOVEL THERAPIES FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG.

Koutsoukos K, Mountzios G.

Future Oncol. 2016 Mar;12(5):659-67.


THERAPIES IN THE PIPELINE FOR SMALL-CELL LUNG CANCER.

Romanidou O, Imbimbo M, Mountzios G, Abidin A, Morgillo F, Califano R.

Br Med Bull. 2016 Sep;119(1):37-48.


Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

Califano R, Romanidou O, Mountzios G, Landi L, Cappuzzo F, Blackhall F.

Drugs. 2016 May;76(8):831-40. 


A POOLED ANALYSIS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER AND THE ROLE OF PD-L1 AS A PREDICTIVE BIOMARKER.

Aguiar PN Jr, Santoro IL, Tadokoro H, de Lima Lopes G, Filardi BA, Tsiatas M, Oliveira P, Castelo-Branco P, Mountzios G, de Mello RA.

Immunotherapy. 2016 Sep;8(9):1011-9. doi: 10.2217/imt-2016-0032


NON-SMALL CELL LUNG CANCER (NSCLC) AND CENTRAL NERVOUS SYSTEM (CNS) METASTASES: ROLE OF TYROSINE KINASE INHIBITORS (TKIS) AND EVIDENCE IN FAVOR OR AGAINST THEIR USE WITH CONCURRENT CRANIAL RADIOTHERAPY

Panagiota Economopoulou,  Giannis Mountzios

Transl Lung Cancer Res. 2016 Dec;5(6):588-598. doi: 10.21037/tlcr.2016.12.06.PMID: 28149754


THE IMPACT OF PACLITAXEL AND CARBOPLATIN CHEMOTHERAPY ON THE AUTONOMOUS NERVOUS SYSTEM OF PATIENTS WITH OVARIAN CANCER.

Emmanouil Dermitzakis; Vasilios K. Kimiskidis; George Lazaridis; Zoi Alexopoulou; Eleni Timotheadou; Alexandros Papanikolaou; Ourania Romanidou; George Georgiadis; Konstantine T Kalogeras; Iakovos Tsiptsios; Basil Tarlatzis; George Fountzilas

BMC Neurol. 2016 Oct 1;16(1):190.  doi: 10.1186/s12883-016-0710-4.


PROGNOSTIC AND PREDICTIVE EFFECTS OF PRIMARY VERSUS SECONDARY PLATINUM RESISTANCE FOR BEVACIZUMAB TREATMENT FOR PLATINUM-RESISTANT OVARIAN CANCER IN THE AURELIA TRIAL.

Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E.

Ann Oncol. 2016 Sep;27(9):1733-9. doi: 10.1093/annonc/mdw236


INTRAVENOUS HIGH-DOSE INTERFERON WITH OR WITHOUT MAINTENANCE TREATMENT IN MELANOMA AT HIGH RISK OF RECURRENCE: META-ANALYSIS OF THREE TRIALS.

Malczewski A, Marshall A, Payne MJ, Mao L, Bafaloukos D, Si L, Pectasides D, Fountzilas G, Guo J, Gogas H, Middleton MR.

Cancer Med. 2016 Jan;5(1):17-23. doi: 10.1002/cam4.563. Epub 2015 Dec 8


POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME WITH CONCURRENT NEPHROTIC SYNDROME IN A PATIENT TREATED WITH PAZOPANIB FOR METASTATIC RENAL CELL CARCINOMA: CASE REPORT AND REVIEW OF THE LITERATURE.

Miaris N, Maltezou M, Papaxoinis G, Visvikis A,SamantasE.

Clin Genitourin Cancer. Published online 2016. doi:10.1016/j.clgc.2016.08.005


ATM SPECIAL ISSUE 


OVERVIEW OF ADVANCES IN CANCER IMMUNOTHERAPY.

Kotoula V, Fountzilas G.

Ann Transl Med. 2016 jul;4(14):260. doi: 10.21037/atm.2016.07.09


HARNESSING THE IMMUNE SYSTEM TO IMPROVE CANCER THERAPY.

Papaioannou NEBeniata OVVitsos PTsitsilonis OSamara P

Ann Transl Med. 2016 Jul;4(14):261. doi: 10.21037/atm.2016.04.01


THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER PERSPECTIVE ON DESIGNING CLINICAL TRIALS WITH IMMUNE THERAPEUTICS.

Menis J, Litière S, Tryfonidis K, Golfinopoulos V.

Ann Transl Med. 2016 Jul;4(14):267. doi: 10.21037/atm.2016.06.19. Review


OPTIMIZED TUMOR CRYPTIC PEPTIDES: THE BASIS FOR UNIVERSAL NEO-ANTIGEN-LIKE TUMOR VACCINES.

Menez-Jamet J, Gallou C, Rougeot A, Kosmatopoulos K.

Ann Transl Med. 2016 Jul;4(14):266. doi: 10.21037/atm.2016.05.15. Review


MELANOMA IMMUNOTHERAPY DOMINATES THE FIELD.

Diamantopoulos P, Gogas H.

Ann Transl Med. 2016 Jul;4(14):269. doi: 10.21037/atm.2016.06.32. Review


THE DUAL ROLE OF COMPLEMENT IN CANCER AND ITS IMPLICATION IN ANTI-TUMOR THERAPY.

Kourtzelis I, Rafail S.

Ann Transl Med. 2016 Jul;4(14):265. doi: 10.21037/atm.2016.06.26. Review


NEOANTIGEN-BASED CANCER IMMUNOTHERAPY.

Bobisse S, Foukas PG, Coukos G, Harari A.

Ann Transl Med. 2016 Jul;4(14):262. doi: 10.21037/atm.2016.06.17. Review


THE SIGNIFICANCE OF TUMOR-ASSOCIATED IMMUNE RESPONSE IN MOLECULAR TAXONOMY, PROGNOSIS AND THERAPY OF COLORECTAL CANCER PATIENTS.

Nearchou A, Pentheroudakis G.

Ann Transl Med. 2016 Jul;4(14):271. doi: 10.21037/atm.2016.05.54. Review


FUTURE PERSPECTIVES IN CANCER IMMUNOTHERAPY.

Tsiatas M, Mountzios G, Curigliano G.

Ann Transl Med. 2016 Jul;4(14):273. doi: 10.21037/atm.2016.07.14


TOXICITY MANAGEMENT OF IMMUNOTHERAPY FOR PATIENTS WITH METASTATIC MELANOMA.

Linardou H, Gogas H.

Ann Transl Med. 2016 Jul;4(14):272. doi: 10.21037/atm.2016.07.10. Review


DNA DAMAGE, TUMOR MUTATIONAL LOAD AND THEIR IMPACT ON IMMUNE RESPONSES AGAINST CANCER.

Liontos M, Anastasiou I, Bamias A, Dimopoulos MA.

Ann Transl Med. 2016 Jul;4(14):264. doi: 10.21037/atm.2016.07.11. Review


TOWARDS TUMOR IMMUNODIAGNOSTICS.

Kourea H, Kotoula V.

Ann Transl Med. 2016 Jul;4(14):263. doi: 10.21037/atm.2016.07.07. Review


IMMUNOTHERAPY IN NON-SMALL CELL LUNG CANCER: THE CLINICAL IMPACT OF IMMUNE RESPONSE AND TARGETING.

Mountzios G, Linardou H, Kosmidis P.

Ann Transl Med. 2016 Jul;4(14):268. doi: 10.21037/atm.2016.06.24. Review

Δημοσιεύσεις 2017

HAPLOTYPE ANALYSIS REVEALS THAT THE RECURRENT BRCA1 DELETION OF EXONS 23 AND 24 IS A GREEK FOUNDER MUTATION.

Apostolou P, Pertesi M, Aleporou-Marinou V, Dimitrakakis C, Papadimitriou C, Razis E, Christodoulou C, Fountzilas G, Yannoukakos D, Konstantopoulou I, Fostira F.

Clin Genet. 2017 Mar;91(3):482-487. doi: 10.1111/cge.12824. Epub 2016 Aug 22.


THE FATE OF BRCA1-RELATED GERMLINE MUTATIONS IN TRIPLE-NEGATIVE BREAST TUMORS.

 Kotoula V, Fostira F, Papadopoulou K, Apostolou P, Tsolaki E, Lazaridis G, Manoussou K, Zagouri F, Pectasides D, Vlachos I, Tikas I, Lakis S, Konstantopoulou I, Pentheroudakis G, Gogas H, Papakostas P, Christodoulou C, Bafaloukos D, Razis E, Karavasilis V, Bamias C, Yannoukakos D, Fountzilas G.

Am J Cancer Res. 2017 Jan 1;7(1):98-114. eCollection 2017.  


 SURROGATE END POINTS FOR OVERALL SURVIVAL IN LOCO-REGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA: AN INDIVIDUAL PATIENT DATA META-ANALYSIS.

Rotolo F, Pignon JP, Bourhis J, Marguet S, Leclercq J, Tong Ng W, Ma J, Chan AT, Huang PY, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Soong YL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lee AW, Blanchard P, Michiels S; MAC-NPC Collaborative Group.

J Natl Cancer Inst. 2017 Apr;109(4). pii: djw239.


ASSOCIATION OF OSTEOPONTIN WITH SPECIFIC PROGNOSTIC FACTORS AND SURVIVAL IN ADJUVANT BREAST CANCER TRIALS OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP.

 Psyrri A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Koutras A, Lazaridis G, Christodoulou C, Pentheroudakis G, Economopoulou P, Laskarakis A, Arapantoni-Dadioti P, Batistatou A, Sotiropoulou M, Aravantinos G, Papakostas P, Kosmidis P, Pectasides D, Fountzilas G.

J Transl Med. 2017 Feb 13;15(1):30. doi: 10.1186/s12967-017-1134-7.


PROGNOSTIC EVALUATION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENOTYPE AND PHENOTYPE PARAMETERS IN TRIPLE-NEGATIVE BREAST CANCERS.

 Levva S, Kotoula V, Kostopoulos I, Manousou K, Papadimitriou C, Papadopoulou K, Lakis S, Koukoulias K, Karavasilis V, Pentheroudakis G, Balassi E, Zagouri F, Kaklamanos IG, Pectasides D, Razis E, Aravantinos G, Papakostas P, Bafaloukos D, Rallis G, Gogas H, Fountzilas G.

Cancer Genomics Proteomics. 2017 May-Jun;14(3):181-195.


CORRELATION OF MYC GENE AND PROTEIN STATUS WITH BREAST CANCER SUBTYPES AND OUTCOME OF PATIENTS TREATED WITH ANTHRACYCLINE-BASED ADJUVANT CHEMOTHERAPY. POOLED ANALYSIS OF 2 HELLENIC COOPERATIVE GROUP PHASE III TRIALS.

Batistatou A, Kotoula V, Bobos M, Kouvatseas G, Zagouri F, Tsolaki E, Gogas H, Koutras A, Pentheroudakis G, Timotheadou E, Pervana S, Goussia A, Petraki K, Sotiropoulou M, Koletsa T, Razis E, Kosmidis P, Aravantinos G, Papadimitriou C, Pectasides D, Fountzilas G.

Clin Breast Cancer. 2017 Jul 13. pii: S1526-8209(17)30138-6. doi: 10.1016/j.clbc.2017.07.004. 


PROTEIN EXPRESSION PATTERNS OF CELL CYCLE REGULATORS IN OPERABLE BREAST CANCER.

 Zagouri F, Kotoula V, Kouvatseas G, Sotiropoulou M, Koletsa T, Gavressea T, Valavanis C, Trihia H, Bobos M, Lazaridis G, Koutras A, Pentheroudakis G, Skarlos P, Bafaloukos D, Arnogiannaki N, Chrisafi S, Christodoulou C, Papakostas P, Aravantinos G, Kosmidis P, Karanikiotis C, Zografos G, Papadimitriou C, Fountzilas G.

PLoS One. 2017 Aug 10;12(8):e0180489. doi: 10.1371/journal.pone.0180489. eCollection 2017. 


LAPATINIB WITH WHOLE BRAIN RADIOTHERAPY IN PATIENTS WITH BRAIN METASTASES FROM BREAST AND NON-SMALL CELL LUNG CANCER: A PHASE II STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG).

Christodoulou C, Kalogera-Fountzila A, Karavasilis V, Kouvatseas G, Papandreou CN, Samantas E, Varaki K, Papadopoulos G, Bobos M, Rallis G, Razis E, Goudopoulou A, Kalogeras KT, Syrigos KN, Fountzilas G.

J Neurooncol. 2017 Sep;134(2):443-451. doi: 10.1007/s11060-017-2548-z 


EVALUATION OF THE PROGNOSTIC VALUE OF RANK, OPG, AND RANKL MRNA EXPRESSION IN EARLY BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINE-BASED ADJUVANT CHEMOTHERAPY.

Timotheadou E, Kalogeras KT, Koliou GA, Wirtz RM, Zagouri F, Koutras A, Veltrup E, Christodoulou C, Pentheroudakis G, Tsiftsoglou A, Papakostas P, Aravantinos G, Venizelos V, Pectasides D, Kosmidis P, Karanikiotis C, Markopoulos C, Gogas H, Fountzilas G.

Transl Oncol. 2017 Aug;10(4):589-598. doi: 10.1016/j.tranon.2017.05.006.


THE PROGNOSTIC VALUE OF THE IMMUNOHISTOCHEMICAL EXPRESSION OF PHOSPHORYLATED RB AND P16 PROTEINS IN ASSOCIATION WITH CYCLIN D1 AND THE P53 PATHWAY IN A LARGE COHORT OF PATIENTS WITH BREAST CANCER TREATED WITH TAXANE-BASED ADJUVANT CHEMOTHERAPY.

Gavressea T, Kalogeras KT, Koliou GA, Zagouri F, Lazaridis G, Gogas H, Tsigaridas K, Koutras A, Petraki K, Markopoulos C, Pazarli E, Aravantinos G, Papadimitriou C, Papakostas P, Koufopoulos N, Karanikiotis C, Chrisafi S, Kalofonos HP, Pectasides D, Fountzilas G, Pavlakis K.

Anticancer Res. 2017 Jun;37(6):2947-2957. 


PROGNOSTIC SUBCELLULAR NOTCH2, NOTCH3 AND JAGGED1 LOCALIZATION PATTERNS IN EARLY TRIPLE-NEGATIVE BREAST CANCER.

Strati TM, Kotoula V, Kostopoulos I, Manousou K, Papadimitriou C, Lazaridis G, Lakis S, Pentheroudakis G, Pectasides D, Pazarli E, Christodoulou C, Razis E, Pavlakis K, Magkou C, Chrisafi S, Aravantinos G, Bafaloukos D, Papakostas P, Gogas H, Kalogeras KT, Fountzilas G.

Anticancer Res. 2017 May;37(5):2323-2334. 


THE CPG ISLAND METHYLATOR PHENOTYPE IS CONCORDANT BETWEEN PRIMARY COLORECTAL CARCINOMA AND MATCHED DISTANT METASTASES.

Cohen SA, Yu M, Baker K, Redman M, Wu C, Heinzerling TJ, Wirtz RM, Charalambous E, Pentheroudakis G, Kotoula V, Kalogeras KT, Fountzilas G, Grady WM.

Clin Epigenetics. 2017 May 2;9:46. doi: 10.1186/s13148-017-0347-1. eCollection 2017. 


ASSOCIATION OF BREAST CANCER RISK IN BRCA1 AND BRCA2 MUTATION CARRIERS WITH GENETIC VARIANTS SHOWING DIFFERENTIAL ALLELIC EXPRESSION: IDENTIFICATION OF A MODIFIER OF BREAST CANCER RISK AT LOCUS 11Q22.3.

Hamdi Y, Soucy P, Kuchenbaeker KB,….G. Fountzilas….

Breast Cancer Res Treat. 2017 Jan;161(1):117-134. 


SAFETY AND EFFICACY OF SINGLE-AGENT BEVACIZUMAB-CONTAINING THERAPY IN ELDERLY PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: SUBGROUP ANALYSIS OF THE RANDOMISED PHASE III AURELIA TRIAL.

Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators.

Gynecol Oncol. 2017 Jan;144(1):65-71. doi: 10.1016/j.ygyno.2016.11.006. 


BEVACIZUMAB WITH OR AFTER CHEMOTHERAPY FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: EXPLORATORY ANALYSES OF THE AURELIA TRIAL.

Bamias AGibbs EKhoon Lee CDavies LDimopoulos MZagouri FVeillard ASKosse JSantaballa AMirza MRTabaro GVergote IBloemendal HLykka MFloquet AGebski VPujade-Lauraine E

Ann Oncol. 2017 Aug 1;28(8):1842-1848. 


WHAT IS THE BEST TREATMENT OF LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA? AN INDIVIDUAL PATIENT DATA NETWORK META-ANALYSIS.

Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, Huang PY, Zhu G, Chua DTT, Chen Y, Mai HQ, Kwong DLW, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Bourhis J, Pignon JP, Blanchard P.

J Clin Oncol. 2017 Feb 10;35(5):498-505. 


CRIZOTINIB FAILURE IN A TPM4-ALK–REARRANGED INFLAMMATORY MYOFIBROBLASTIC TUMOR WITH AN EMERGING ALK KINASE DOMAIN MUTATION

Kalliopi Tsakiri, Vassiliki Kotoula, Sotirios Lakis, Judith Muller, Florentia Fostira, Mattheos Bobos, Prodromos Hytiroglou, George Fountzilas

JCO Precision Oncology 2017 :1, 1-7 

Δημοσιεύσεις 2018

PREVALENT SOMATIC BRCA1 MUTATIONS SHAPE CLINICALLY RELEVANT GENOMIC PATTERNS OF NASOPHARYNGEAL CARCINOMA IN SOUTHEAST EUROPE.

Fountzilas G, Psyrri A, Giannoulatou E, Tikas I, Manousou K, Rontogianni D, Ciuleanu E, Ciuleanu T, Resiga L, Zaramboukas T, Papadopoulou K, Bobos M, Chrisafi S, Tsolaki E, Markou K, Giotakis E, Koutras A, Psoma E, Kalogera-Fountzila A, Skondra M, Bamia C, Pectasides D, Kotoula V.

Int J Cancer. 2018 Jan 1;142(1):66-80.


PHASE II STUDY OF PANITUMUMAB COMBINED WITH CAPECITABINE AND OXALIPLATIN AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER PATIENTS: CLINICAL RESULTS INCLUDING EXTENDED TUMOR GENOTYPING.

Papaxoinis G, Kotoula V, Giannoulatou E, Koliou GA, Karavasilis V, Lakis S, Koureas A, Bobos M, Chalaralambous E, Daskalaki E, Chatzopoulos K, Tsironis G, Pazarli E, Chrisafi S, Samantas E, Kaklamanos IG, Varthalitis I, Konstantara A, Syrigos KN, Pentheroudakis G, Pectasides D, Fountzilas G.

Med Oncol. 2018 May 31;35(7):101. doi: 10.1007/s12032-018-1160-1.


AMALTHEA: A PROSPECTIVE, SINGLE-ARM STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) EVALUATING THE EFFICACY AND SAFETY OF 1ST LINE FOLFIRI+AFLIBERCEPT FOR SIX MONTHS FOLLOWED BY AFLIBERCEPT MAINTENANCE IN PATIENTS WITH METASTATIC COLORECTAL CANCER.

G. Pentheroudakis, V. Kotoula, G.A. Koliou, V. Karavasilis, E. Samantas, G. Aravantinos, L. Kalogeropoulou, I. Souglakos, N. Kentepozidis, G. Koumakis, J. Sgouros, G. Zarkavelis, I. Efstratiou, K. Laschos,  C. Petraki, I. Tikas,  C. Poulios, A. Voutsina, A. Goudopoulou, D. Bafaloukos, E. Vrettou, A. Kalogera-Fountzila, D. Pectasides, G. Fountzilas

Clin Colorectal Cancer. 2018 Dec;17(4):e631-e637. doi: 10.1016/j.clcc.2018.06.003. Epub 2018 Jun 15.


GENOTYPING AND MRNA PROFILING REVEAL ACTIONABLE MOLECULAR TARGETS IN BILIARY TRACT CANCERS.

Papadopoulou K, Murray S, Manousou K, Tikas I, Dervenis C, Sgouros J, Rontogianni D, Lakis S, Bobos M, Poulios C, Pervana S, Lazaridis G, Fountzilas G, Kotoula V.

Am J Cancer Res. 2018 Jan 1;8(1):2-15. eCollection 2018.


GEMCITABINE COMBINED WITH THE mTOR INHIBITOR TEMSIROLIMUS IN PATIENTS WITH INOPERABLE OR METASTATIC PANCREATIC CANCER. A Hellenic Cooperative Oncology Group phase I/II study.

V. Karavasilis, E. Samantas, G.A. Koliou, A. Kalogera-Fountzila, G. Pentheroudakis, I. Varthalitis, H. Linardou, G. Rallis, M. Skondra, G. Papadopoulos, G. Papatsibas, J. Sgouros, A. Goudopoulou, K. T. Kalogeras, C. Dervenis, D. Pectasides, G. Fountzilas

Target Oncol. 2018 Nov 28. doi: 10.1007/s11523-018-0605-y. [Epub ahead of print]


PROGNOSTIC IMPLICATIONS OF TUMOR GENOTYPES AND CD8+ INFILTRATES IN EARLY-STAGE COLORECTAL CANCER

E. Fountzilas, V. Kotoula, I. Tikas, K. Manousou, K. Papadopoulou, C. Poulios, V. Karavasilis, I. Efstratiou, D. Pectasides, K. Papaparaskeva, I. Varthalitis, C. Christodoulou, G. Papatsibas, S. Chrisafi, G.K. Glantzounis, A. Psyrri, G. Aravantinos, G.A. Koliou, G. K. Koukoulis, G. E. Pentheroudakis, G. Fountzilas

Oncotarget. 2018 Nov 2;9(86):35623-35638. doi: 10.18632/oncotarget.26256.


CHARACTERIZATION AND PREVALENCE OF TWO NOVEL CHEK2 LARGE DELETIONS IN GREEK BREAST CANCER PATIENTS.

Apostolou P, Fostira F, Mollaki V, Delimitsou A, Vlassi M, Pentheroudakis G, Faliakou E, Kollia P, Fountzilas G, Yannoukakos D, Konstantopoulou I.

J Hum Genet. 2018 Jul;63(8):877-886. doi: 10.1038/s10038-018-0466-3.


TUMOR PIK3CA GENOTYPE AND PROGNOSIS IN EARLY-STAGE BREAST CANCER: A POOLED ANALYSIS OF INDIVIDUAL PATIENT DATA.

Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, O’Toole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA Jr, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S.

J Clin Oncol. 2018 Apr 1;36(10):981-990. doi: 10.1200/JCO.2017.74.8301.


GERMLINE DELETERIOUS MUTATIONS IN GENES OTHER THAN BRCA2 ARE INFREQUENT IN MALE BREAST CANCER.

Fostira F, Saloustros E, Apostolou P, Vagena A, Kalfakakou D, Mauri D, Tryfonopoulos D, Georgoulias V, Yannoukakos D, Fountzilas G, Konstantopoulou I.

Breast Cancer Res Treat. 2018 May;169(1):105-113. doi: 10.1007/s10549-018-4661-x.


CORRELATION OF MYC GENE AND PROTEIN STATUS WITH BREAST CANCER SUBTYPES AND OUTCOME OF PATIENTS TREATED WITH ANTHRACYCLINE-BASED ADJUVANT CHEMOTHERAPY. POOLED ANALYSIS OF 2 HELLENIC COOPERATIVE GROUP PHASE III TRIALS.

Batistatou A, Kotoula V, Bobos M, Kouvatseas G, Zagouri F, Tsolaki E, Gogas H, Koutras A, Pentheroudakis G, Timotheadou E, Pervana S, Goussia A, Petraki K, Sotiropoulou M, Koletsa T, Razis E, Kosmidis P, Aravantinos G, Papadimitriou C, Pectasides D, Fountzilas G.

Clin Breast Cancer. 2018 Feb;18(1):53-62.e3. doi: 10.1016/j.clbc.2017.07.004.


ASSOCIATIONS OF ANGIOGENESIS-RELATED PROTEINS WITH SPECIFIC PROGNOSTIC FACTORS, BREAST CANCER SUBTYPES AND SURVIVAL OUTCOME IN EARLY-STAGE BREAST CANCER PATIENTS.

A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) TRIAL.

A. Goussia, N. Simou, F. Zagouri, K. Manousou, G. Lazaridis, H. Gogas, A. Koutras, M. Sotiropoulou, G. Pentheroudakis, D. Bafaloukos, C. Markopoulos, H. Patsea, C. Christodoulou, P. Papakostas, T. Zaramboukas, E. Samantas, P. Kosmidis, V. Venizelos, C. Karanikiotis, G. Papatsibas, G. Xepapadakis, K.T. Kalogeras, C. Bamia, M.A. Dimopoulos, V. Malamou-Mitsi, G. Fountzilas, A. Batistatou

PLoS One. 2018 Jul 31;13(7):e0200302. doi: 10.1371/journal.pone.0200302.


EVALUATION OF THE PROGNOSTIC VALUE OF CD3, CD8 AND FOXP3 MRNA EXPRESSION IN EARLY BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINE-BASED ADJUVANT CHEMOTHERAPY

M. Tsiatas, K.T. Kalogeras, K. Manousou, R.M. Wirtz, H. Gogas, E. Veltrup, F. Zagouri, G. Lazaridis, A. Koutras, C. Christodoulou, G. Pentheroudakis, C. Petraki, D. Bafaloukos, D. Pectasides, P. Kosmidis, E. Samantas, C. Karanikiotis, P. Papakostas, M.A. Dimopoulos, G. Fountzilas

Cancer Med. 2018 Oct;7(10):5066-5082. doi: 10.1002/cam4.1730.


EVALUATION OF THE INSULIN-LIKE GROWTH FACTOR RECEPTOR PATHWAY IN PATIENTS WITH ADVANCED BREAST CANCER TREATED WITH TRASTUZUMAB

C. Christodoulou, G. Oikonomopoulos, G.A. Koliou, I. Kostopoulos, V. Kotoula, M. Bobos, G. Pentheroudakis, G. Lazaridis, M. Skondra, S. Chrisafi, A. Koutras, D. Bafaloukos, E. Razis, K. Papadopoulou, P. Papakostas, H. P. Kalofonos, D. Pectasides, P. Skarlos, K. T. Kalogeras, G. Fountzilas

Cancer Genomics Proteomics. 2018 Nov-Dec;15(6):461-471. doi: 10.21873/cgp.20105.


TREATING EGFR-MUTATED ONCOGENE-ADDICTED ADVANCED NON-SMALL CELL LUNG CANCER IN THE ERA OF ECONOMIC CRISIS IN GREECE: CHALLENGES AND OPPORTUNITIES

E. Fountzilas, S. Levva, G. Mountzios, G. Polychronidou, N. Maniadakis, V. Kotoula, G. Fountzilas
J Glob Oncol. 2018 Sep;(4):1-12. doi: 10.1200/JGO.18.00115.


BRIDGING CANCER BIOLOGY WITH THE CLINIC COMPREHENDING AND EXPLOITING IDH MUTATIONS IN GLIOMAS

O. Romanidou, V. Kotoula, G. Fountzilas

Cancer Genomics Proteomics. 2018 Sep-Oct;15(5):421-436. doi: 10.21873/cgp.20101. Review.


MISMATCH REPAIR DEFICIENCY AND ABERRATIONS IN THE NOTCH AND HEDGEHOG PATHWAYS ARE OF PROGNOSTIC VALUE IN PATIENTS WITH ENDOMETRIAL CANCER

G. Polychronidou, V. Kotoula, K. Manousou, I. Kostopoulos, G. Karayannopoulou, M. Bobos, I. Efstratiou,  D. Dionysopoulos,  K. Chatzopoulos,  S. Lakis, S. Chrisafi, D. Tsolakidis, A. Papanikolaou;  N. Dombros, G. Fountzilas

PLoS One. 2018 Dec 6;13(12):e0208221. doi: 10.1371/journal.pone.0208221.


ANNALS OF TRANSLATIONAL MEDICINE – Special Issue (NSCLC)


Lung cancer: biology and technology foster therapeutic innovation

Giannis Mountzios 


The emerging treatment landscape of advanced non-small cell lung cancer

Panagiota Economopoulou, Giannis Mountzios 


Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?

Panagiotis Baxevanos, Giannis Mountzios  


Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)

Giannis Mountzios 


Treating ALK-positive non-small cell lung cancer

Dimitrios C. Ziogas, Anna Tsiara, Georgios Tsironis, Maria Lykka, Michalis Liontos, Aristotelis Bamias, Meletios-Athanasios Dimopoulos  


Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer

Stavros Gkolfinopoulos, Giannis Mountzios 


Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore? 

Georgios Tsironis, Dimitrios C. Ziogas, Anastasios Kyriazoglou, Marita Lykka, Konstantinos Koutsoukos, Aristotelis Bamias, Meletios-Athanasios Dimopoulos 


Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) 

Anna Tsiara, Michalis Liontos, Maria Kaparelou, Roubini Zakopoulou, Aristotelis Bamias, Meletios-Athanasios Dimopoulos 


Advanced small cell lung cancer (SCLC): new challenges and new expectations

Nikolaos Tsoukalas, Eleni Aravantinou-Fatorou, Panagiotis Baxevanos, Maria Tolia, Konstantinos Tsapakidis, Michail Galanopoulos, Michail Liontos, George Kyrgias 


Advances on systemic treatment for lung neuroendocrine neoplasms 

Nikolaos Tsoukalas, Panagiotis Baxevanos, Eleni Aravantinou-Fatorou, Maria Tolia, Michail Galanopoulos, Konstantinos Tsapakidis, George Kyrgias, Christos Toumpanakis, Gregory Kaltsas

Δημοσιεύσεις 2019

ASSOCIATION OF NOTCH AND HEDGEHOG PATHWAY ACTIVATION WITH PROGNOSIS IN EARLY-STAGE COLORECTAL CANCER.

Rallis G, Koletsa T, Saridaki Z, Manousou K, Koliou GA, Kostopoulos I, Kotoula V, Makatsoris T, Kourea HP, Raptou G, Chrisafi S, Samantas E, Papaparaskeva K, Pazarli E, Papakostas P, Kafiri G, Mauri D, Papoudou-Bai A, Christodoulou C, Petraki K, Dombros N, Pectasides D, Fountzilas G.

Anticancer Res. 2019 Apr;39(4):2129-2138. doi: 10.21873/anticanres.13326. 


PROGNOSTIC IMPLICATIONS OF MISMATCH REPAIR DEFICIENCY IN PATIENTS WITH NON-METASTATIC COLORECTAL AND ENDOMETRIAL CANCER

E Fountzilas, V Kotoula, G Pentheroudakis, K Manousou, G Polychronidou, E Vrettou, C Poulios, I Papadopoulou, G Raptou, E Pectasides, G Karayannopoulou, S Chrisafi, P Papakostas, T Makatsoris, I Varthalitis, A Psyrri, E Samantas, M Bobos, C Christodoulou, C Papadimitriou, G Nasioulas, D Pectasides, G Fountzilas. ESMO Open 2019;4:e000474. doi:10.1136/esmoopen-2018-00047.


GENETIC MAPPING OF PANCREATIC CANCER BY TARGETED NEXT GENERATION SEQUENCING IN A COHORT OF PATIENTS MANAGED WITH NAB-PACLITAXEL-BASED CHEMOTHERAPY OR AGENTS TARGETING THE EGFR AXIS: A RETROSPECTIVE ANALYSIS OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG).

G. Zarkavelis, V. Kotoula, G.A. Koliou, K. Papadopoulou, I. Tikas, V. Karavasilis, E. Samantas, C. Dervenis, I. Efstratiou, I. Nicolaou, D. Apessou, G. Kafiri, T. Koletsa, I. Bompolaki, G. Rallis, A. Batistatou, G. Glantzounis, D. Pectasides, G. Fountzilas, G. Pentheroudakis.

ESMO Open. 2019 Sep 18;4(5):e000525. doi: 10.1136/esmoopen-2019-000525.


ANGIOGENIC AND ANTI-ANGIOGENIC VEGFA SPLICE VARIANTS IN COLORECTAL CANCER: A PROSPECTIVE RETROSPECTIVE COHORT STUDY IN PATIENTS TREATED WITH IRINOTECAN-BASED CHEMOTHERAPY AND BEVACIZUMAB

G Pentheroudakis, L Mavroeidis, K Papadopoulou, G-A Koliou, C Bamia, K Chatzopoulos, E Samantas, D Mauri, I Efstratiou, D Pectasides, T Makatsoris, D Bafaloukos, P Papakostas, G Papatsibas, IBombolaki, S Chrisafi, HP Kourea, K Petraki, G Kafiri, G Fountzilas,VKotoula

Clin Colorectal Cancer. 2019 Jul 15. pii: S1533-0028(18)30554-1. doi: 10.1016/j.clcc.2019.07.007. 


OPPOSITE PROGNOSTIC IMPACT OF SINGLE PTEN-LOSS AND PIK3CA MUTATIONS IN EARLY HIGH-RISK BREAST CANCER.

Lazaridis G, Kotoula V, Vrettou E, Kostopoulos I, Manousou K, Papadopoulou K, Giannoulatou E, Bobos M, Sotiropoulou M, Pentheroudakis G, Efstratiou I, Papoudou-Bai A, Psyrri A, Christodoulou C, Gogas H, Koutras A, Timotheadou E, Pectasides D, Zagouri F, Fountzilas G.

Cancer Genomics Proteomics. 2019 May-Jun;16(3):195-206. doi: 10.21873/cgp.20125. 


PALB2 C.2257C>T TRUNCATING VARIANT IS A GREEK FOUNDER AND IS ASSOCIATED WITH HIGH BREAST CANCER RISK.

Vagena A, Papamentzelopoulou M, Kalfakakou D, Kollia P, Papadimitriou C, Psyrri A, Apostolou P, Fountzilas G, Konstantopoulou I, Yannoukakos D, Fostira F.

J Hum Genet. 2019 May 14. doi: 10.1038/s10038-019-0612-6.


PROGNOSTIC IMPACT OF SRC, CDKN1B, AND JAK2 EXPRESSION IN METASTATIC BREAST CANCER PATIENTS TREATED WITH TRASTUZUMAB.

Economopoulou P, Kotoula V, Koliou GA, Papadopoulou K, Christodoulou C, Pentheroudakis G, Lazaridis G, Arapantoni-Dadioti P, Koutras A, Bafaloukos D, Papakostas P, Patsea H, Pavlakis K, Pectasides D, Kotsakis A, Razis E, Aravantinos G, Samantas E, Kalogeras KT, Economopoulos T, Psyrri A, Fountzilas G.

Transl Oncol. 2019 May;12(5):739-748. doi: 10.1016/j.tranon.2019.02.010. 


RELAPSED AND DE NOVO METASTATIC HER2-POSITIVE BREAST CANCER TREATED WITH TRASTUZUMAB: TUMOR GENOTYPES AND CLINICAL MEASURES ASSOCIATED WITH PATIENT OUTCOME.

Kotoula V, Tsakiri K, Koliou GA, Lazaridis G, Papadopoulou K, Giannoulatou E, Tikas I, Christodoulou C, Chatzopoulos K, Bobos M, Pentheroudakis G, Tsolaki E, Batistatou A, Kotsakis A, Koutras A, Linardou H, Razis E, Res E, Pectasides D, Fountzilas G.

Clin Breast Cancer. 2019 Apr;19(2):113-125.e4. doi: 10.1016/j.clbc.2018.10.014. 


CYCLIN D1 DIFFERENTIAL ACTIVATION AND ITS PROGNOSTIC IMPACT IN ADVANCED BREAST CANCER PATIENTS TREATED WITH TRASTUZUMAB

G Mountzios, V Kotoula, G-A Koliou, K Papadopoulou, G Lazaridis, C Christodoulou, G Pentheroudakis, M Skondra, A Koutras, H Linardou, E Razis, P Papakostas, S Chrisafi, G Aravantinos, I Nicolaou, A Goussia, KT Kalogeras, D Pectasides, G Fountzilas

ESMO Open. 2019 May 12;4(2):e000441. doi: 10.1136/esmoopen-2018-000441.


INCREASING THE DOSE INTENSITY OF CHEMOTHERAPY BY MORE FREQUENT ADMINISTRATION OR SEQUENTIAL SCHEDULING: A PATIENT-LEVEL META-ANALYSIS OF 37 298 WOMEN WITH EARLY BREAST CANCER IN 26 RANDOMISED TRIALS.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Gray RBradley R, …. Fountzilas G, …. Koliou GA…..

Lancet. 2019 Apr 6;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4.


GENOTYPING KRAS AND EGFR MUTATIONS IN GREEK PATIENTS WITH NON-SMALL-CELL LUNG CANCER: INCIDENCE, SIGNIFICANCE AND IMPLICATIONS FOR TREATMENT.

Linardou H, Kotoula V, Kouvatseas G, Mountzios G, Karavasilis V, Samantas E, Kalogera-Fountzila A, Televantou D, Papadopoulou K, Mavropoulou X, Daskalaki E, Zaramboukas T, Efstratiou I, Lampaki S, Rallis G, Res E, Syrigos KN, Kosmidis PA, Pectasides D, Fountzilas G.

Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):531-541. doi: 10.21873/cgp.20155. 


PATHOGENIC BRCA1 MUTATIONS MAY BE NECESSARY BUT NOT SUFFICIENT FOR TISSUE GENOMIC HETEROGENEITY: DEEP SEQUENCING DATA FROM OVARIAN CANCER PATIENTS.

Kotoula V, Lakis S, Tikas I, Giannoulatou E, Lazaridis G, Papadopoulou K, Manoussou K, Efstratiou I, Papanikolaou A, Fostira F, Vlachos I, Tarlatzis B, Fountzilas G.

Gynecol Oncol. 2019 Feb;152(2):375-386. doi: 10.1016/j.ygyno.2018.11.016.


THE COMBINATION OF BEVACIZUMAB/TEMSIROLIMUS AFTER FIRST-LINE ANTI-VEGF THERAPY IN ADVANCED RENAL-CELL CARCINOMA: A CLINICAL AND BIOMARKER STUDY.

Bamias A, Karavasilis V, Gavalas N, Tzannis K, Samantas E, Aravantinos G, Koutras A, Gkerzelis I, Kostouros E, Koutsoukos K, Zagouri F, Fountzilas G, Dimopoulos MA.

Int J Clin Oncol. 2019 Apr;24(4):411-419. doi: 10.1007/s10147-018-1361-9.


PREVALENCE AND FOUNDER EFFECT OF THE BRCA1 P.(VAL1833MET) VARIANT IN THE GREEK POPULATION, WITH FURTHER EVIDENCE FOR PATHOGENICITY AND RISK MODIFICATION.

Papamentzelopoulou M, Apostolou P, Fostira F, Dimitrakakis C, Loutradis D, Fountzilas G, Yannoukakos D, Konstantopoulou I.

Cancer Genet. 2019 Sep;237:90-96. doi: 10.1016/j.cancergen.2019.06.006.


COMPARISON OF SOMATIC VARIANT DETECTION ALGORITHMS USING ION TORRENT TARGETED DEEP SEQUENCING DATA.

Wang QKotoula VHsu PCPapadopoulou KHo JWKFountzilas GGiannoulatou E

BMC Med Genomics. 2019 Dec 24;12(Suppl 9):181. doi: 10.1186/s12920-019-0636-y. 

Δημοσιεύσεις 2020

PATHOGENIC MUTATIONS AND OVERALL SURVIVAL IN 3,084 PATIENTS WITH CANCER: THE HELLENIC COOPERATIVE ONCOLOGY GROUP PRECISION MEDICINE INITIATIVE

Elena Fountzilas, Vassiliki Kotoula, Georgia-Angeliki Koliou, Eleni Giannoulatou, Helen Gogas, Christos Papadimitriou, Ioannis Tikas, Jianhua Zhang, Kyriaki Papadopoulou, Flora Zagouri, Christos Christodoulou, Angelos Koutras, Thomas Makatsoris, Sofia Chrisafi, Helena Linardou, Ioannis Varthalitis, George Papatsibas, Evangelia Razis, Pavlos Papakostas, Epaminontas Samantas, Gerasimos Aravantinos, Dimitrios Bafaloukos, Paris Kosmidis, Anna Koumarianou, Amanda Psyrri, Georgios Pentheroudakis, Dimitrios Pectasides, Andrew Futreal, George Fountzilasand Apostolia M. Tsimberidou

Oncotarget, 2020, Vol. 11, (No. 1), pp: 1-14


MULTISITE TUMOR SAMPLING REVEALS EXTENSIVE HETEROGENEITY OF TUMOR AND HOST IMMUNE RESPONSE IN OVARIAN CANCER

Sotirios LakisVassiliki KotoulaGeorgia-Angeliki KoliouIoannis EfstratiouSofia ChrisafiAlexios PapanikolaouPantelis ZebekakisGeorge Fountzilas

Cancer Genomics Proteomics. Sep-Oct 2020;17(5):529-541.doi: 10.21873/cgp.20209.


Α RARE SOLITARY SPINAL CORD METASTASIS AFTER EPITHELIAL OVARIAN CANCER DIAGNOSIS

Adamantia Nikolaidi, Kyriaki Papadopoulou, Kalliopi Tsakiri, Elisabeth Psoma, Dimitris Zevgaridis, Christos Konstantaras, Ilias Athanasiadis, Florentia Fostira, George Fountzilas

Clinical Oncology: Case Reports. 2020


PHASE 2 STUDY OF CABAZITAXEL AS SECOND-LINE TREATMENT IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TAXANES-A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) TRIAL.

Koutras A, Zagouri F, Koliou GA, Psoma E, Chryssogonidis I, Lazaridis G, Tryfonopoulos D, Kotsakis A, Res E, Kentepozidis NK, Razis E, Psyrri A, Koumakis G, Kalofonos HP, Dimopoulos MA, Fountzilas G.

Br J Cancer. 2020 Aug;123(3):355-361. doi: 10.1038/s41416-020-0909-4.PMID: 32488135


PROGNOSTIC IMPACT OF STROMAL AND INTRATUMORAL CD3, CD8 AND FOXP3 IN ADJUVANTLY TREATED BREAST CANCER: DO THEY ADD INFORMATION OVER STROMAL TUMOR-INFILTRATING LYMPHOCYTE DENSITY?

Koletsa T, Kotoula V, Koliou GA, Manousou K, Chrisafi S, Zagouri F, Sotiropoulou M, Pentheroudakis G, Papoudou-Bai A, Christodoulou C, Xepapadakis G, Zografos G, Petraki K, Pazarli E, Koutras A, Kourea HP, Bafaloukos D, Chatzopoulos K, Iliadis A, Markopoulos C, Venizelos V, Arnogiannaki N, Kalogeras KT, Kostopoulos I, Gogas H, Fountzilas G.

Cancer Immunol Immunother. 2020 Aug;69(8):1549-1564. doi: 10.1007/s00262-020-02557-0. 


TUMOR MUTATIONAL PATTERNS AND INFILTRATING LYMPHOCYTE DENSITY IN YOUNG AND ELDERLY PATIENTS WITH BREAST CANCER.

Nikolaidi A, Kotoula V, Koliou GA, Giannoulatou E, Papadopoulou K, Zagouri F, Pentheroudakis G, Gogas H, Bobos M, Chatzopoulos K, Oikonomopoulos G, Pectasides D, Saloustros E, Arnogiannaki N, Nicolaou I, Papakostas P, Bompolaki I, Aravantinos G, Athanasiadis I, Fountzilas G.

Cancer Genomics Proteomics. 2020 Mar-Apr;17(2):181-193. doi: 10.21873/cgp.20179.PMID: 32108041


THE ROLE OF CXCL13 AND CXCL9 IN EARLY BREAST CANCER

E Razis, KT Kalogeras, I Kotsantis, GA Koliou, K Manousou, R Wirtz, E Veltrup, H Patsea, N Poulakaki, D Dionysopoulos, S Pervana, H Gogas, A Koutras, G Pentheroudakis, C Christodoulou, H Linardou, K Pavlakis, T Koletsa, D Pectasides, F Zagouri, G Fountzilas

Clin Breast Cancer. 2020 Feb;20(1):e36-e53. doi: 10.1016/j.clbc.2019.08.008. PMID: 31699671


REAL-WORLD CLINICAL OUTCOME AND TOXICITY DATA AND ECONOMIC ASPECTS IN PATIENTS WITH ADVANCED BREAST CANCER TREATED WITH CYCLIN-DEPENDENT KINASE 4/6 (CDK4/6) INHIBITORS COMBINED WITH ENDOCRINE THERAPY: THE EXPERIENCE OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP.

Fountzilas E, Koliou GA, Vozikis A, Rapti V, Nikolakopoulos A, Boutis A, Christopoulou A, Kontogiorgos I, Karageorgopoulou S, Lalla E, Tryfonopoulos D, Boukovinas I, Rapti C, Nikolaidi A, Karteri S, Moirogiorgou E, Binas I, Mauri D, Aravantinos G, Zagouri F, Saridaki Z, Psyrri A, Bafaloukos D, Koumarianou A, Res E, Linardou H, Mountzios G, Razis E, Fountzilas G, Koumakis G.

ESMO Open. 2020 Aug;5(4):e000774. doi: 10.1136/esmoopen-2020-000774.PMID: 32817060


EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS THERAPY ALONE OR IN COMBINATION WITH OCTREOTIDE IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS. A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY.

Koumarianou A, Pectasides D, Koliou GA, Dionysopoulos D, Kolomodi D, Poulios C, Skondra M, Sgouros J, Pentheroudakis G, Kaltsas G, Fountzilas G.

Biology (Basel). 2020 Mar 9;9(3):51. doi: 10.3390/biology9030051.PMID: 32182791


PROGNOSTIC BIOMARKERS IN EARLY-STAGE GASTRIC ADENOCARCINOMA TREATED WITH ADJUVANT CHEMORADIOTHERAPY.

Pectasides E, Chatzidakis I, Kotoula V, Koliou GA, Papadopoulou K, Giannoulatou E, Giannouzakos VG, Bobos M, Papavasileiou C, Chrisafi S, Florou A, Pectasides D, Fountzilas G.

Cancer Genomics Proteomics. 2020 May-Jun;17(3):277-290. doi: 10.21873/cgp.20188.PMID: 32345669


PATHOLOGY OF BRCA1- AND BRCA2-ASSOCIATED BREAST CANCERS: KNOWN AND LESS KNOWN CONNECTIONS.

Fountzilas E, Konstantopoulou I, Vagena A, Apostolou P, Papadimitriou C, Christodoulou C, Tryfonopoulos D, Manousou K, Delimitsou A, Papamentzelopoulou M, Fountzilas G, Yannoukakos D, Fostira F.

Clin Breast Cancer. 2020 Apr;20(2):152-159. doi: 10.1016/j.clbc.2019.08.003. PMID: 31980407


ONE IN THREE HIGHLY SELECTED GREEK PATIENTS WITH BREAST CANCER CARRIES A LOSS-OF-FUNCTION VARIANT IN A CANCER SUSCEPTIBILITY GENE

Florentia Fostira, Irene Konstantopoulou, Paraskevi Apostolou, Myrto S. Papamentzelopoulou, Christos Papadimitriou, Eleni Faliakou, Christos Christodoulou, Ioannis Boukovinas, Evangelia Razis, Dimitrios Tryfonopoulos, Vasileios Barbounis, Andromachi Vagena, Ioannis S. Vlachos, Despoina Kalfakakou, George Fountzilas, Drakoulis Yannoukakos

J Med Genet. 2020 Jan;57(1):53-61. doi: 10.1136/jmedgenet-2019-106189. Epub 2019 Jul 12.PMID: 31300551


GENETIC VARIATIONS OF VEGFA GENE ARE ASSOCIATED WITH INFILTRATION OF ADJACENT TISSUES AND THE CLINICAL OUTCOME OF PATIENTS WITH NASOPHARYNGEAL CARCINOMA.

Psoma E, Koliou GA, Dimitrakopoulos FI, Papadopoulou K, Rontogianni D, Bobos M, Visvikis A, Kosmidis PA, Fountzilas G, Constantinidis J, Kalogera-Fountzila A.

Anticancer Res. 2020 Feb;40(2):677-688. doi: 10.21873/anticanres.13997.PMID: 32014908


TUMOR INFILTRATING LYMPHOCYTES AND CD8+ T-CELL SUBSETS AS PROGNOSTIC MARKERS IN PATIENTS WITH OPERABLE LARYNGEAL SQUAMOUS CELL CARCINOMA

K Chatzopoulos, V Kotoula, K Manousou, K Markou, K Vlachtsis, N Angouridakis, A Nikolaou, M Vassilakopoulou, A Psyrri, G Fountzilas

Head Neck Pathol. 2020 Sep;14(3):689-700. doi: 10.1007/s12105-019-01101-6. PMID: 31749124


IMPACT OF BEVACIZUMAB VERSUS ERLOTINIB ON TUMOR METRICS IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SMALL CELL LUNG CANCER: A STUDY BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP.

Mountzios G, Mavropoulou X, Koliou GA, Linardou H, Samantas E, Kosmidis P, Fountzilas G, Charitandi A, Kalogera-Fountzila A.

Anticancer Res. 2020 Apr;40(4):2095-2106. doi: 10.21873/anticanres. 14168. PMID: 3223490


FIRST LINE GEMCITABINE/PAZOPANIB IN LOCALLY ADVANCED AND/OR METASTATIC BILIARY TRACT CARCINOMA. A HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE II STUDY.

Sgouros J, Aravantinos G, Koliou GA, Pentheroudakis G, Zagouri F, Psyrri A, Lampropoulou DI, Demiri S, Pectasides D, Razis E, Fountzilas G, Samantas E.

Anticancer Res. 2020 Feb;40(2):929-938. doi: 10.21873/anticanres.14026. PMID: 32014937


IS THERE AN INDEPENDENT ROLE OF TERT AND NF1 IN HIGH GRADE GLIOMAS?

Razis E, Kotoula V, Koliou GA, Papadopoulou K, Vrettou E, Giannoulatou E, Tikas I, Labropoulos SV, Rigakos G, Papaemmanoyil S, Romanidou O, Bourkoula E, Nomikos P, Iliadis G, Nasioulas G, Selviaridis P, Polyzoidis K, Fountzilas G.

Transl Oncol. 2020 Feb;13(2):346-354. doi: 10.1016/j.tranon.2019.10.016. PMID: 31891871 

Δημοσιεύσεις 2021

GENOTYPE-PHENOTYPE ASSOCIATIONS IN COLORECTAL ADENOCARCINOMAS AND THEIR MATCHED METASTASES.

Chatzopoulos K, Kotoula V, Koliou GA, Giannoulatou E, Papadopoulou K, Karavasilis V, Pazarli E, Pervana S, Kafiri G, Tsoulfas G, Chrisafi S, Sgouramali H, Papakostas P, Pectasides D, Hytiroglou P, Pentheroudakis G, Fountzilas G.

Hum Pathol. 2021 Jan;107:104-116. doi: 10.1016/j.humpath.2020.10.009. PMID: 33161028


CLINICAL SIGNIFICANCE OF GERMLINE CANCER PREDISPOSING VARIANTS IN UNSELECTED EUROPEAN PATIENTS WITH PANCREATIC ADENOCARCINOMA

Elena Fountzilas, Alexia Eliades, Georgia-Angeliki Koliou, Achilleas Achilleos, Charalambos Loizides, Kyriakos Tsangaras, Dimitrios Pectasides, Joseph Sgouros, Pavlos Papakostas, Grigorios Rallis, Amanda Psyrri, Christos Papadimitriou, Georgios Oikonomopoulos, Konstantinos Ferentinos, Anna Koumarianou, George Zarkavelis, Christos Dervenis, Gerasimos Aravantinos, Dimitrios Bafaloukos, Paris Kosmidis, George Papaxoinis, Maria Theochari, Ioannis Varthalitis, Nikolaos Kentepozidis, Georgios Rigakos, Zacharenia Saridaki, Adamantia Nikolaidi, Athina Christopoulou, Florentia Fostira, Epaminontas Samantas, Elena Kypri, Marios Ioannides, George Koumbaris, George Fountzilas, Philippos C. Patsalis

Cancers (Basel). 2021 Jan 8;13(2):198. doi: 10.3390/cancers13020198. PMID: 33429865


AGAPP: EFFICACY OF FIRST-LINE CISPLATIN, 5-FLUOROURACIL WITH AFATINIB IN INOPERABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CARCINOMAS. A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY.

Zarkavelis G, Samantas E, Koliou GA, Papadopoulou K, Mauri D, Aravantinos G, Batistatou A, Pazarli E, Tryfonopoulos D, Tsipoura A, Bobos M, Psyrri A, Makatsoris T, Petraki C, Pectasides D, Fountzilas G, Pentheroudakis G.

Acta Oncol. 2021 May 18:1-9. doi: 10.1080/0284186X.2021.1912822. PMID: 34003074


EVALUATION OF THE ROLE OF P95 HER2 ISOFORM IN TRASTUZUMAB EFFICACY IN METASTATIC BREAST CANCER.

Rigakos G, Razis E, Koliou GA, Oikonomopoulos G, Tsolaki E, Sperinde J, Chrisafi S, Zarkavelis G, Pazarli E, Batistatou A, Kourea HP, Papakostas P, Bafaloukos D, Asimakopoulou NI, Res E, Kotsakis A, Pectasides D, Koutras A, Christodoulou C, Fountzilas G.

Anticancer Res. 2021 Apr;41(4):1793-1802. doi: 10.21873/anticanres. 14945. PMID: 33813384


ANDROGEN RECEPTOR AND PIM1 EXPRESSION IN TUMOR TISSUE OF PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER.

Ntzifa A, Strati A, Koliou GA, Zagouri F, Pectasides D, Pentheroudakis G, Christodoulou C, Gogas H, Magkou C, Petraki C, Kosmidis P, Aravantinos G, Kotoula V, Fountzilas G, Lianidou E.

Cancer Genomics Proteomics. 2021 Mar-Apr;18(2):147-156. doi: 10.21873/cgp.20249.PMID: 33608311


CHEK2 PATHOGENIC VARIANTS IN GREEK BREAST CANCER PATIENTS: EVIDENCE FOR STRONG ASSOCIATIONS WITH ESTROGEN RECEPTOR POSITIVITY, OVERUSE OF RISK-REDUCING PROCEDURES AND POPULATION FOUNDER EFFECTS.

Apostolou P, Dellatola V, Papadimitriou C, Kalfakakou D, Fountzilas E, Faliakou E, Fountzilas G, Romanidou O, Konstantopoulou I, Fostira F.

Cancers (Basel). 2021 Apr 27;13(9):2106. doi: 10.3390/cancers13092106. PMID: 33925588


FOLLOW-UP OF TISSUE GENOMICS IN BRCA1/2 CARRIERS WHO UNDERWENT PROPHYLACTIC SURGERIES.

Kotoula V, Papadopoulou K, Tikas I, Fostira F, Vrettou E, Chrisafi S, Fountzilas E, Koliou GA, Apostolou P, Papazisis K, Zaramboukas T, Asimaki-Vlachopoulou A, Miliaras S, Ananiadis A, Poulios C, Natsiopoulos I, Tsiftsoglou A, Demiri E, Fountzilas G.

Breast Cancer. 2021 Nov;28(6):1367-1382. doi: 10.1007/s12282-021-01276-3. PMID: 34304347


GENETIC VARIATION IN THE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGFA) GENE AT RS13207351 IS ASSOCIATED WITH OVERALL SURVIVAL OF PATIENTS WITH HEAD AND NECK CANCER.

Dimitrakopoulos FI, Koliou GA, Kotoula V, Papadopoulou K, Markou K, Vlachtsis K, Angouridakis N, Karasmanis I, Nikolaou A, Psyrri A, Visvikis A, Kosmidis P, Fountzilas G, Koutras A.

Cancers (Basel). 2021 Mar 8;13(5):1163. doi: 10.3390/cancers13051163.

PMID: 33800431


GENOTYPING DATA OF ROUTINELY PROCESSED MATCHED PRIMARY/METASTATIC TUMOR SAMPLES

Vassiliki Kotoula, Kyriakos Chatzopoulos, Kyriaki Papadopoulou, Eleni Giannoulatou, Georgia-Angeliki Koliou, Vasilios Karavasilis, Elissavet Pazarli, Stavroula Pervana, Georgia Kafiri, Georgios Tsoulfas, Sofia Chrisafia , Helen Sgouramali , Pavlos Papakostas , Dimitrios Pectasides , Prodromos Hytiroglou , George Pentheroudakis, George Fountzilas

Data in Brief 34 (2021) 106646, DOI: 10.1016/j.humpath.2020.10.009


AN OBSERVATIONAL STUDY TO ASSESS THE MOLECULAR EPIDEMIOLOGY AND DIRECT MEDICAL COSTS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN PATIENTS WITH ADVANCED EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER TREATED WITH AFATINIB IN REAL-WORLD CLINICAL SETTINGS IN GREECE

Giannis Mountzios, Sofia Lampaki, Georgia-Angeliki Koliou, Athanassios Vozikis,  Ioannis Kontogiorgos, Panagiotis Papantoniou,  Margarita- Ioanna Koufaki, Eleni Res, Anastasios Boutis,  Athina Christopoulou, Nicoleta Pastelli, Anastasios Grivas, Gerasimos Aravantinos,  Efthalia Lalla, Georgios Oikonomopoulos, Anna Koumarianou, Dionisios Spyratos, Dimitrios Bafaloukos, Georgios Rigakos, Pavlos Papakotoulas, George Fountzilas, Helena Linardou

Lung Cancer: Targets and Therapy, 2021:12 93–102


TUMOR GENOTYPING AND HOMOLOGOUS RECOMBINATION REPAIR GENE VARIANTS IN PATIENTS WITH EPITHELIAL OVARIAN CANCER: IS PATHOGENIC ENOUGH?

Fountzilas E, Kotoula V, Koliou GA, Liontos M, Papadopoulou K, Giannoulatou E, Papanikolaou A, Tikas I, Chrisafi S, Mauri D, Chatzopoulos K, Fostira F, Pectasides D, Oikonomopoulos G, Aivazi D, Andrikopoulou A, Visvikis A, Aravantinos G, Zagouri F, Fountzilas G.

Front Oncol. 2021 Jun 1;11:683057. doi: 10.3389/fonc.2021.683057. PMID: 34141624


RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH CANCER (RECOVER STUDY): A PROSPECTIVE COHORT STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP.

Linardou H, Spanakis N, Koliou GA, Christopoulou A, Karageorgopoulou S, Alevra N, Vagionas A, Tsoukalas N, Sgourou S, Fountzilas E, Sgouros J, Razis E, Chatzokou D, Lampaki S, Res E, Saridaki Z, Mountzios G, Saroglou G, Fountzilas G.

Cancers (Basel). 2021 Sep 15;13(18):4621. doi: 10.3390/cancers13184621.PMID: 34572848 


WHEN CASCADE TESTING FOR FAMILIAL VARIANT SEEMS INADEQUATE TO PROVIDE CLINICALLY ACTIONABLE INFORMATION FOR BLOOD RELATIVES.

Apostolou P, Fostira F, Fountzilas G, Razis E, Yannoukakos D, Konstantopoulou I.

Cancer Genet. 2021 Nov;258-259:49-50. doi: 10.1016/j.cancergen.2021.08.003.  


META-ANALYSIS OF CHEMOTHERAPY IN HEAD AND NECK CANCER (MACH-NC): AN UPDATE ON 107 RANDOMIZED TRIALS AND 19,805 PATIENTS, ON BEHALF OF MACH-NC GROUP.

Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, Burtness B, Ghi MG, Cohen EEW, Grau C, Wolf G, Hitt R, Corvò R, Budach V, Kumar S, Laskar SG, Mazeron JJ, Zhong LP, Dobrowsky W, Ghadjar P, Fallai C, Zakotnik B, Sharma A, Bensadoun RJ, Ruo Redda MG, Racadot S, Fountzilas G, Brizel D, Rovea P, Argiris A, Nagy ZT, Lee JW, Fortpied C, Harris J, Bourhis J, Aupérin A, Blanchard P, Pignon JP; MACH-NC Collaborative Group.

Radiother Oncol. 2021 Mar;156:281-293. doi: 10.1016/j.radonc.2021.01.013. PMID: 33515668 


CLINICAL SIGNIFICANCE OF MAJOR ANGIOGENESIS-RELATED EFFECTORS IN PATIENTS WITH METASTATIC BREAST CANCER TREATED WITH TRASTUZUMAB-BASED REGIMENS.

Kourea HP, Dimitrakopoulos FI, Koliou GA, Batistatou A, Papadopoulou K, Bobos M, Asimaki-Vlachopoulou A, Chrisafi S, Pavlakis K, Chatzopoulos K, Galani E, Pentheroudakis G, Pectasides D, Bafaloukos D, Res E, Papakostas P, Koutras A, Kotoula V, Fountzilas G.

Cancer Res Treat. 2021 Nov 17. doi: 10.4143/crt.2021.748. Online ahead of print. PMID: 34793664 


META-ANALYSIS OF CHEMOTHERAPY IN NASOPHARYNX CARCINOMA (MAC-NPC): AN UPDATE ON 26 TRIALS AND 7080 PATIENTS

Pierre Blanchard, ….. George Fountzilas…..Jean-Pierre Pignon, on behalf of the MAC-NPC collaborative Group

Clinical and translational radiation oncology, 2021 Nov 26;32:59-68.

 doi: 10.1016/j.ctro.2021.11.007. eCollection 2022 Jan.

Δημοσιεύσεις 2022

mRNA EXPRESSION OF SPECIFIC HER LIGANDS AND THEIR ASSOCIATION WITH CLINICAL OUTCOME IN PATIENTS WITH METASTATIC BREAST CANCER TREATED WITH TRASTUZUMAB.

Rapti V, Moirogiorgou E, Koliou GA, Papadopoulou K, Binas I, Pentheroudakis G, Bafaloukos D, Bobos M, Chatzopoulos K, Chrisafi S, Christodoulou C, Nicolaou I, Sotiropoulou M, Magkou C, Koutras A, Papakostas P, Kotsakis A, Razis E, Psyrri A, Tryfonopoulos D, Pectasides D, Res E, Alexopoulos A, Kotoula V, Fountzilas G.

Oncol Lett. 2022 Jan;23(1):23. doi: 10.3892/ol.2021.13141. PMID: 34868360


REAL-WORLD SAFETY AND EFFICACY DATA OF IMMUNOTHERAPY IN PATIENTS WITH CANCER AND AUTOIMMUNE DISEASE: THE EXPERIENCE OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP.

Fountzilas E, Lampaki S, Koliou GA, Koumarianou A, Levva S, Vagionas A, Christopoulou A, Laloysis A, Psyrri A, Binas I, Mountzios G, Kentepozidis N, Kotsakis A, Saloustros E, Boutis A, Nikolaidi A, Fountzilas G, Georgoulias V, Chrysanthidis M, Kotteas E, Vo H, Tsiatas M, Res E, Linardou H, Daoussis D, Bompolaki I, Andreadou A, Papaxoinis G, Spyratos D, Gogas H, Syrigos KN, Bafaloukos D.

Cancer Immunol Immunother. 2022 Feb;71(2):327-337. doi: 10.1007/s00262-021-02985-6. PMID: 34164709


CANCER RISKS ASSOCIATED WITH BRCA1 AND BRCA2 PATHOGENIC VARIANTS.

Li S, Silvestri V, Leslie G…Fountzilas G…

J Clin Oncol 2022 May 10;40(14):1529-1541. doi: 10.1200/JCO.21.02112. 


DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY IN THE TRASTUZUMAB ERA: FINAL LONG-TERM RESULTS OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP PHASE III HE10/05 TRIAL.

Zagouri F, Koliou GA, Dimitrakopoulos F, Papadimitriou C, Binas I, Koutras A, Papakostas P, Markopoulos C, Venizelos V, Xepapadakis G, Andrikopoulou Α, Karanikiotis C, Psyrri A, Bafaloukos D, Kosmidis P, Aravantinos G, Res E, Mauri D, Koumarianou A, Petraki K, Tsipoura A, Pectasides D, Gogas H, Fountzilas G.

Br J Cancer. 2022 Sep;127(4):695-703. doi: 10.1038/s41416-022-01846-y. PMID: 35610366 


INVESTIGATION OF PROGNOSTIC BIOMARKERS IN PATIENTS WITH UROTHELIAL CARCINOMA TREATED WITH PLATINUM-BASED REGIMENS.

Papadopoulou K, Koliou GA, Tsimiliotis D, Kotoula V, Foukas P, Goussia A, Tsiatas M, Visvikis A, Chatzopoulos K, Nifora M, Charchanti A, Koumarianou A, Christodoulou C, Pectasides D, Psyrri A, Fostira F, Fountzilas G, Samantas E.

Urol Oncol. 2022, S1078-1439(22)00266-6. doi: 10.1016/j.urolonc.2022.07.007. PMID: 36041976


LUNG CANCER AS A PREDOMINANT FEATURE IN A PATIENT WITH PEUTZ-JEGHERS SYNDROME: CASE REPORT.

Fostira F, Fountzilas E, Papadopoulou K, Karaiskos T, Mpatsi O, Pastelli N, Mountzios G, Konstantopoulou I, Fountzilas G.

Thorac Cancer. 2022 Jun;13(12):1862-1865. doi: 10.1111/1759-7714.14447. PMID: 35543335